U.S. patent application number 14/079118 was filed with the patent office on 2014-07-17 for alpha-amylase mutants.
This patent application is currently assigned to NOVOZYMES A/S. The applicant listed for this patent is NOVOZYMES A/S. Invention is credited to Henrik Bisgaard-Frantzen, Torben Vedel Borchert, Lisbeth Hedegaard, Bjarne Ronfeldt Nielsen, Vibeke Skovgaard Nielsen, Helle Outtrup, Allan Svendsen.
Application Number | 20140200172 14/079118 |
Document ID | / |
Family ID | 27512781 |
Filed Date | 2014-07-17 |
United States Patent
Application |
20140200172 |
Kind Code |
A1 |
Svendsen; Allan ; et
al. |
July 17, 2014 |
Alpha-Amylase Mutants
Abstract
The invention relates to a novel Termamyl-like alpha-amylase,
and Termamyl-like alpha-amylases comprising mutations in two,
three, four, five or six regions/positions. The variants have
increased thermostability at acidic pH and/or at low Ca.sup.2+
concentrations (relative to the parent). The invention also relates
to a DNA construct comprising a DNA sequence encoding an
alpha-amylase variant of the invention, a recombinant expression
vector which carries a DNA construct of the invention, a cell which
is transformed with a DNA construct of the invention, the use of an
alpha-amylase variant of the invention for washing and/or
dishwashing, textile desizing, starch liquefaction, a detergent
additive comprising an alpha-amylase variant of the invention, a
manual or automatic dishwashing detergent composition comprising an
alpha-amylase variant of the invention, a method for generating a
variant of a parent Termamyl-like alpha-amylase, which variant
exhibits increased thermostability at acidic pH and/or at low
Ca.sup.2+ concentrations (relative to the parent).
Inventors: |
Svendsen; Allan; (Birkeroed,
DK) ; Borchert; Torben Vedel; (Copenhagen, DK)
; Bisgaard-Frantzen; Henrik; (Bagsvaerd, DK) ;
Outtrup; Helle; (Ballerup, DK) ; Nielsen; Bjarne
Ronfeldt; (Virum, DK) ; Nielsen; Vibeke
Skovgaard; (Bagsvaerd, DK) ; Hedegaard; Lisbeth;
(Sjodborg, DK) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
NOVOZYMES A/S |
Bagsvaerd |
|
DK |
|
|
Assignee: |
NOVOZYMES A/S
Bagsvaerd
DK
|
Family ID: |
27512781 |
Appl. No.: |
14/079118 |
Filed: |
November 13, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13556623 |
Jul 24, 2012 |
|
|
|
14079118 |
|
|
|
|
12493860 |
Jun 29, 2009 |
8263368 |
|
|
13556623 |
|
|
|
|
10327837 |
Dec 23, 2002 |
7566561 |
|
|
12493860 |
|
|
|
|
09545586 |
Apr 7, 2000 |
6528298 |
|
|
10327837 |
|
|
|
|
09290734 |
Apr 13, 1999 |
6361989 |
|
|
09545586 |
|
|
|
|
09170670 |
Oct 13, 1998 |
6187576 |
|
|
09290734 |
|
|
|
|
60063306 |
Oct 28, 1997 |
|
|
|
Current U.S.
Class: |
510/392 ;
435/202 |
Current CPC
Class: |
C11D 3/38618 20130101;
C12Y 302/01001 20130101; C11D 3/386 20130101; C11D 3/38609
20130101; C12N 9/2417 20130101 |
Class at
Publication: |
510/392 ;
435/202 |
International
Class: |
C12N 9/28 20060101
C12N009/28; C11D 3/386 20060101 C11D003/386 |
Foreign Application Data
Date |
Code |
Application Number |
Oct 13, 1997 |
DK |
PA 1172/97 |
Mar 31, 1999 |
DK |
PA 1999 00439 |
Claims
1. An isolated polypeptide having alpha-amylase activity, selected
from the group consisting of: (a) a polypeptide having an amino
acid sequence which has at least 96% identity with amino acids 1 to
485 of SEQ ID NO:24 or SEQ ID NO:26; (b) a polypeptide which is
encoded by a nucleic acid sequence which hybridizes under medium
stringency conditions with (i) the nucleic acid sequence of SEQ ID
NO: 23 or SEQ ID NO: 25, (ii) the cDNA sequence of SEQ ID NO: 23 or
SEQ ID NO: 25, (iii) a subsequence of (i) or (ii) of at least 100
nucleotides, or (iv) a complementary strand of (i), (ii), or (iii);
(c) an allelic variant of (a) or (b); (d) a fragment of (a), (b),
or (c) that has alpha-amylase activity; (e) a pH optimum determined
using the Phadebas method (37.degree. C.) in the range between pH 8
and 9; (f) a temperature optimum determined using the Phasebas
method (pH 9.0) in the range between 55 and 65.degree. C.; (g) a pI
between 7-8 determined by isoelectric focusing (Pharmacia,
Ampholine, pH 3.5-9.3); and (h) improved wash and/or dishwash
performance between pH 9-11.
2. A variant of a parent Termamyl-like alpha-amylase with
alpha-amylase activity comprising mutations in two, three, four,
five, or six of the following regions/positions or in corresponding
positions in other parent Termamyl-like alpha-amylases: (relative
to SEQ ID NO: 1): 1: R181*, G182*, T183*, G184* 2:
N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 3:
V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; 4:
E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 5:
E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 6:
K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; (relative to SEQ ID NO:
2): 1: R181*,G182*,D183*,G184* 2:
N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 3:
V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; 4:
E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 5:
E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 6:
K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; (Relative to SEQ ID NO:
3): 1: R179*,G180,I181*,G182* 2:
N193A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 3:
L204A,R,D,N,C,E,Q,G,H,I,K,M,F,P,S,T,W,Y,V; 4:
E210A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 5:
E214A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 6:
S267A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,T,W,Y,V relative to SEQ ID NO:
4): 1: N190A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 2:
I201A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V; 3:
D207A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 4:
E211A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 5:
Q264A,R,D,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V; (relative to SEQ ID NO:
5): 1: R176*,G177*,E178,G179* 2:
N190A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 3:
V201A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; 4:
D207A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 5:
E211A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 6:
Q264A,R,D,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V; (relative to SEQ ID NO:
6): 1: R181*,G182*,H183*,G184* 2:
N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 3:
I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V; 4:
E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 5:
E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 6:
K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; and (relative to SEQ ID
NO: 24): 1: R181*,G182*,H183*,G184* 2:
N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 3:
I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V; 4:
E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 5:
E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; 6:
K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V.
3. A detergent composition comprising an alpha-amylase variant of
claim 2 and a surfactant.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. application Ser.
No. 13/556,623 filed Jul. 24, 2012, which is a division of U.S.
application Ser. No. 12/493,860 filed Jun. 29, 2009 (now U.S. Pat.
No. 8,263,368), which is a divisional of U.S. application Ser. No.
10/327,837 filed Dec. 23, 2002 (now U.S. Pat. No. 7,566,561), which
is a divisional of U.S. application Ser. No. 09/545,586 filed on
Apr. 7, 2000 (now U.S. Pat. No. 6,528,298), which is a divisional
of U.S. application Ser. No. 09/290,734 filed on Apr. 13, 1999 (now
U.S. Pat. No. 6,361,989), which is a continuation-in-part of U.S.
application Ser. No. 09/170,670 filed on Oct. 13, 1998 (now U.S.
Pat. No. 6,187,576), and claims priority under 35 U.S.C. 119 of
Danish application nos. 1172/97 and PA 1999 00439 filed on Oct. 13,
1997 and Mar. 31, 1999, respectively, and U.S. provisional
application No. 60/063,306 filed on Oct. 28, 1997, the contents of
which are fully incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates a novel alpha-amylase within
the family of Termamyl-like alpha-amylases suitable for detergents.
The invention also relates to variants (mutants) of parent
Termamyl-like alpha-amylases, notably variants exhibiting increased
thermostability at acidic pH and/or at low Ca.sup.2+ concentrations
(relative to the parent) which are advantageous with respect to
applications of the variants in, industrial starch processing
particularly (e.g., starch liquefaction or saccharification). Said
alpha-amylase and alpha-amylase variants of the invention may
advantageously also be used in detergents.
BACKGROUND OF THE INVENTION
[0003] Alpha-Amylases (alpha-1,4-glucan-4-glucanohydrolases, EC
3.2.1.1) constitute a group of enzymes which catalyze hydrolysis of
starch and other linear and branched 1,4-glucosidic oligo- and
polysaccharides.
[0004] There is a very extensive body of patent and scientific
literature relating to this industrially very important class of
enzymes.
[0005] A number of alpha-amylase such as Termamyl-like
alpha-amylases variants are known from, e.g., WO 90/11352, WO
95/10603, WO 95/26397, WO 96/23873 and WO 96/23874.
[0006] Among more recent disclosures relating to alpha-amylases, WO
96/23874 provides three-dimensional, X-ray crystal structural data
for a Termamyl-like alpha-amylase which consists of the 300
N-terminal amino acid residues of the B. amyloliquefaciens
alpha-amylase and amino acids 301-483 of the C-terminal end of the
B. licheniformis alpha-amylase comprising the amino acid sequence
(the latter being available commercially under the tradename
Termamyl.TM.), and which is thus closely related to the
industrially important Bacillus alpha-amylases (which in the
present context are embraced within the meaning of the term
"Termamyl-like alpha-amylases", and which include, inter alfa, the
B. licheniformis, B. amyloliquefaciens and B. stearothermophilus
alpha-amylases). WO 96/23874 further describes methodology for
designing, on the basis of an analysis of the structure of a parent
Termamyl-like alpha-amylase, variants of the parent Termamyl-like
alpha-amylase which exhibit altered properties relative to the
parent.
[0007] WO 95/35382 (Gist Brocades B.V.) concerns amylolytic enzymes
derived from B. licheniformis with improved properties allowing
reduction of the Ca.sup.2+ concentration under application without
a loss of performance of the enzyme. The amylolytic enzyme
comprises one or more amino acid changes at positions selected from
the group of 104, 128, 187, 188 of the B. licheniformis
alpha-amylase sequence.
[0008] WO 96/23873 (Novo Nordisk) discloses Termamyl-like
alpha-amylase variants which have increased thermostability
obtained by pairwise deletion in the region R181*, G182*, T183* and
G184* of the sequence shown in SEQ ID NO: 1 herein.
[0009] WO 97/00324 (KAO) discloses a gene encoding an alkaline
liquefying alpha-amylase derived from Bacillus sp. strain
KSM-AP1378 with the deposited no. FERM BP-3048 suitable for
detergents.
BRIEF DISCLOSURE OF THE INVENTION
[0010] The present invention relates to a novel alpha-amylase and
to novel alpha-amylolytic variants (mutants) of a Termamyl-like
alpha-amylase, in particular variants exhibiting increased
thermostability (relative to the parent) which are advantageous in
connection with the industrial processing of starch (starch
liquefaction, saccharification and the like). The novel
alpha-amylase is suitable for laundry washing and dishwash as is
has a high activity under wash conditions at alkaline pHs in the
range 9-11.
[0011] The inventors have surprisingly found out that in case of
combining two, three, four, five or six mutations (will be
described below), the thermostability of Termamyl-like
alpha-amylases is increased at acidic pH and/or at low Ca.sup.2+
concentration in comparison to single mutations, such as the
mutation disclosed in WO 96/23873 (Novo Nordisk), i.e., pairwise
deletion in the region R181*, G182*, T183* and G184* of the
sequence shown in SEQ ID NO: 1 herein.
[0012] The invention further relates to DNA constructs encoding
variants of the invention, to composition comprising variants of
the invention, to methods for preparing variants of the invention,
and to the use of variants and compositions of the invention, alone
or in combination with other alpha-amylolytic enzymes, in various
industrial processes, e.g., starch liquefaction.
BRIEF DESCRIPTION OF THE DRAWING
[0013] FIGS. 1, 1A and B is an alignment of the amino acid
sequences of nine parent Termamyl-like alpha-amylases. The numbers
on the Extreme left designate the respective amino acid sequences
as follows: [0014] 1: SEQ ID NO: 2, [0015] 2: Bacillus sp. strain
KSM-AP1378 disclosed in WO 97/00324 [0016] 3: SEQ ID NO: 1, [0017]
4: SEQ ID NO: 5, [0018] 5: SEQ ID NO: 4, [0019] 6: SEQ ID NO: 3.
[0020] 7: Partial alpha-amylase sequence [0021] 8: SEQ ID NO: 24
[0022] 9: SEQ ID NO: 26.
[0023] FIG. 2 shows the pH Profile of the AA560 alpha-amylase
compared to the SP722 and SP690 alpha-amylases. The pH profile was
measured at 37.degree. C. The activity is shown in absolute values
as Abs650/mg.
[0024] FIG. 3 shows the Temperature Profile of the AA560
alpha-amylase compared to the SP722 and SP690 alpha-amylases. The
temperature profile shown as Abs650/mg.
[0025] FIG. 4 shows the wash performance of AA560 in the AP Model
Detergent 97 in comparison to SP722, SP690 and Termamyl.RTM..
[0026] FIG. 5 shows the wash performance of AA560 in the Omo Multi
Acao in comparison to SP722, SP690 and Termamyl.RTM..
[0027] FIG. 6 shows the wash performance of AA560 in the Omo
Concentrated in comparison to SP722, SP690 and Termamyl.RTM..
[0028] FIG. 7 shows the wash performance of AA560 in the Ariel
Futur liquid in comparison to SP722, SP690 and Termamyl.RTM..
DETAILED DISCLOSURE OF THE INVENTION
Alpha-Amylase Activity Determination
[0029] Alpha-Amylases (alpha-1,4-glucan-4-glucanohydrolases, EC
3.2.1.1) constitute a group of enzymes which catalyze hydrolysis of
starch and other linear and branched 1,4-glucosidic oligo- and
polysaccharides. For purposes of the present invention,
alpha-amylase activity may be determined using the Phadebas assay,
the pNPG7 assay and the BS-alpha-amylase activity assay described
below in the "Materials and Methods" section.
The Novel Alpha-Amylase
Microbial Source
[0030] The novel alkaline alpha-amylase of the invention may be
derived from a strain of Bacillus. Preferred strains are of
Bacillus sp. DSM 12649 (the AA560 alpha-amylase) or Bacillus sp.
DSM 12648 (the AA349 alpha-amylase). These strains were deposited
on 25 Jan. 1999 by the inventors under the terms of the Budapest
Treaty on the International Recognition of the Deposit of
Microorganisms for the Purposes of Patent Procedure at Deutshe
Sammmlung von Microorganismen und Zellkulturen GmbH (DSMZ),
Mascheroder Weg 1b, D-38124 Braunschweig DE.
[0031] Escherichia coli strains termed NN049467 and NN049470
containing the alpha-amylase genes in plasmids pLiH1274 (AA349) and
plasmid pTVB299 (AA560) have also been deposited on 7 Apr. 1999
under the terms of the Budapest Treaty with the Deutshe Sammmlung
von Microorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg
1b, D-38124 Braunschweig DE, and given the accession numbers
DSM12761 and DSM12764, respectively.
Homology of Enzyme
[0032] In a first embodiment, the present invention relates to
isolated polypeptides having an amino acid sequence which has a
degree of identity to amino acids 1 to 485 of SEQ ID NO: 24 or SEQ
ID NO: 26 (i.e., the mature polypeptide) of at least about 96%,
preferably at least about 97%, more preferably at least about 98%,
even more preferably at least about 99%, which have alpha-amylase
activity (hereinafter "homologous polypeptides"). In a preferred
embodiment, the homologous polypeptides have an amino acid sequence
which differs by five amino acids, preferably by four amino acids,
more preferably by three amino acids, even more preferably by two
amino acids, and most preferably by one amino acid from amino acids
1 to 485 of SEQ ID NO: 24 or SEQ ID NO: 26. It is to be noted that
SEQ ID NO: 24 and SEQ ID NO: 26 are identical. However, the DNA
sequences, i.e., SEQ ID NO: 23 and SEQ ID NO: 25, respectively,
encoding the alpha-amylase of the invention shown in SEQ ID NO: 24
and SEQ ID NO: 26 are not identical.
[0033] The amino acid sequence homology may be determined as the
degree of identity between the two sequences indicating a
derivation of the first sequence from the second. The homology may
suitably be determined by means of computer programs known in the
art. Thus, GAP provided in GCG version 8 (Needleman and Wunsch,
1970, Journal of Molecular Biology 48, 443-453) may be used for a
pairwise alignment of the sequences and calculation of the degree
of identity or degree of homology using the default settings.
Alternatively, Gap from GCG version 9 may be used with a translated
version 8 peptide scoring matrix, a gap creation penalty of 30, a
gap extension penalty of 1 using ntol's matrix
(http://plasmid/.about.bioweb/matrix/) without end gap penalty.
Homology (Identity) of the Novel Alpha-Amylase to Known Bacillus
sp. Alpha-Amylases
[0034] A homology search of known sequences showed homologies for
the sequences of the invention with a number of Bacillus amylases
in the range 65-95% on amino acid basis determined as described
above.
[0035] Specifically, the most homologous alpha-amylases found are
SP690 (SEQ ID NO: 1 of U.S. Pat. No. 5,856,164 which is about 87%
homologous), SP722 (SEQ ID NO: 2 of U.S. Pat. No. 5,856,164 which
is about 87% homologous), the mature part (i.e., amino acids no.
31-516) of the alpha-amylase obtained from Bacillus sp. KSM-AP1378
disclosed as SEQ ID NO: 2 of WO 97/00324 which is about 86%
homologous, and the alpha-amylase disclosed in Tsukamoto et al.,
1988, Biochem. Biophys. Res. Commun. 151: 25-33) which is about 95%
homologous to SEQ ID NO: 24 and SEQ ID NO: 26 determined as
describe above.
[0036] Preferably, the polypeptides of the present invention
comprise the amino acid sequence of SEQ ID NO: 24 or SEQ ID NO: 26
or allelic variants thereof; or fragments thereof that have
alpha-amylase activity. SEQ ID NO: 24 and SEQ ID NO: 26 show the
mature part of the alkaline alpha-amylase of the invention.
[0037] A fragment of SEQ ID NO: 24 or SEQ ID NO: 26 are
polypeptides having one or more amino acids deleted from the amino
and/or carboxyl terminus of this amino acid sequence.
[0038] An allelic variant denotes any of two or more alternative
forms of a gene occupying the same chromosomal locus. Allelic
variation arises naturally through mutation, and may result in
polymorphism within populations. Gene mutations can be silent (no
change in the encoded polypeptide) or may encode polypeptides
having altered amino acid sequences. An allelic variant of a
polypeptide is a polypeptide encoded by an allelic variant of a
gene.
[0039] The amino acid sequences of the homologous polypeptides may
differ from the amino acid sequence of SEQ ID NO: 24 or SEQ ID NO:
26 by an insertion or deletion of one or more amino acid residues
and/or the substitution of one or more amino acid residues by
different amino acid residues. Preferably, amino acid changes are
of a minor nature, that is conservative amino acid substitutions
that do not significantly affect the folding and/or activity of the
protein; small deletions, typically of one to about 30 amino acids;
small amino- or carboxyl-terminal extensions, such as an
amino-terminal methionine residue; a small linker peptide of up to
about 20-25 residues; or a small extension that facilitates
purification by changing net charge or another function, such as a
poly-histidine tract, an antigenic epitope or a binding domain.
[0040] Examples of conservative substitutions are within the group
of basic amino acids (arginine, lysine and histidine), acidic amino
acids (glutamic acid and aspartic acid), polar amino acids
(glutamine and asparagine), hydrophobic amino acids (leucine,
isoleucine and valine), aromatic amino acids (phenylalanine,
tryptophan and tyrosine), and small amino acids (glycine, alanine,
serine, threonine and methionine). Amino acid substitutions which
do not generally alter the specific activity are known in the art
and are described, for example, by H. Neurath and R. L. Hill, 1979,
In, The Proteins, Academic Press, New York. The most commonly
occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser,
Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro,
Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly as well as
these in reverse.
[0041] In a second embodiment, the present invention relates to
isolated polypeptides having alpha-amylase activity which are
encoded by nucleic acid sequences which hybridize under medium
stringency conditions, preferably medium-high stringency
conditions, more preferably high stringency conditions, and most
preferably very high stringency conditions with a nucleic acid
probe which hybridizes under the same conditions with (i) the
nucleic acid sequence of SEQ ID NO: 23 or SEQ ID NO: 25, (ii) the
cDNA sequence of SEQ ID NO: 23 or SEQ ID NO: 25, (iii) a
subsequence of (i) or (ii), or (iv) a complementary strand of (i),
(ii), or (iii) (Sambrook et al., 1989, Molecular Cloning, A
Laboratory Manual, 2d edition, Cold Spring Harbor, N.Y.). The
subsequence of SEQ ID NO: 23 or SEQ ID NO: 25 may be at least 100
nucleotides or preferably at least 200 nucleotides. Moreover, the
subsequence may encode a polypeptide fragment which has
alpha-amylase activity. The polypeptides may also be allelic
variants or fragments of the polypeptides that have alpha-amylase
activity.
[0042] The nucleic acid sequence of SEQ ID NO: 23 or SEQ ID NO: 25
or a subsequence thereof, as well as the amino acid sequence of SEQ
ID NO: 24 or SEQ ID NO: 26 or a fragment thereof, may be used to
design a nucleic acid probe to identify and clone DNA encoding
polypeptides having alpha-amylase activity from strains of
different genera or species according to methods well known in the
art. In particular, such probes can be used for hybridization with
the genomic or cDNA of the genus or species of interest, following
standard Southern blotting procedures, in order to identify and
isolate the corresponding gene therein. Such probes can be
considerably shorter than the entire sequence, but should be at
least 15, preferably at least 25, and more preferably at least 35
nucleotides in length. Longer probes can also be used. Both DNA and
RNA probes can be used. The probes are typically labelled for
detecting the corresponding gene (for example, with .sup.32P,
.sup.3H, .sup.35S, biotin, or avidin). Such probes are encompassed
by the present invention.
[0043] Thus, a genomic DNA or cDNA library prepared from such other
organisms may be screened for DNA which hybridizes with the probes
described above and which encodes a polypeptide having
alpha-amylase activity. Genomic or other DNA from such other
organisms may be separated by agarose or polyacrylamide gel
electrophoresis, or other separation techniques. DNA from the
libraries or the separated DNA may be transferred to and
immobilized on nitrocellulose or other suitable carrier material.
In order to identify a clone or DNA which is homologous with SEQ ID
NO: 23 or SEQ ID NO: 25 or subsequences thereof, the carrier
material is used in a Southern blot.
[0044] For purposes of the present invention, hybridization
indicates that the nucleic acid sequence hybridizes to a nucleic
acid probe corresponding to the nucleic acid sequence shown in SEQ
ID NO: 23 or SEQ ID NO: 25, its complementary strand, or
subsequences thereof, under medium to very high stringency
conditions. Molecules to which the nucleic acid probe hybridizes
under these conditions are detected using X-ray film.
[0045] In another preferred embodiment, the nucleic acid probe is
the nucleic acid sequence contained in plasmids pLiH1274 (AA349) or
pTVB299 (AA560) which are contained in Escherichia coli DSM12761 or
Escherichia coli DSM12764, respectively, or, wherein the nucleic
acid sequence encodes a polypeptide having acid alpha-amylase
activity of the invention and shown in SEQ ID NO: 24 and SEQ ID NO:
26, respectively.
[0046] For long probes of at least 100 nucleotides in length,
medium to very high stringency conditions are defined as
prehybridization and hybridization at 42.degree. C. in
5.times.SSPE, 0.3% SDS, 200 ig/ml sheared and denatured salmon
sperm DNA, 35% formamide for medium and medium-high stringencies,
or 50% formamide for high and very high stringencies, following
standard Southern blotting procedures.
[0047] For long probes of at least 100 nucleotides in length, the
carrier material is finally washed three times each for 15 minutes
using 2.times.SSC, 0.2% SDS preferably at least at 55.degree. C.
(medium stringency), preferably at least at 60.degree. C.
(medium-high stringency), more preferably at least at 65.degree. C.
(high stringency), and most preferably at least at 70.degree. C.
(very high stringency).
[0048] For short probes which are about 15 nucleotides to about 70
nucleotides in length, stringency conditions are defined as
prehybridization, hybridization, and washing post-hybridization at
5.degree. C. to 10.degree. C. below the calculated T.sub.n, using
the calculation according to Bolton and McCarthy (1962, Proceedings
of the National Academy of Sciences USA 48:1390) in 0.9 M NaCl,
0.09 M Tris-HCl pH 7.6, 6 mM EDTA, 0.5% NP-40, 1.times.Denhardt's
solution, 1 mM sodium pyrophosphate, 1 mM sodium monobasic
phosphate, 0.1 mM ATP, and 0.2 mg of yeast RNA per ml following
standard Southern blotting procedures.
[0049] For short probes which are about 15 nucleotides to about 70
nucleotides in length, the carrier material is washed once in
6.times.SCC plus 0.1% SDS for 15 minutes and twice each for 15
minutes using 6.times.SSC at 5.degree. C. to 10.degree. C. below
the calculated T.sub.m.
[0050] In a third embodiment, the present invention relates to
isolated polypeptides, i.e., the polypeptides shown in SEQ ID NO:
24 or SEQ ID NO: 26, having the following physicochemical
properties:
[0051] A pH optimum (see FIG. 2) determined using the Phadebas
method (37.degree. C.) was found to be in the range between pH 8
and 9, more precisely at about 8.5.
[0052] A temperature optimum (See FIG. 3) determined using the
Phasebas method (pH 9.0) was found to be in the range between 55
and 65.degree. C., more precisely about 60.degree. C.
[0053] A pI between 7-8 (See Table 1 in Example 11) was determined
by isoelectric focusing (Pharmacia, Ampholine, pH 3.5-9.3).
[0054] A specific activity (see Table 1 of Example 11) of 35,000
NU/ml was determined using the Phadebas method and 6,000 NU/ml
using the pNPG7 method.
[0055] The alpha-amylase of the present invention have at least
20%, preferably at least 40%, more preferably at least 60%, even
more preferably at least 80%, even more preferably at least 90%,
and most preferably at least 100% of the alpha-amylase activity of
the mature alpha-amylase shown in SEQ ID NO: 24 and SEQ ID NO:
26.
[0056] An alpha-amylase of the present invention may be obtained
from microorganisms of any genus. For purposes of the present
invention, the term "obtained from" as used herein in connection
with a given source shall mean that the alpha-amylase encoded by
the nucleic acid sequence is produced by the source or by a cell in
which the nucleic acid sequence from the source has been
inserted.
[0057] An alpha-amylase of the present invention is a bacterial
polypeptide. For example, the polypeptide may be a gram positive
bacterial polypeptide such as a Bacillus polypeptide, e.g., a
Bacillus alkalophilus, Bacillus amyloliquefaciens, Bacillus brevis,
Bacillus circulans, Bacillus coagulans, Bacillus lautus, Bacillus
lentus, Bacillus licheniformis, Bacillus megaterium, Bacillus
stearothermophilus, Bacillus subtilis, or Bacillus thuringiensis
polypeptide; or a Streptomyces polypeptide, e.g., a Streptomyces
lividans or Streptomyces murinus polypeptide; or a gram negative
bacterial polypeptide, e.g., an E. coli or a Pseudomonas sp.
polypeptide.
[0058] In another preferred embodiment, the polypeptide is a
Bacillus sp. polypeptide, more preferred embodiment, the
polypeptide is a Bacillus sp. DSM 12648 or Bacillus sp. DSM 12649
polypeptide, e.g., the polypeptides with the amino acid sequence of
SEQ ID NO: 24 and SEQ ID NO: 26, respectively.
[0059] It will be understood that for the aforementioned species,
the invention encompasses both the perfect and imperfect states,
and other taxonomic equivalents, e.g., anamorphs, regardless of the
species name by which they are known. Those skilled in the art will
readily recognize the identity of appropriate equivalents.
[0060] Strains of these species are readily accessible to the
public in a number of culture collections, such as the American
Type Culture Collection (ATCC), Deutsche Sammlung von
Mikroorganismen and Zellkulturen GmbH (DSM), Centraalbureau Voor
Schimmelcultures (CBS), and Agricultural Research Service Patent
Culture Collection, Northern Regional Research Center (NRRL).
[0061] Furthermore, such polypeptides may be identified and
obtained from other sources including microorganisms isolated from
nature (e.g., soil, composts, water, etc.) using the
above-mentioned probes. Techniques for isolating microorganisms
from natural habitats are well known in the art. The nucleic acid
sequence may then be derived by similarly screening a genomic or
cDNA library of another microorganism. Once a nucleic acid sequence
encoding a polypeptide has been detected with the probe(s), the
sequence may be isolated or cloned by utilizing techniques which
are known to those of ordinary skill in the art (see, e.g.,
Sambrook et al., 1989, supra).
[0062] As defined herein, an "isolated" polypeptide is a
polypeptide which is essentially free of other non-alpha-amylase
polypeptides, e.g., at least about 20% pure, preferably at least
about 40% pure, more preferably about 60% pure, even more
preferably about 80% pure, most preferably about 90% pure, and even
most preferably about 95% pure, as determined by SDS-PAGE.
[0063] Polypeptides encoded by nucleic acid sequences of the
present invention also include fused polypeptides or cleavable
fusion polypeptides in which another polypeptide is fused at the
N-terminus or the C-terminus of the polypeptide or fragment
thereof. A fused polypeptide is produced by fusing a nucleic acid
sequence (or a portion thereof) encoding another polypeptide to a
nucleic acid sequence (or a portion thereof) of the present
invention. Techniques for producing fusion polypeptides are known
in the art, and include ligating the coding sequences encoding the
polypeptides so that they are in frame and that expression of the
fused polypeptide is under control of the same promoter(s) and
terminator.
Mutants of the Novel Alpha-Amylase
[0064] Specifically contemplated mutants of the novel alpha-amylase
shown in SEQ ID NO: 24 (or SEQ ID NO: 26) are described in the
following. A mutant alpha-amylase of the invention is characterized
by the fact that one or more of the methionine amino acid residues
is exchanged with any amino acid residue except for Cys and Met.
Thus, according to the invention the amino acid residues to replace
the methionine amino acid residue are the following: Ala, Arg, Asn,
Asp, Gln, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro, Ser, Thr, Trp,
Tyr, and Val.
[0065] A preferred embodiment of the mutant alpha-amylase of the
invention is characterized by the fact that one or more of the
methionine amino acid residues is (are) exchanged with a Leu, Thr,
Ala, Gly, Ser, Ile, or Val amino acid residue, preferably a Leu,
Thr, Ala, or Gly amino acid residue. In this embodiment a very
satisfactory activity level and stability in the presence of
oxidizing agents is obtained. Specifically this means that one or
more of the methiones in the following position may be replaced or
deleted using any suitable technique known in the art, including
especially site directed mutagenesis and gene shuffling.
Contemplated position, using the SEQ ID NO: 24 numbering, are: 9,
10, 105, 116, 202, 208, 261, 309, 323, 382, 430, 440.
[0066] In a preferred embodiment of the mutant alpha-amylase of the
invention is characterized by the fact that the methionine amino
acid residue at position 202 is exchanged with any of amino acid
residue expect for Cys and Met, preferably with a Leu, Thr, Ala,
Gly, Ser, Ile, or Asp.
[0067] Other contemplated preferred mutations include deletion of
one, two or more residues of amino acids R181, G182, D183 or G184,
K185, G186 or substitution of one or more of these residues. A
preferred mutation is the deletion of D183-G184. Particularly
relevant mutations are substitutions of G186 with Ala, Arg, Asn,
Asp, Cys, Gln, Glu, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr,
Trp, Tyr, and Val. A particularly preferred substitution is
G186R.
[0068] Also contemplated is substitution of N195 with Ala, Arg,
Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro,
Ser, Thr, Trp, Tyr, and Val. A particularly interesting
substitution is N195F.
[0069] The following combinations of the above mentioned mutations
include: deletion of D183-G184+N195F, deletion of D183-G184+G186R,
deletion of D183-G184+G186R+N195F and G186R+N195F.
Nucleic Acid Sequences
[0070] The present invention also relates to isolated nucleic acid
sequences which encode a polypeptide of the present invention. In a
preferred embodiment, the nucleic acid sequence is set forth in SEQ
ID NO: 23 or SEQ ID NO: 25. In another more preferred embodiment,
the nucleic acid sequence is the sequence contained in plasmid
pLiH1274 (AA349) or plasmid pTVB299 (AA560) that is contained in
Escherichia coli DSM12761 and Escherichia coli DSM12764,
respectively. In another preferred embodiment, the nucleic acid
sequence is the mature polypeptide coding region of SEQ ID NO: 23
or SEQ ID NO: 25. The present invention also encompasses nucleic
acid sequences which encode a polypeptide having the amino acid
sequence of SEQ ID NO: 24 which differ from SEQ ID NO: 23 or SEQ ID
NO: 25 by virtue of the degeneracy of the genetic code. The present
invention also relates to subsequences of SEQ ID NO: 23 or SEQ ID
NO: 25 which encode fragments of SEQ ID NO: 24 or SEQ ID NO: 26,
respectively, that have alpha-amylase activity.
[0071] Subsequences of SEQ ID NO: 23 or SEQ ID NO: 25 are nucleic
acid sequences encompassed by SEQ ID NO: 23 or SEQ ID NO: 25 except
that one or more nucleotides from the 5' and/or 3' end have been
deleted.
[0072] The present invention also relates to mutant nucleic acid
sequences comprising at least one mutation in the mature
polypeptide coding sequence of SEQ ID NO:1 or SEQ ID NO: 3, in
which the mutant nucleic acid sequence encodes a polypeptide which
consists of amino acids 1 to 485 of SEQ ID NO: 24 or SEQ ID NO:
26.
[0073] The techniques used to isolate or clone a nucleic acid
sequence encoding a polypeptide are known in the art and include
isolation from genomic DNA, preparation from cDNA, or a combination
thereof. The cloning of the nucleic acid sequences of the present
invention from such genomic DNA can be effected, e.g., by using the
well known polymerase chain reaction (PCR) or antibody screening of
expression libraries to detect cloned DNA fragments with shared
structural features. See, e.g., Innis et al., 1990, PCR: A Guide to
Methods and Application, Academic Press, New York. Other nucleic
acid amplification procedures such as ligase chain reaction (LCR),
ligated activated transcription (LAT) and nucleic acid
sequence-based amplification (NASBA) may be used. The nucleic acid
sequence may be cloned from a strain of Bacillus, or another or
related organism and thus, for example, may be an allelic or
species variant of the polypeptide encoding region of the nucleic
acid sequence.
[0074] The term "isolated nucleic acid sequence" as used herein
refers to a nucleic acid sequence which is essentially free of
other nucleic acid sequences, e.g., at least about 20% pure,
preferably at least about 40% pure, more preferably at least about
60% pure, even more preferably at least about 80% pure, and most
preferably at least about 90% pure as determined by agarose
electrophoresis. For example, an isolated nucleic acid sequence can
be obtained by standard cloning procedures used in genetic
engineering to relocate the nucleic acid sequence from its natural
location to a different site where it will be reproduced. The
cloning procedures may involve excision and isolation of a desired
nucleic acid fragment comprising the nucleic acid sequence encoding
the polypeptide, insertion of the fragment into a vector molecule,
and incorporation of the recombinant vector into a host cell where
multiple copies or clones of the nucleic acid sequence will be
replicated. The nucleic acid sequence may be of genomic, cDNA, RNA,
semisynthetic, synthetic origin, or any combinations thereof.
Homology of DNA Sequence Encoding the Enzyme
[0075] The present invention also relates to nucleic acid sequences
which have a degree of homology to the mature polypeptide coding
sequence of SEQ ID NO: 23 (i.e., nucleotides 1 to 1458) or SEQ ID
NO: 25 (i.e., nucleotide 1 to 1458) of at least about 96% homology
on DNA level, preferably about 97%, preferably about 98%, more
preferably about 99% homology, which encode an active
polypeptide.
[0076] The DNA sequence homology may be determined as the degree of
identity between the two sequences indicating a derivation of the
first sequence from the second. The homology may suitably be
determined by means of computer programs known in the art such as
GAP provided in the GCG program package (described above). Thus,
Gap GCGv8 may be used with the following default parameters: GAP
creation penalty of 5.0 and GAP extension penalty of 0.3, default
scoring matrix. GAP uses the method of Needleman/Wunsch/Sellers to
make alignments.
[0077] Modification of a nucleic acid sequence encoding a
polypeptide of the present invention may be necessary for the
synthesis of polypeptides substantially similar to the polypeptide.
The term "substantially similar" to the polypeptide refers to
non-naturally occurring forms of the polypeptide. These
polypeptides may differ in some engineered way from the polypeptide
isolated from its native source, e.g., variants that differ in
specific activity, thermostability, pH optimum, or the like. The
variant sequence may be constructed on the basis of the nucleic
acid sequence presented as the polypeptide encoding part of SEQ ID
NO: 23 or SEQ ID NO: 25, e.g., a subsequence thereof, and/or by
introduction of nucleotide substitutions which do not give rise to
another amino acid sequence of the polypeptide encoded by the
nucleic acid sequence, but which correspond to the codon usage of
the host organism intended for production of the enzyme, or by
introduction of nucleotide substitutions which may give rise to a
different amino acid sequence. For a general description of
nucleotide substitution, see, e.g., Ford et al., 1991, Protein
Expression and Purification 2: 95-107.
[0078] It will be apparent to those skilled in the art that such
substitutions can be made outside the regions critical to the
function of the molecule and still result in an active polypeptide.
Amino acid residues essential to the activity of the polypeptide
encoded by the isolated nucleic acid sequence of the invention, and
therefore preferably not subject to substitution, may be identified
according to procedures known in the art, such as site-directed
mutagenesis or alanine-scanning mutagenesis (see, e.g., Cunningham
and Wells, 1989, Science 244: 1081-1085). In the latter technique,
mutations are introduced at every positively charged residue in the
molecule, and the resultant mutant molecules are tested for
[enzyme] activity to identify amino acid residues that are critical
to the activity of the molecule. Sites of substrate-enzyme
interaction can also be determined by analysis of the
three-dimensional structure as determined by such techniques as
nuclear magnetic resonance analysis, crystallography or
photoaffinity labelling (see, e.g., de Vos et al., 1992, Science
255: 306-312; Smith et al., 1992, Journal of Molecular Biology 224:
899-904; Wlodaver et al., 1992, FEBS Letters 309: 59-64).
[0079] The present invention also relates to isolated nucleic acid
sequences encoding a polypeptide of the present invention, which
hybridize under medium stringency conditions, preferably
medium-high stringency conditions, more preferably high stringency
conditions, and most preferably very high stringency conditions
with a nucleic acid probe which hybridizes under the same
conditions with the nucleic acid sequence of SEQ ID NO:1 or SEQ ID
NO: 3 or its complementary strand; or allelic variants and
subsequences thereof (Sambrook et al., 1989, supra), as defined
herein.
[0080] The present invention also relates to isolated nucleic acid
sequences produced by (a) hybridizing a DNA under medium,
medium-high, high, or very high stringency conditions with the
sequence of SEQ ID NO: 23 or SEQ ID NO: 25, or their complementary
strands, or a subsequence thereof; and (b) isolating the nucleic
acid sequence. The subsequence is preferably a sequence of at least
100 nucleotides such as a sequence which encodes a polypeptide
fragment which has alpha-amylase activity.
Methods for Producing Mutant Nucleic Acid Sequences
[0081] The present invention further relates to methods for
producing a mutant nucleic acid sequence, comprising introducing at
least one mutation into the mature polypeptide coding sequence of
SEQ ID NO: 23 or SEQ ID NO: 25 or a subsequence thereof, wherein
the mutant nucleic acid sequence encodes a polypeptide which
consists of 1 to 485 of SEQ ID NO: 24 or SEQ ID NO: 26 or a
fragment thereof which has alpha-amylase activity.
[0082] The introduction of a mutation into the nucleic acid
sequence to exchange one nucleotide for another nucleotide may be
accomplished by site-directed mutagenesis using any of the methods
known in the art. Particularly useful is the procedure which
utilizes a supercoiled, double stranded DNA vector with an insert
of interest and two synthetic primers containing the desired
mutation. The oligonucleotide primers, each complementary to
opposite strands of the vector, extend during temperature cycling
by means of Pfu DNA polymerase. On incorporation of the primers, a
mutated plasmid containing staggered nicks is generated. Following
temperature cycling, the product is treated with DpnI which is
specific for methylated and hemimethylated DNA to digest the
parental DNA template and to select for mutation-containing
synthesized DNA. Other procedures known in the art may also be
used. These other procedures include gene shuffling, e.g., as
described in WO 95/22625 (from Affymax Technologies N.V.) and WO
96/00343 (from Novo Nordisk A/S).
Nucleic Acid Constructs
[0083] The present invention also relates to nucleic acid
constructs comprising a nucleic acid sequence of the present
invention operably linked to one or more control sequences which
direct the expression of the coding sequence in a suitable host
cell under conditions compatible with the control sequences.
Expression will be understood to include any step involved in the
production of the polypeptide including, but not limited to,
transcription, post-transcriptional modification, translation,
post-translational modification, and secretion.
[0084] "Nucleic acid construct" is defined herein as a nucleic acid
molecule, either single- or double-stranded, which is isolated from
a naturally occurring gene or which has been modified to contain
segments of nucleic acid which are combined and juxtaposed in a
manner which would not otherwise exist in nature. The term nucleic
acid construct is synonymous with the term expression cassette when
the nucleic acid construct contains all the control sequences
required for expression of a coding sequence of the present
invention. The term "coding sequence" is defined herein as a
portion of a nucleic acid sequence which directly specifies the
amino acid sequence of its protein product. The boundaries of the
coding sequence are generally determined by a ribosome binding site
(prokaryotes) or by the ATG start codon (eukaryotes) located just
upstream of the open reading frame at the 5' end of the mRNA and a
transcription terminator sequence located just downstream of the
open reading frame at the 3' end of the mRNA. A coding sequence can
include, but is not limited to, DNA, cDNA, and recombinant nucleic
acid sequences.
[0085] An isolated nucleic acid sequence encoding a polypeptide of
the present invention may be manipulated in a variety of ways to
provide for expression of the polypeptide. Manipulation of the
nucleic acid sequence prior to its insertion into a vector may be
desirable or necessary depending on the expression vector. The
techniques for modifying nucleic acid sequences utilizing
recombinant DNA methods are well known in the art.
[0086] The term "control sequences" is defined herein to include
all components which are necessary or advantageous for the
expression of a polypeptide of the present invention. Each control
sequence may be native or foreign to the nucleic acid sequence
encoding the polypeptide. Such control sequences include, but are
not limited to, a leader, polyadenylation sequence, propeptide
sequence, promoter, signal peptide sequence, and transcription
terminator. At a minimum, the control sequences include a promoter,
and transcriptional and translational stop signals. The control
sequences may be provided with linkers for the purpose of
introducing specific restriction sites facilitating ligation of the
control sequences with the coding region of the nucleic acid
sequence encoding a polypeptide. The term "operably linked" is
defined herein as a configuration in which a control sequence is
appropriately placed at a position relative to the coding sequence
of the DNA sequence such that the control sequence directs the
expression of a polypeptide.
Promoter Sequence
[0087] The control sequence may be an appropriate promoter
sequence, a nucleic acid sequence which is recognized by a host
cell for expression of the nucleic acid sequence. The promoter
sequence contains transcriptional control sequences which mediate
the expression of the polypeptide. The promoter may be any nucleic
acid sequence which shows transcriptional activity in the host cell
of choice including mutant, truncated, and hybrid promoters, and
may be obtained from genes encoding extracellular or intracellular
polypeptides either homologous or heterologous to the host
cell.
[0088] Examples of suitable promoters for directing the
transcription of the nucleic acid constructs of the present
invention, especially in a bacterial host cell, are the promoters
obtained from the E. coli lac operon, Streptomyces coelicolor
agarase gene (dagA), Bacillus subtilis levansucrase gene (sacB),
Bacillus licheniformis alpha-amylase gene (amyL), Bacillus
stearothermophilus maltogenic amylase gene (amyM), Bacillus
amyloliquefaciens alpha-amylase gene (amyQ), Bacillus licheniformis
penicillinase gene (penP), Bacillus subtilis xylA and xylB genes,
and prokaryotic beta-lactamase gene (VIIIa-Kamaroff et al., 1978,
Proceedings of the National Academy of Sciences USA 75: 3727-3731),
as well as the tac promoter (DeBoer et al., 1983, Proceedings of
the National Academy of Sciences USA 80: 21-25). Further promoters
are described in "Useful proteins from recombinant bacteria" in
Scientific American, 1980, 242: 74-94; and in Sambrook et al.,
1989, supra.
Terminator Sequence
[0089] The control sequence may also be a suitable transcription
terminator sequence, a sequence recognized by a host cell to
terminate transcription. The terminator sequence is operably linked
to the 3' terminus of the nucleic acid sequence encoding the
polypeptide. Any terminator which is functional in the host cell of
choice may be used in the present invention.
Signal Peptide
[0090] The control sequence may also be a signal peptide coding
region that codes for an amino acid sequence linked to the amino
terminus of a polypeptide and directs the encoded polypeptide into
the cell's secretory pathway. The 5' end of the coding sequence of
the nucleic acid sequence may inherently contain a signal peptide
coding region naturally linked in translation reading frame with
the segment of the coding region which encodes the secreted
polypeptide. Alternatively, the 5' end of the coding sequence may
contain a signal peptide coding region which is foreign to the
coding sequence. The foreign signal peptide coding region may be
required where the coding sequence does not naturally contain a
signal peptide coding region. Alternatively, the foreign signal
peptide coding region may simply replace the natural signal peptide
coding region in order to enhance secretion of the polypeptide.
However, any signal peptide coding region which directs the
expressed polypeptide into the secretory pathway of a host cell of
choice may be used in the present invention.
[0091] Effective signal peptide coding regions for bacterial host
cells are the signal peptide coding regions obtained from the genes
for Bacillus NCIB 11837 maltogenic amylase, Bacillus
stearothermophilus alpha-amylase, Bacillus licheniformis
subtilisin, Bacillus licheniformis beta-lactamase, Bacillus
stearothermophilus neutral proteases (nprT, nprS, nprM), and
Bacillus subtilis prsA. Further signal peptides are described by
Simonen and Palva, 1993, Microbiological Reviews 57: 109-137.
Regulatory System
[0092] It may also be desirable to add regulatory sequences which
allow the regulation of the expression of the polypeptide relative
to the growth of the host cell. Examples of regulatory systems are
those which cause the expression of the gene to be turned on or off
in response to a chemical or physical stimulus, including the
presence of a regulatory compound. Regulatory systems in
prokaryotic systems include the lac, tac, and trp operator systems.
In yeast, the ADH2 system or GAL1 system may be used. In
filamentous fungi, the TAKA alpha-amylase promoter, Aspergillus
niger glucoamylase promoter, and Aspergillus oryzae glucoamylase
promoter may be used as regulatory sequences. Other examples of
regulatory sequences are those which allow for gene amplification.
In eukaryotic systems, these include the dihydrofolate reductase
gene which is amplified in the presence of methotrexate, and the
metallothionein genes which are amplified with heavy metals. In
these cases, the nucleic acid sequence encoding the polypeptide
would be operably linked with the regulatory sequence.
Expression Vectors
[0093] The present invention also relates to recombinant expression
vectors comprising a nucleic acid sequence of the present
invention, a promoter, and transcriptional and translational stop
signals. The various nucleic acid and control sequences described
above may be joined together to produce a recombinant expression
vector which may include one or more convenient restriction sites
to allow for insertion or substitution of the nucleic acid sequence
encoding the polypeptide at such sites. Alternatively, the nucleic
acid sequence of the present invention may be expressed by
inserting the nucleic acid sequence or a nucleic acid construct
comprising the sequence into an appropriate vector for expression.
In creating the expression vector, the coding sequence is located
in the vector so that the coding sequence is operably linked with
the appropriate control sequences for expression.
[0094] The recombinant expression vector may be any vector (e.g., a
plasmid or virus) which can be conveniently subjected to
recombinant DNA procedures and can bring about the expression of
the nucleic acid sequence. The choice of the vector will typically
depend on the compatibility of the vector with the host cell into
which the vector is to be introduced. The vectors may be linear or
closed circular plasmids.
[0095] The vector may be an autonomously replicating vector, i.e.,
a vector which exists as an extrachromosomal entity, the
replication of which is independent of chromosomal replication,
e.g., a plasmid, an extrachromosomal element, a minichromosome, or
an artificial chromosome. The vector may contain any means for
assuring self-replication. Alternatively, the vector may be one
which, when introduced into the host cell, is integrated into the
genome and replicated together with the chromosome(s) into which it
has been integrated. Furthermore, a single vector or plasmid or two
or more vectors or plasmids which together contain the total DNA to
be introduced into the genome of the host cell, or a transposon may
be used.
[0096] The vectors of the present invention preferably contain one
or more selectable markers which permit easy selection of
transformed cells. A selectable marker is a gene the product of
which provides for biocide or viral resistance, resistance to heavy
metals, prototrophy to auxotrophs, and the like. Examples of
bacterial selectable markers are the dal genes from Bacillus
subtilis or Bacillus licheniformis, or markers which confer
antibiotic resistance such as ampicillin, kanamycin,
chloramphenicol or tetracycline resistance. Suitable markers for
yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3.
A selectable marker for use in a filamentous fungal host cell may
be selected from the group including, but not limited to, amdS
(acetamidase), argB (ornithine carbamoyltransferase), bar
(phosphinothricin acetyltransferase), hygB (hygromycin
phosphotransferase), niaD (nitrate reductase), pyrG
(orotidine-5'-phosphate decarboxylase), sC (sulfate
adenyltransferase), trpC (anthranilate synthase), as well as
equivalents thereof. Preferred for use in an Aspergillus cell are
the amdS and pyrG genes of Aspergillus nidulans or Aspergillus
oryzae and the bar gene of Streptomyces hygroscopicus.
[0097] The vectors of the present invention preferably contain an
element(s) that permits stable integration of the vector into the
host cell genome or autonomous replication of the vector in the
cell independent of the genome of the cell.
[0098] For integration into the host cell genome, the vector may
rely on the nucleic acid sequence encoding the polypeptide or any
other element of the vector for stable integration of the vector
into the genome by homologous or nonhomologous recombination.
Alternatively, the vector may contain additional nucleic acid
sequences for directing integration by homologous recombination
into the genome of the host cell. The additional nucleic acid
sequences enable the vector to be integrated into the host cell
genome at a precise location(s) in the chromosome(s). To increase
the likelihood of integration at a precise location, the
integrational elements should preferably contain a sufficient
number of nucleic acids, such as 100 to 1,500 base pairs,
preferably 400 to 1,500 base pairs, and most preferably 800 to
1,500 base pairs, which are highly homologous with the
corresponding target sequence to enhance the probability of
homologous recombination. The integrational elements may be any
sequence that is homologous with the target sequence in the genome
of the host cell. Furthermore, the integrational elements may be
non-encoding or encoding nucleic acid sequences. On the other hand,
the vector may be integrated into the genome of the host cell by
non-homologous recombination.
[0099] For autonomous replication, the vector may further comprise
an origin of replication enabling the vector to replicate
autonomously in the host cell in question. Examples of bacterial
origins of replication are the origins of replication of plasmids
pBR322, pUC19, pACYC177, and pACYC184 permitting replication in E.
coli, and pUB110, pE194, pTA1060, and pAMR1 permitting replication
in Bacillus. Examples of origins of replication for use in a yeast
host cell are the 2 micron origin of replication, ARS1, ARS4, the
combination of ARS1 and CEN3, and the combination of ARS4 and CEN6.
The origin of replication may be one having a mutation which makes
its functioning temperature-sensitive in the host cell (see, e.g.,
Ehrlich, 1978, Proceedings of the National Academy of Sciences USA
75: 1433).
[0100] More than one copy of a nucleic acid sequence of the present
invention may be inserted into the host cell to increase production
of the gene product. An increase in the copy number of the nucleic
acid sequence can be obtained by integrating at least one
additional copy of the sequence into the host cell genome or by
including an amplifiable selectable marker gene with the nucleic
acid sequence where cells containing amplified copies of the
selectable marker gene, and thereby additional copies of the
nucleic acid sequence, can be selected for by cultivating the cells
in the presence of the appropriate selectable agent.
[0101] The procedures used to ligate the elements described above
to construct the recombinant expression vectors of the present
invention are well known to one skilled in the art (see, e.g.,
Sambrook et al., 1989, supra).
Host Cells
[0102] The present invention also relates to recombinant host
cells, comprising a nucleic acid sequence of the invention, which
are advantageously used in the recombinant production of the
polypeptides. A vector comprising a nucleic acid sequence of the
present invention is introduced into a host cell so that the vector
is maintained as a chromosomal integrant or as a self-replicating
extra-chromosomal vector as described earlier. The term "host cell"
encompasses any progeny of a parent cell that is not identical to
the parent cell due to mutations that occur during replication. The
choice of a host cell will to a large extent depend upon the gene
encoding the polypeptide and its source.
[0103] The host cell may be a unicellular microorganism, e.g., a
prokaryote, or a non-unicellular microorganism, e.g., a
eukaryote.
[0104] Useful unicellular cells are bacterial cells such as gram
positive bacteria including, but not limited to, a Bacillus cell,
e.g., Bacillus alkalophllus, Bacillus amyloliquefaciens, Bacillus
brevis, Bacillus circulans, Bacillus clausii, Bacillus coagulans,
Bacillus lautus, Bacillus lentus, Bacillus licheniformis, Bacillus
megaterium, Bacillus stearothermophilus, Bacillus subtilis, and
Bacillus thuringiensis; or a Streptomyces cell, e.g., Streptomyces
lividans or Streptomyces murinus, or gram negative bacteria such as
E. coli and Pseudomonas sp. In a preferred embodiment, the
bacterial host cell is a Bacillus lentus, Bacillus licheniformis,
Bacillus stearothermophilus or Bacillus subtilis cell. In another
preferred embodiment, the Bacillus cell is an alkalophilic
Bacillus.
[0105] The introduction of a vector into a bacterial host cell may,
for instance, be effected by protoplast transformation (see, e.g.,
Chang and Cohen, 1979, Molecular General Genetics 168: 111-115),
using competent cells (see, e.g., Young and Spizizin, 1961, Journal
of Bacteriology 81: 823-829, or Dubnau and Davidoff-Abelson, 1971,
Journal of Molecular Biology 56: 209-221), electroporation (see,
e.g., Shigekawa and Dower, 1988, Biotechniques 6: 742-751), or
conjugation (see, e.g., Koehler and Thorne, 1987, Journal of
Bacteriology 169: 5771-5278).
Methods of Production
[0106] The present invention also relates to methods for producing
an alpha-amylase of the present invention comprising (a)
cultivating a strain, which in its wild-type form is capable of
producing the polypeptide, to produce a supernatant comprising the
polypeptide; and (b) recovering the polypeptide. Preferably, the
strain is of the genus Bacillus sp.
[0107] The present invention also relates to methods for producing
an alpha-amylase of the present invention comprising (a)
cultivating a host cell under conditions conducive for production
of the polypeptide; and (b) recovering the polypeptide.
[0108] The present invention also relates to methods for producing
an alpha-amylase of the present invention comprising (a)
cultivating a host cell under conditions conducive for production
of the polypeptide, wherein the host cell comprises a mutant
nucleic acid sequence having at least one mutation in the mature
polypeptide coding region of SEQ ID NO: 23 or SEQ ID NO: 25,
wherein the mutant nucleic acid sequence encodes a polypeptide
which consists of amino acids 1 to 485 of SEQ ID NO: 24 or SEQ ID
NO: 26, and (b) recovering the polypeptide.
Mutant Alpha-Amylase
[0109] The present invention also relates to alpha-amylase
mutants.
The Termamyl-Like Alpha-Amylase
[0110] It is well known that a number of alpha-amylases produced by
Bacillus spp. are highly homologous on the amino acid level. For
instance, the B. licheniformis alpha-amylase comprising the amino
acid sequence shown in SEQ ID NO: 4 (commercially available as
Termamyl.TM.) has been found to be about 89% homologous with the B.
amyloliquefaciens alpha-amylase comprising the amino acid sequence
shown in SEQ ID NO: 5 and about 79% homologous with the B.
stearothermophilus alpha-amylase comprising the amino acid sequence
shown in SEQ ID NO: 3. Further homologous alpha-amylases include an
alpha-amylase derived from a strain of the Bacillus sp. NCIB 12289,
NCIB 12512, NCIB 12513 or DSM 9375, all of which are described in
detail in WO 95/26397, and the alpha-amylase described by Tsukamoto
et al., Biochemical and Biophysical Research Communications, 151
(1988), pp. 25-31. Also the novel alpha-amylase of the invention,
of which a specific embodiment is shown in SEQ ID NO: 24 (and SEQ
ID NO: 26), is contemplated as the parent alpha-amylase to be
mutated according to the invention.
[0111] Still further homologous alpha-amylases include the
alpha-amylase produced by the B. licheniformis strain described in
EP 0252666 (ATCC 27811), and the alpha-amylases identified in WO
91/00353 and WO 94/18314. Other commercial Termamyl-like B.
licheniformis alpha-amylases are Duramyl.TM. from Novo Nordisk,
Optitherm.TM. and Takatherm.TM. (available from Solvay),
Maxamyl.TM. (available from Gist-brocades/Genencor), Spezym AA.TM.
and Spezyme Delta AA.TM. (available from Genencor), and
Keistase.TM. (available from Daiwa).
[0112] Because of the substantial homology found between these
alpha-amylases, they are considered to belong to the same class of
alpha-amylases, namely the class of "Termamyl-like
alpha-amylases".
[0113] Accordingly, in the present context, the term "Termamyl-like
alpha-amylase" is intended to indicate an alpha-amylase which, at
the amino acid level, exhibits a substantial homology to
Termamyl.TM., i.e., the B. licheniformis alpha-amylase having the
amino acid sequence shown in SEQ ID NO: 4 herein. In other words, a
Termamyl-like alpha-amylase is an alpha-amylase which has the amino
acid sequence shown in SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7 or 8 herein,
and the amino acid sequence shown in SEQ ID NO: 1 of WO 95/26397
(the same as the amino acid sequence shown as SEQ ID NO: 7 herein)
or in SEQ ID NO: 2 of WO 95/26397 (the same as the amino acid
sequence shown as SEQ ID NO: 8 herein) or in Tsukamoto et al.,
1988, (which amino acid sequence is shown in SEQ ID NO: 6 herein)
or i) which displays at least 60%, preferred at least 70%, more
preferred at least 75%, even more preferred at least 80%,
especially at least 85%, especially preferred at least 90%, even
especially more preferred at least 95% homology with at least one
of said amino acid sequences shown in SEQ ID NOS: 1 or 2 or 3 or 4
or 5 or 6 or 7 or 8 and/or ii) displays immunological
cross-reactivity with an antibody raised against at least one of
said alpha-amylases, and/or iii) is encoded by a DNA sequence which
hybridizes to the DNA sequences encoding the above-specified
alpha-amylases which are apparent from SEQ ID NOS: 9, 10, 11, 12 or
13 of the present application (which encoding sequences encode the
amino acid sequences shown in SEQ ID NOS: 1, 2, 3, 4 and 5 herein,
respectively), from SEQ ID NO: 4 of WO 95/26397 (which DNA
sequence, together with the stop codon TAA, is shown in SEQ ID NO:
14 herein and encodes the amino acid sequence shown in SEQ ID NO: 8
herein) and from SEQ ID NO: 5 of WO 95/26397 (shown in SEQ ID NO:
15 herein), respectively.
[0114] In connection with property i), the "homology" may be
determined by use of any conventional algorithm, preferably by use
of the GAP progamme from the GCG package version 7.3 (June 1993)
using default values for GAP penalties, which is a GAP creation
penalty of 3.0 and GAP extension penalty of 0.1, (Genetic Computer
Group (1991) Programme Manual for the GCG Package, version 7, 575
Science Drive, Madison, Wis., USA 53711).
[0115] A structural alignment between Termamyl and a Termamyl-like
alpha-amylase may be used to identify equivalent/corresponding
positions in other Termamyl-like alpha-amylases. One method of
obtaining said structural alignment is to use the Pile Up programme
from the GCG package using default values of gap penalties, i.e., a
gap creation penalty of 3.0 and gap extension penalty of 0.1. Other
structural alignment methods include the hydrophobic cluster
analysis (Gaboriaud et al., 1987, FEBS Letters 224:149-155) and
reverse threading (Huber and Torda, 1998, Protein Science 7(1):
142-149.
[0116] Property ii) of the alpha-amylase, i.e., the immunological
cross reactivity, may be assayed using an antibody raised against,
or reactive with, at least one epitope of the relevant
Termamyl-like alpha-amylase. The antibody, which may either be
monoclonal or polyclonal, may be produced by methods known in the
art, e.g., as described by Hudson et al., Practical Immunology,
Third edition (1989), Blackwell Scientific Publications. The
immunological cross-reactivity may be determined using assays known
in the art, examples of which are Western Blotting or radial
immunodiffusion assay, e.g., as described by Hudson et al., 1989.
In this respect, immunological cross-reactivity between the
alpha-amylases having the amino acid sequences SEQ ID NO: 1, 2, 3,
4, 5, 6, 7, or 8 respectively, have been found.
[0117] The oligonucleotide probe used in the characterization of
the Termamyl-like alpha-amylase in accordance with property iii)
above may suitably be prepared on the basis of the full or partial
nucleotide or amino acid sequence of the alpha-amylase in
question.
[0118] Suitable conditions for testing hybridization involve
presoaking in 5.times.SSC and prehybridizing for 1 hour at
.about.40.degree. C. in a solution of 20% formamide,
5.times.Denhardt's solution, 50 mM sodium phosphate, pH 6.8, and 50
mg of denatured sonicated calf thymus DNA, followed by
hybridization in the same solution supplemented with 100 mM ATP for
18 hours at .about.40.degree. C., followed by three times washing
of the filter in 2.times.SSC, 0.2% SDS at 40.degree. C. for 30
minutes (low stringency), preferred at 50.degree. C. (medium
stringency), more preferably at 65.degree. C. (high stringency),
even more preferably at .about.75.degree. C. (very high
stringency). More details about the hybridization method can be
found in Sambrook et al., Molecular Cloning: A Laboratory Manual,
2nd Ed., Cold Spring Harbor, 1989.
[0119] In the present context, "derived from" is intended not only
to indicate an alpha-amylase produced or producible by a strain of
the organism in question, but also an alpha-amylase encoded by a
DNA sequence isolated from such strain and produced in a host
organism transformed with said DNA sequence. Finally, the term is
intended to indicate an alpha-amylase which is encoded by a DNA
sequence of synthetic and/or cDNA origin and which has the
identifying characteristics of the alpha-amylase in question. The
term is also intended to indicate that the parent alpha-amylase may
be a variant of a naturally occurring alpha-amylase, i.e., a
variant which is the result of a modification (insertion,
substitution, deletion) of one or more amino acid residues of the
naturally occurring alpha-amylase.
Parent Hybrid Alpha-Amylases
[0120] The parent alpha-amylase may be a hybrid alpha-amylase,
i.e., an alpha-amylase which comprises a combination of partial
amino acid sequences derived from at least two alpha-amylases.
[0121] The parent hybrid alpha-amylase may be one which on the
basis of amino acid homology and/or immunological cross-reactivity
and/or DNA hybridization (as defined above) can be determined to
belong to the Termamyl-like alpha-amylase family. In this case, the
hybrid alpha-amylase is typically composed of at least one part of
a Termamyl-like alpha-amylase and part(s) of one or more other
alpha-amylases selected from Termamyl-like alpha-amylases or
non-Termamyl-like alpha-amylases of microbial (bacterial or fungal)
and/or mammalian origin.
[0122] Thus, the parent hybrid alpha-amylase may comprise a
combination of partial amino acid sequences deriving from at least
two Termamyl-like alpha-amylases, or from at least one
Termamyl-like and at least one non-Termamyl-like bacterial
alpha-amylase, or from at least one Termamyl-like and at least one
fungal alpha-amylase. The Termamyl-like alpha-amylase from which a
partial amino acid sequence derives may, e.g., be any of those
specific Termamyl-like alpha-amylases referred to herein.
[0123] For instance, the parent alpha-amylase may comprise a
C-terminal part of an alpha-amylase derived from a strain of B.
licheniformis, and a N-terminal part of an alpha-amylase derived
from a strain of B. amyloliquefaciens or from a strain of B.
stearothermophilus. For instance, the parent alpha-amylase may
comprise at least 430 amino acid residues of the C-terminal part of
the B. licheniformis alpha-amylase, and may, e.g., comprise a) an
amino acid segment corresponding to the 37 N-terminal amino acid
residues of the B. amyloliquefaciens alpha-amylase having the amino
acid sequence shown in SEQ ID NO: 5 and an amino acid segment
corresponding to the 445 C-terminal amino acid residues of the B.
licheniformis alpha-amylase having the amino acid sequence shown in
SEQ ID NO: 4, or b) an amino acid segment corresponding to the 68
N-terminal amino acid residues of the B. stearothermophilus
alpha-amylase having the amino acid sequence shown in SEQ ID NO: 3
and an amino acid segment corresponding to the 415 C-terminal amino
acid residues of the B. licheniformis alpha-amylase having the
amino acid sequence shown in SEQ ID NO: 4.
[0124] The non-Termamyl-like alpha-amylase may, e.g., be a fungal
alpha-amylase, a mammalian or a plant alpha-amylase or a bacterial
alpha-amylase (different from a Termamyl-like alpha-amylase).
Specific examples of such alpha-amylases include the Aspergillus
oryzae TAKA alpha-amylase, the A. niger acid alpha-amylase, the
Bacillus subtilis alpha-amylase, the porcine pancreatic
alpha-amylase and a barley alpha-amylase. All of these
alpha-amylases have elucidated structures which are markedly
different from the structure of a typical Termamyl-like
alpha-amylase as referred to herein.
[0125] The fungal alpha-amylases mentioned above, i.e., derived
from A. niger and A. oryzae, are highly homologous on the amino
acid level and generally considered to belong to the same family of
alpha-amylases. The fungal alpha-amylase derived from Aspergillus
oryzae is commercially available under the tradename
Fungamyl.TM..
[0126] Furthermore, when a particular variant of a Termamyl-like
alpha-amylase (variant of the invention) is referred to--in a
conventional manner--by reference to modification (e.g., deletion
or substitution) of specific amino acid residues in the amino acid
sequence of a specific Termamyl-like alpha-amylase, it is to be
understood that variants of another Termamyl-like alpha-amylase
modified in the equivalent position(s) (as determined from the best
possible amino acid sequence alignment between the respective amino
acid sequences) are encompassed thereby.
[0127] A preferred embodiment of a variant of the invention is one
derived from a B. licheniformis alpha-amylase (as parent
Termamyl-like alpha-amylase), e.g., one of those referred to above,
such as the B. licheniformis alpha-amylase having the amino acid
sequence shown in SEQ ID NO: 4.
Construction of Variants of the Invention
[0128] The construction of the variant of interest may be
accomplished by cultivating a microorganism comprising a DNA
sequence encoding the variant under conditions which are conducive
for producing the variant. The variant may then subsequently be
recovered from the resulting culture broth. This is described in
detail further below.
Altered Properties of Variants of the Invention
[0129] The following discusses the relationship between mutations
which may be present in variants of the invention, and desirable
alterations in properties (relative to those a parent,
Termamyl-like alpha-amylase) which may result therefrom.
Increased Thermostability at Acidic pH and/or at Low Ca.sup.2+
Concentration
[0130] Mutations of particular relevance in relation to obtaining
variants according to the invention having increased
thermostability at acidic pH and/or at low Ca.sup.2+ concentration
include mutations at the following positions (relative to B.
licheniformis alpha-amylase, SEQ ID NO: 4): H156, N172, A181, N188,
N190, H205, D207, A209, A210, E211, Q264, N265.
[0131] In the context of the invention the term "acidic pH" means a
pH below 7.0, especially below the pH range, in which industrial
starch liquefaction processes are normally performed, which is
between pH 5.5 and 6.2.
[0132] In the context of the present invention the term "low
Calcium concentration" means concentrations below the normal level
used in industrial starch liquefaction. Normal concentrations vary
depending of the concentration of free Ca.sup.2+ in the corn.
Normally a dosage corresponding to 1 mM (40 ppm) is added which
together with the level in corn gives between 40 and 60 ppm free
Ca.sup.2+.
[0133] In the context of the invention the term "high
tempertatures" means temperatures between 95.degree. C. and
160.degree. C., especially the temperature range in which
industrial starch liquefaction processes are normally performed,
which is between 95.degree. C. and 105.degree. C.
[0134] The inventors have now found that the thermostability at
acidic pH and/or at low Ca.sup.2+ concentration may be increased
even more by combining certain mutations including the above
mentioned mutations and/or I201 with each other.
[0135] Said "certain" mutations are the following (relative to B.
licheniformis alpha-amylase, SEQ ID NO: 4): [0136] N190, D207,
E211, Q264 and I201.
[0137] Said mutation may further be combined with deletions in one,
preferably two or even three positions as described in WO 96/23873
(i.e., in positions R181, G182, T183, G184 in SEQ ID NO: 1 herein).
According to the invention variants of a parent Termamyl-like
alpha-amylase with alpha-amylase activity comprising mutations in
two, three, four, five or six of the above positions are
contemplated.
[0138] It should be emphasized that not only the Termamyl-like
alpha-amylases mentioned specifically below are contemplated. Also
other commercial Termamyl-like alpha-amylases are contemplated. An
unexhaustive list of such alpha-amylases is the following:
alpha-amylases produced by the B. licheniformis strain described in
EP 0252666 (ATCC 27811), and the alpha-amylases identified in WO
91/00353 and WO 94/18314. Other commercial Termamyl-like B.
licheniformis alpha-amylases are Optitherm.TM. and Takatherm.TM.
(available from Solvay), Maxamyl.TM. (available from
Gist-brocades/Genencor), Spezym AA.TM. Spezyme Delta AA.TM.
(available from Genencor), and Keistase.TM. (available from
Daiwa).
[0139] It may be mentioned here that amino acid residues,
respectively, at positions corresponding to N190, I201, D207 and
E211, respectively, in SEQ ID NO: 4 constitute amino acid residues
which are conserved in numerous Termamyl-like alpha-amylases. Thus,
for example, the corresponding positions of these residues in the
amino acid sequences of a number of Termamyl-like alpha-amylases
which have already been mentioned (vide supra) are as follows:
TABLE-US-00001 TABLE 1 Termamyl-like alpha-amylase N I D E Q B.
licheniformis (SEQ ID NO: 4) N190 I201 D207 E211 Q264 B.
amyloliquefaciens (SEQ ID NO: 5) N190 V201 D207 E211 Q264 B.
stearothermophilus (SEQ ID NO: 3) N193 L204 E210 E214 -- Bacillus
WO 95/26397 (SEQ ID NO: 2) N195 V206 E212 E216 -- Bacillus WO
95/26397 (SEQ ID NO: 1) N195 V206 E212 E216 -- "Bacillus sp. #707"
(SEQ ID NO: 6) N195 I206 E212 E216 -- Bacillus sp. AA560 (SEQ ID
NO: 24) N195 I206 E212 E216 --
[0140] Mutations of these conserved amino acid residues are very
important in relation to improving thermostability at acidic pH
and/or at low calcium concentration, and the following mutations
are of particular interest in this connection (with reference to
the numbering of the B. licheniformis amino acid sequence shown in
SEQ ID NO: 4).
[0141] Pair-wise amino acid deletions at positions corresponding to
R179-G182 in SEQ ID NO: 5 corresponding to a gap in SEQ ID NO: 4.
when aligned with a numerous Termamyl-like alpha-amylases. Thus,
for example, the corresponding positions of these residues in the
amino acid sequences of a number of Termamyl-like alpha-amylases
which have already been mentioned (vide supra) are as follows:
TABLE-US-00002 TABLE 2 Pair wise amino acid Termamyl-like
alpha-amylase deletions among B. amyloliquefaciens (SEQ ID NO: 5)
R176, G177, E178, G179 B. stearothermophilus (SEQ ID NO: 3) R179,
G180, I181, G182 Bacillus WO 95/26397 (SEQ ID NO: 2) R181, G182,
T183, G184 Bacillus WO 95/26397 (SEQ ID NO: 1) R181, G182, D183,
G184 "Bacillus sp. #707" (SEQ ID NO: 6) R181, G182, H183, G184
Bacillus sp. (AA560) (SEQ ID NO: 24) R181, G182, H183, G184
[0142] When using SEQ ID NO: 1-6 or SEQ ID NO: 24 (or SEQ ID NO:
26) as the backbone (i.e., as the parent Termamyl-like
alpha-amylase) two, three, four, five or six mutations may
according to the invention be made in the following
regions/positions to increase the thermostability at acidic pH
and/or at low Ca.sup.2+ concentrations (relative to the parent):
[0143] (Relative to SEQ ID NO: 1 Herein): [0144] 1: R181*, G182*,
T183*, G184* [0145] 2: N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V;
[0146] 3: V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; [0147] 4:
E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0148] 5:
E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0149] 6:
K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0150] (Relative to SEQ
ID NO: 2 Herein): [0151] 1: R181*,G182*,D183*,G184* [0152] 2:
N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0153] 3:
V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; [0154] 4:
E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0155] 5:
E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0156] 6:
K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0157] (Relative to SEQ
ID NO: 3 Herein): [0158] 1: R179*,G180,I181*,G182* [0159] 2:
N193A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0160] 3:
L204A,R,D,N,C,E,Q,G,H,I,K,M,F,P,S,T,W,Y,V; [0161] 4:
E210A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0162] 5:
E214A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0163] 6:
S267A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,T,W,Y,V [0164] Relative to SEQ ID
NO: 4 Herein): [0165] 1: Q178*,G179* [0166] 2:
N190A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0167] 3:
I201A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V; [0168] 4:
D207A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0169] 5:
E211A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0170] 6:
Q264A,R,D,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0171] (Relative to SEQ
ID NO: 5 Herein): [0172] 1: R176*,G177*,E178,G179* [0173] 2:
N190A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0174] 3:
V201A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; [0175] 4:
D207A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0176] 5:
E211A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0177] 6:
Q264A,R,D,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0178] (Relative to SEQ
ID NO: 6 Herein): [0179] 1: R181*,G182*,H183*,G184* [0180] 2:
N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0181] 3:
I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V; [0182] 4:
E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0183] 5:
E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0184] 6:
K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; and [0185] (Relative to
SEQ ID NO: 24) [0186] 1: R181*,G182*,H183*,G184* [0187] 2:
N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0188] 3:
I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V; [0189] 4:
E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0190] 5:
E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0191] 6:
K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V.
[0192] Contemplated according to the present invention is combining
three, four, five or six mutation.
[0193] Specific double mutations for backbone SEQ ID NO: 1-6 and
SEQ ID NO: 24 and SEQ ID NO: 26 are listed in the following.
[0194] Using SEQ ID NO: 1 as the backbone the following double
mutations are contemplated according to the invention: [0195]
-R181*/G182*/N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0196]
-G182*/T183*/N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0197]
-T183*/G184*/N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0198]
-R181*/G182*/V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; [0199]
-G182*/T183*/V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; [0200]
-T183*/G184*/V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; [0201]
-R181*/G182*/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0202]
-G182*/T183*/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0203]
-T183*/G184*/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V: [0204]
-R181*/G182*/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0205]
-G182*/T183*/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0206]
-T183*/G184*/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0207]
-R181*/G182*/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0208]
-G182*/T183*/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0209]
-T183*/G184*/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0210]
-N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V/V206A,R,D,N,C,E,Q,G,H,I,L,K,M,-
F,P,S,T,W,Y; [0211]
-N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,-
P,S,T,W,Y,V; [0212]
-N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,-
P,S,T,W,Y,V; [0213]
-N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,-
P,S,T,W,Y,V; [0214]
-V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,-
P,S,T,W,Y,V; [0215]
-V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,-
P,S,T,W,Y,V; [0216]
-V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,-
P,S,T,W,Y,V; [0217]
-E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,-
P,S,T,W,Y,V; [0218]
E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P-
,S,T,W,Y,V; [0219]
-E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,-
P,S,T,W,Y,V;
[0220] Using SEQ ID NO: 2 as the backbone the following double
mutations are contemplated according to the invention: [0221]
-R181*/G182*/N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0222]
-G182*/D183*/N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0223]
-D183*/G184*/N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0224]
-R181*/G182*/V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; [0225]
-G182*/T183*/V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; [0226]
-T183*/G184*/V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; [0227]
-R181*/G182*/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0228]
-G182*/T183*/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0229]
-T183*/G184*/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0230]
-R181*/G182*/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0231]
-G182*/T183*/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0232]
-T183*/G184*/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0233]
-R181*/G182*/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0234]
-G182*/T183*/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0235]
-T183*/G184*/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0236]
-N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0237]
/V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; [0238]
-N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0239]
/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0240]
-N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0241]
/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0242]
-N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0243]
/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0244]
-V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y [0245]
/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0246]
-V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y [0247]
/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0248]
-V206A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y [0249]
/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0250]
-E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0251]
/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0252]
-E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0253]
/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0254]
-E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0255]
/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V;
[0256] Using SEQ ID NO: 3 as the backbone the following double
mutations are contemplated according to the invention: [0257]
-R179*/G180*/N193A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0258]
-G180*/I181*/N193A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0259]
-I181*/G182*/N193A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0260]
-R179*/G180*/L204A,R,D,N,C,E,Q,G,H,I,K,M,F,P,S,T,W,Y,V; [0261]
-G180*/I181*/L204A,R,D,N,C,E,Q,G,H,I,K,M,F,P,S,T,W,Y,V; [0262]
-I181*/G182*/L204A,R,D,N,C,E,Q,G,H,I,K,M,F,P,S,T,W,Y,V; [0263]
-R179*/G180*/E210A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0264]
-G180*/I181*/E210A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0265]
-I181*/G182*/E210A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0266]
-R179*/G180*/E214A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0267]
-G180*/I181*/E214A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0268]
-I181*/G182*/E214A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0269]
-R179*/G180*/S267A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,T,W,Y,V; [0270]
-G180*/I181*/S267A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,T,W,Y,V; [0271]
-I181*/G182*/S267A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,T,W,Y,V; [0272]
-N193A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0273]
/L204A,R,D,N,C,E,Q,G,H,I,K,M,F,P,S,T,W,Y,V; [0274]
-N193A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0275]
/E210A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0276]
-N193A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0277]
/E214A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0278]
-N193A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0279]
/S267A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,T,W,Y,V; [0280]
-L204A,R,D,N,C,E,Q,G,H,I,K,M,F,P,S,T,W,Y,V [0281]
/E210A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0282]
-L204A,R,D,N,C,E,Q,G,H,I,K,M,F,P,S,T,W,Y,V [0283]
/E214A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0284]
-L204A,R,D,N,C,E,Q,G,H,I,K,M,F,P,S,T,W,Y,V [0285]
/S267A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,T,W,Y,V; [0286]
-E210A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0287]
/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0288]
-E210A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0289]
/S267A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,T,W,Y,V; [0290]
-E214A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0291]
/S267A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,T,W,Y,V;
[0292] Using SEQ ID NO: 4 as the backbone the following double
mutations are contemplated according to the invention: [0293]
-Q178*/G179*/N190A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0294]
-Q178*/G179*/I201A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V; [0295]
-Q178*/G179*/D207A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0296]
-Q178*/G179*/E211A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0297]
-R179*/G180*/Q264A,R,D,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0298]
-N190/I201A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V; [0299]
-N190/D207A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0300]
-N190/E211A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0301]
-N190/Q264A,R,D,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0302]
-I201/D207A,R,N,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0303]
-I201/E211A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0304]
-I201/Q264A,R,D,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0305]
-D207/E211A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0306]
-D207/Q264A,R,D,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0307]
-E211/Q264A,R,D,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V;
[0308] Using SEQ ID NO: 5 as the backbone the following double
mutations are contemplated according to the invention: [0309]
-R176*/G177*/N190A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0310]
-G177*/E178*/N190A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0311]
-E178*/G179*/N190A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0312]
-R176*/G177*/V201A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; [0313]
-G176*/E178*N201A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; [0314]
-E178*/G179*N201A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; [0315]
-R176*/G177*/D207A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0316]
-G177*/E178*/D207A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0317]
-E178*/G179*/D207A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0318]
-R176*/G177*/E211A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0319]
-G177*/E178*/E211A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0320]
-E178*/G179*/E211A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0321]
-R176*/G177*/Q264A,R,D,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0322]
-G177*/E178*/Q264A,R,D,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0323]
-E178*/G179*/Q264A,R,D,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0324]
-N190A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0325]
/V201A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y; [0326]
-N190A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0327]
/D207A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0328]
-N190A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0329]
/E211A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0330]
-N190A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0331]
/Q264A,R,D,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0332]
-V201A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y [0333]
/D207A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0334]
-V201A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y [0335]
/E211A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0336]
-V201A,R,D,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y [0337]
/Q264A,R,D,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0338]
-D207A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0339]
/E211A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0340]
-D207A,R,N,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0341]
/Q264A,R,D,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0342]
-E211A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0343]
/Q264A,R,D,N,C,E,G,H,I,L,K,M,F,P,S,T,W,Y,V. [0344] Using SEQ ID NO:
6 as the backbone the following double mutations are contemplated
according to the invention: [0345]
-R181*/G182*/N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0346]
-G182*/H183*/N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0347]
-H183*/G184*/N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0348]
-R181*/G182*/I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V; [0349]
-G182*/H183*/I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V; [0350]
-H183*/G184*/I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V; [0351]
-R181*/G182*/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0352]
-G182*/H183*/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0353]
-H183*/G184*/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0354]
-R181*/G182*/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0355]
-G182*/H183*/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0356]
-H183*/G184*/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0357]
-R181*/G182*/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0358]
-G182*/H183*/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0359]
-H183*/G184*/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0360]
-N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0361]
/I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V; [0362]
-N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0363]
/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0364]
-N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0365]
/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0366]
-N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0367]
/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0368]
-I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V [0369]
/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0370]
-I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V [0371]
/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0372]
-I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V [0373]
/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0374]
-E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,-
P,S,T,W,Y,V; [0375]
-E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,-
P,S,T,W,Y,V; [0376]
-E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,-
P,S,T,W,Y,V.
[0377] Using SEQ ID NO: 24 as the backbone the following double
mutations are contemplated according to the invention: [0378]
-R181*/G182*/N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0379]
-G182*/H183*/N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0380]
-H183*/G184*/N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0381]
-R181*/G182*/I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V; [0382]
-G182*/H183*/I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V; [0383]
-H183*/G184*/I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V; [0384]
-R181*/G182*/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0385]
-G182*/H183*/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0386]
-H183*/G184*/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0387]
-R181*/G182*/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0388]
-G182*/H183*/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0389]
-H183*/G184*/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0390]
-R181*/G182*/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0391]
-G182*/H183*/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0392]
-H183*/G184*/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0393]
-N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0394]
/I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V; [0395]
-N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0396]
/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0397]
-N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0398]
/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0399]
-N195A,R,D,C,E,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V [0400]
/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0401]
-I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V [0402]
/E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0403]
-I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V [0404]
/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V; [0405]
-I206A,R,D,N,C,E,Q,G,H,L,K,M,F,P,S,T,W,Y,V [0406]
/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,P,S,T,W,Y,V; [0407]
-E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V/E216A,R,D,N,C,Q,G,H,I,L,K,M,F,-
P,S,T,W,Y,V; [0408]
-E212A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,-
P,S,T,W,Y,V; [0409]
-E216A,R,D,N,C,Q,G,H,I,L,K,M,F,P,S,T,W,Y,V/K269A,R,D,N,C,E,Q,G,H,I,L,M,F,-
P,S,T,W,Y,V.
[0410] All Termamyl-like alpha-amylase defined above may suitably
be used as backbone for preparing variants of the invention.
[0411] However, in a preferred embodiment the variant comprises the
following mutations: N190F/Q264S in SEQ ID NO: 4 or in
corresponding positions in another parent Termamyl-like
alpha-amylases.
[0412] In another embodiment the variant of the invention comprises
the following mutations: I181*/G182*/N193F in SEQ ID NO: 3 (TVB146)
or in corresponding positions in another parent Termamyl-like
alpha-amylases. Said variant may further comprise a substitution in
position E214Q.
[0413] In a preferred embodiment of the invention the parent
Termamyl-like alpha-amylase is a hybrid alpha-amylase of SEQ ID NO:
4 and SEQ ID NO: 5. Specifically, the parent hybrid Termamyl-like
alpha-amylase may be a hybrid alpha-amylase comprising the 445
C-terminal amino acid residues of the B. licheniformis
alpha-amylase shown in SEQ ID NO: 4 and the 37 N-terminal amino
acid residues of the alpha-amylase derived from B.
amyloliquefaciens shown in SEQ ID NO: 5, which may suitably further
have the following mutations: H156Y+A181T+N190F+A209V+Q264S (using
the numbering in SEQ ID NO: 4). The latter mentioned hybrid is used
in the examples below and is referred to as LE174.
General Mutations of the Invention
[0414] It may be preferred that a variant of the invention
comprises one or more modifications in addition to those outlined
above. Thus, it may be advantageous that one or more proline
residues present in the part of the alpha-amylase variant which is
modified is/are replaced with a non-proline residue which may be
any of the possible, naturally occurring non-proline residues, and
which preferably is an alanine, glycine, serine, threonine, valine
or leucine.
[0415] Analogously, it may be preferred that one or more cysteine
residues present among the amino acid residues with which the
parent alpha-amylase is modified is/are replaced with a
non-cysteine residue such as serine, alanine, threonine, glycine,
valine or leucine.
[0416] Furthermore, a variant of the invention may--either as the
only modification or in combination with any of the above outlined
modifications--be modified so that one or more Asp and/or Glu
present in an amino acid fragment corresponding to the amino acid
fragment 185-209 of SEQ ID NO: 4 is replaced by an Asn and/or Gln,
respectively. Also of interest is the replacement, in the
Termamyl-like alpha-amylase, of one or more of the Lys residues
present in an amino acid fragment corresponding to the amino acid
fragment 185-209 of SEQ ID NO: 4 by an Arg.
[0417] It will be understood that the present invention encompasses
variants incorporating two or more of the above outlined
modifications.
[0418] Furthermore, it may be advantageous to introduce
point-mutations in any of the variants described herein.
[0419] Mutations with may suitably made include mutations in the
following positions: H133, M15, M197, A209.
Cloning a DNA Sequence Encoding an Alpha-Amylase
[0420] The DNA sequence encoding a parent alpha-amylase may be
isolated from any cell or microorganism producing the alpha-amylase
in question, using various methods well known in the art. First, a
genomic DNA and/or cDNA library should be constructed using
chromosomal DNA or messenger RNA from the organism that produces
the alpha-amylase to be studied. Then, if the amino acid sequence
of the alpha-amylase is known, homologous, labelled oligonucleotide
probes may be synthesized and used to identify
alpha-amylase-encoding clones from a genomic library prepared from
the organism in question. Alternatively, a labelled oligonucleotide
probe containing sequences homologous to a known alpha-amylase gene
could be used as a probe to identify alpha-amylase-encoding clones,
using hybridization and washing conditions of lower stringency.
[0421] Yet another method for identifying alpha-amylase-encoding
clones would involve inserting fragments of genomic DNA into an
expression vector, such as a plasmid, transforming
alpha-amylase-negative bacteria with the resulting genomic DNA
library, and then plating the transformed bacteria onto agar
containing a substrate for alpha-amylase, thereby allowing clones
expressing the alpha-amylase to be identified.
[0422] Alternatively, the DNA sequence encoding the enzyme may be
prepared synthetically by established standard methods, e.g., the
phosphoroamidite method described by Beaucage and Caruthers (1981)
or the method described by Matthes et al. (1984). In the
phosphoroamidite method, oligonucleotides are synthesized, e.g., in
an automatic DNA synthesizer, purified, annealed, ligated and
cloned in appropriate vectors.
[0423] Finally, the DNA sequence may be of mixed genomic and
synthetic origin, mixed synthetic and cDNA origin or mixed genomic
and cDNA origin, prepared by ligating fragments of synthetic,
genomic or cDNA origin (as appropriate, the fragments corresponding
to various parts of the entire DNA sequence), in accordance with
standard techniques. The DNA sequence may also be prepared by
polymerase chain reaction (PCR) using specific primers, for
instance as described in U.S. Pat. No. 4,683,202 or Saiki et al.
(1988).
Site-Directed Mutagenesis
[0424] Once an alpha-amylase-encoding DNA sequence has been
isolated, and desirable sites for mutation identified, mutations
may be introduced using synthetic oligonucleotides. These
oligonucleotides contain nucleotide sequences flanking the desired
mutation sites; mutant nucleotides are inserted during
oligonucleotide synthesis. In a specific method, a single-stranded
gap of DNA, bridging the alpha-amylase-encoding sequence, is
created in a vector carrying the alpha-amylase gene. Then the
synthetic nucleotide, bearing the desired mutation, is annealed to
a homologous portion of the single-stranded DNA. The remaining gap
is then filled in with DNA polymerase I (Klenow fragment) and the
construct is ligated using T4 ligase. A specific example of this
method is described in Morinaga et al. (1984). U.S. Pat. No.
4,760,025 discloses the introduction of oligonucleotides encoding
multiple mutations by performing minor alterations of the cassette.
However, an even greater variety of mutations can be introduced at
any one time by the Morinaga method, because a multitude of
oligonucleotides, of various lengths, can be introduced.
[0425] Another method for introducing mutations into
alpha-amylase-encoding DNA sequences is described in Nelson and
Long (1989). It involves the 3-step generation of a PCR fragment
containing the desired mutation introduced by using a chemically
synthesized DNA strand as one of the primers in the PCR reactions.
From the PCR-generated fragment, a DNA fragment carrying the
mutation may be isolated by cleavage with restriction endonucleases
and reinserted into an expression plasmid.
Random Mutagenesis
[0426] Random mutagenesis is suitably performed either as localised
or region-specific random mutagenesis in at least three parts of
the gene translating to the amino acid sequence shown in question,
or within the whole gene.
[0427] The random mutagenesis of a DNA sequence encoding a parent
alpha-amylase may be conveniently performed by use of any method
known in the art.
[0428] In relation to the above, a further aspect of the present
invention relates to a method for generating a variant of a parent
alpha-amylase, e.g., wherein the variant exhibits altered or
increased thermal stability relative to the parent, the method
comprising:
[0429] (a) subjecting a DNA sequence encoding the parent
alpha-amylase to random mutagenesis,
[0430] (b) expressing the mutated DNA sequence obtained in step (a)
in a host cell, and
[0431] (c) screening for host cells expressing an alpha-amylase
variant which has an altered property (i.e., thermal stability)
relative to the parent alpha-amylase.
[0432] Step (a) of the above method of the invention is preferably
performed using doped primers.
[0433] For instance, the random mutagenesis may be performed by use
of a suitable physical or chemical mutagenizing agent, by use of a
suitable oligonucleotide, or by subjecting the DNA sequence to PCR
generated mutagenesis. Furthermore, the random mutagenesis may be
performed by use of any combination of these mutagenizing agents.
The mutagenizing agent may, e.g., be one which induces transitions,
transversions, inversions, scrambling, deletions, and/or
insertions.
[0434] Examples of a physical or chemical mutagenizing agent
suitable for the present purpose include ultraviolet (UV)
ir-radiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine
(MNNG), O-methyl hydroxylamine, nitrous acid, ethyl methane
sulphonate (EMS), sodium bisulphite, formic acid, and nucleotide
analogues. When such agents are used, the mutagenesis is typically
performed by incubating the DNA sequence encoding the parent enzyme
to be mutagenized in the presence of the mutagenizing agent of
choice under suitable conditions for the mutagenesis to take place,
and selecting for mutated DNA having the desired properties.
[0435] When the mutagenesis is performed by the use of an
oligonucleotide, the oligonucleotide may be doped or spiked with
the three non-parent nucleotides during the synthesis of the
oligonucleotide at the positions which are to be changed. The
doping or spiking may be done so that codons for unwanted amino
acids are avoided. The doped or spiked oligonucleotide can be
incorporated into the DNA encoding the alpha-amylase enzyme by any
published technique, using e.g., PCR, LCR or any DNA polymerase and
ligase as deemed appropriate.
[0436] Preferably, the doping is carried out using "constant random
doping", in which the percentage of wild-type and mutation in each
position is predefined. Furthermore, the doping may be directed
toward a preference for the introduction of certain nucleotides,
and thereby a preference for the introduction of one or more
specific amino acid residues. The doping may be made, e.g., so as
to allow for the introduction of 90% wild type and 10% mutations in
each position. An additional consideration in the choice of a
doping scheme is based on genetic as well as protein-structural
constraints. The doping scheme may be made by using the DOPE
program which, inter alfa, ensures that introduction of stop codons
is avoided.
[0437] When PCR-generated mutagenesis is used, either a chemically
treated or non-treated gene encoding a parent alpha-amylase is
subjected to PCR under conditions that increase the
mis-incorporation of nucleotides (Deshler 1992; Leung et al.,
Technique, Vol. 1, 1989, pp. 11-15).
[0438] A mutator strain of E. coli (Fowler et al., 1974, Molec.
Gen. Genet. 133: 179-191), S. cereviseae or any other microbial
organism may be used for the random mutagenesis of the DNA encoding
the alpha-amylase by, e.g., transforming a plasmid containing the
parent glycosylase into the mutator strain, growing the mutator
strain with the plasmid and isolating the mutated plasmid from the
mutator strain. The mutated plasmid may be subsequently transformed
into the expression organism.
[0439] The DNA sequence to be mutagenized may be conveniently
present in a genomic or cDNA library prepared from an organism
expressing the parent alpha-amylase. Alternatively, the DNA
sequence may be present on a suitable vector such as a plasmid or a
bacteriophage, which as such may be incubated with or other-wise
exposed to the mutagenizing agent. The DNA to be mutagenized may
also be present in a host cell either by being integrated in the
genome of said cell or by being present on a vector harboured in
the cell. Finally, the DNA to be mutagenized may be in isolated
form. It will be understood that the DNA sequence to be subjected
to random mutagenesis is preferably a cDNA or a genomic DNA
sequence.
[0440] In some cases it may be convenient to amplify the mutated
DNA sequence prior to performing the expression step b) or the
screening step c). Such amplification may be performed in
accordance with methods known in the art, the presently preferred
method being PCR-generated amplification using oligonucleotide
primers prepared on the basis of the DNA or amino acid sequence of
the parent enzyme.
[0441] Subsequent to the incubation with or exposure to the
mutagenizing agent, the mutated DNA is expressed by culturing a
suitable host cell carrying the DNA sequence under conditions
allowing expression to take place. The host cell used for this
purpose may be one which has been transformed with the mutated DNA
sequence, optionally present on a vector, or one which was carried
the DNA sequence encoding the parent enzyme during the mutagenesis
treatment. Examples of suitable host cells are the following: gram
positive bacteria such as Bacillus subtilis, Bacillus
licheniformis, Bacillus lentus, Bacillus brevis, Bacillus
stearothermophilus, Bacillus alkalophilus, Bacillus
amyloliquefaciens, Bacillus coagulans, Bacillus circulans, Bacillus
lautus, Bacillus megaterium, Bacillus thuringiensis, Streptomyces
lividans or Streptomyces murinus; and gram-negative bacteria such
as E. coli.
[0442] The mutated DNA sequence may further comprise a DNA sequence
encoding functions permitting expression of the mutated DNA
sequence.
Localized Random Mutagenesis
[0443] The random mutagenesis may be advantageously localized to a
part of the parent alpha-amylase in question. This may, e.g., be
advantageous when certain regions of the enzyme have been
identified to be of particular importance for a given property of
the enzyme, and when modified are expected to result in a variant
having improved properties. Such regions may normally be identified
when the tertiary structure of the parent enzyme has been
elucidated and related to the function of the enzyme.
[0444] The localized, or region-specific, random mutagenesis is
conveniently performed by use of PCR generated mutagenesis
techniques as described above or any other suitable technique known
in the art. Alternatively, the DNA sequence encoding the part of
the DNA sequence to be modified may be isolated, e.g., by insertion
into a suitable vector, and said part may be subsequently subjected
to mutagenesis by use of any of the mutagenesis methods discussed
above.
Alternative Methods of Providing Alpha-Amylase Variants
[0445] Alternative methods for providing variants of the invention
include gene shuffling method known in the art including the
methods, e.g., described in WO 95/22625 (from Affymax Technologies
N.V.) and WO 96/00343 (from Novo Nordisk A/S).
Expression of Alpha-Amylase Variants
[0446] According to the invention, a DNA sequence encoding the
variant produced by methods described above, or by any alternative
methods known in the art, can be expressed, in enzyme form, using
an expression vector which typically includes control sequences
encoding a promoter, operator, ribosome binding site, translation
initiation signal, and, optionally, a repressor gene or various
activator genes.
[0447] The recombinant expression vector carrying the DNA sequence
encoding an alpha-amylase variant of the invention may be any
vector which may conveniently be subjected to recombinant DNA
procedures, and the choice of vector will often depend on the host
cell into which it is to be introduced. Thus, the vector may be an
autonomously replicating vector, i.e., a vector which exists as an
extrachromosomal entity, the replication of which is independent of
chromosomal replication, e.g., a plasmid, a bacteriophage or an
extrachromosomal element, minichromosome or an artificial
chromosome. Alternatively, the vector may be one which, when
introduced into a host cell, is integrated into the host cell
genome and replicated together with the chromosome(s) into which it
has been integrated.
[0448] In the vector, the DNA sequence should be operably connected
to a suitable promoter sequence. The promoter may be any DNA
sequence which shows transcriptional activity in the host cell of
choice and may be derived from genes encoding proteins either
homologous or heterologous to the host cell. Examples of suitable
promoters for directing the transcription of the DNA sequence
encoding an alpha-amylase variant of the invention, especially in a
bacterial host, are the promoter of the lac operon of E. coli, the
Streptomyces coelicolor agarase gene dagA promoters, the promoters
of the Bacillus licheniformis alpha-amylase gene (amyL), the
promoters of the Bacillus stearothermophilus maltogenic amylase
gene (amyM), the promoters of the Bacillus amyloliquefaciens
alpha-amylase (amyQ), the promoters of the Bacillus subtilis xylA
and xylB genes etc. For transcription in a fungal host, examples of
useful promoters are those derived from the gene encoding A. oryzae
TAKA amylase, Rhizomucor miehei aspartic proteinase, A. niger
neutral alpha-amylase, A. niger acid stable alpha-amylase, A. niger
glucoamylase, Rhizomucor miehei lipase, A. oryzae alkaline
protease, A. oryzae triose phosphate isomerase or A. nidulans
acetamidase.
[0449] The expression vector of the invention may also comprise a
suitable transcription terminator and, in eukaryotes,
polyadenylation sequences operably connected to the DNA sequence
encoding the alpha-amylase variant of the invention. Termination
and polyadenylation sequences may suitably be derived from the same
sources as the promoter.
[0450] The vector may further comprise a DNA sequence enabling the
vector to replicate in the host cell in question. Examples of such
sequences are the origins of replication of plasmids pUC19,
pACYC177, pUB110, pE194, pAMB1 and pIJ702.
[0451] The vector may also comprise a selectable marker, e.g., a
gene the product of which complements a defect in the host cell,
such as the dal genes from B. subtilis or B. licheniformis, or one
which confers antibiotic resistance such as ampicillin, kanamycin,
chloramphenicol or tetracyclin resistance. Furthermore, the vector
may comprise Aspergillus selection markers such as amdS, argB, niaD
and sC, a marker giving rise to hygromycin resistance, or the
selection may be accomplished by co-transformation, e.g., as
described in WO 91/17243.
[0452] While intracellular expression may be advantageous in some
respects, e.g., when using certain bacteria as host cells, it is
generally preferred that the expression is extracellular. In
general, the Bacillus alpha-amylases mentioned herein comprise a
preregion permitting secretion of the expressed protease into the
culture medium. If desirable, this preregion may be replaced by a
different preregion or signal sequence, conveniently accomplished
by substitution of the DNA sequences encoding the respective
preregions.
[0453] The procedures used to ligate the DNA construct of the
invention encoding an alpha-amylase variant, the promoter,
terminator and other elements, respectively, and to insert them
into suitable vectors containing the information necessary for
replication, are well known to persons skilled in the art (cf., for
instance, Sambrook et al., Molecular Cloning: A Laboratory Manual,
2nd Ed., Cold Spring Harbor, 1989).
[0454] The cell of the invention, either comprising a DNA construct
or an expression vector of the invention as defined above, is
advantageously used as a host cell in the recombinant production of
an alpha-amylase variant of the invention. The cell may be
transformed with the DNA construct of the invention encoding the
variant, conveniently by integrating the DNA construct (in one or
more copies) in the host chromosome. This integration is generally
considered to be an advantage as the DNA sequence is more likely to
be stably maintained in the cell. Integration of the DNA constructs
into the host chromosome may be performed according to conventional
methods, e.g., by homologous or heterologous recombination.
Alternatively, the cell may be transformed with an expression
vector as described above in connection with the different types of
host cells.
[0455] The cell of the invention may be a cell of a higher organism
such as a mammal or an insect, but is preferably a microbial cell,
e.g., a bacterial or a fungal (including yeast) cell.
[0456] Examples of suitable bacteria are gram-positive bacteria
such as Bacillus subtilis, Bacillus licheniformis, Bacillus lentus,
Bacillus brevis, Bacillus stearothermophilus, Bacillus
alkalophilus, Bacillus amyloliquefaciens, Bacillus coagulans,
Bacillus circulans, Bacillus lautus, Bacillus megaterium, Bacillus
thuringiensis, or Streptomyces lividans or Streptomyces murinus, or
gram-negative bacteria such as E. coli. The transformation of the
bacteria may, for instance, be effected by protoplast
transformation or by using competent cells in a manner known per
se.
[0457] The yeast organism may favourably be selected from a species
of Saccharomyces or Schizosaccharomyces, e.g., Saccharomyces
cerevisiae. The filamentous fungus may advantageously belong to a
species of Aspergillus, e.g., Aspergillus oryzae or Aspergillus
niger. Fungal cells may be transformed by a process involving
protoplast formation and transformation of the protoplasts followed
by regeneration of the cell wall in a manner known per se. A
suitable procedure for transformation of Aspergillus host cells is
described in EP 238 023.
[0458] In yet a further aspect, the present invention relates to a
method of producing an alpha-amylase variant of the invention,
which method comprises cultivating a host cell as described above
under conditions conducive to the production of the variant and
recovering the variant from the cells and/or culture medium.
[0459] The medium used to cultivate the cells may be any
conventional medium suitable for growing the host cell in question
and obtaining expression of the alpha-amylase variant of the
invention. Suitable media are available from commercial suppliers
or may be prepared according to published recipes (e.g., as
described in catalogues of the American Type Culture
Collection).
[0460] The alpha-amylase variant secreted from the host cells may
conveniently be recovered from the culture medium by well-known
procedures, including separating the cells from the medium by
centrifugation or filtration, and precipitating proteinaceous
components of the medium by means of a salt such as ammonium
sulphate, followed by the use of chromatographic procedures such as
ion exchange chromatography, affinity chromatography, or the
like.
Compositions
[0461] In a still further aspect, the present invention relates to
compositions comprising an alpha-amylase or alpha-amylase variant
of the present invention. Preferably, the compositions are enriched
in an alpha-amylase or alpha-amylase variant of the present
invention. In the present context, the term "enriched" indicates
that the alpha-amylase activity of the composition has been
increased, e.g., with an enrichment factor of 1.1.
[0462] The composition may comprise an alpha-amylase or
alpha-amylase variant of the invention as the major enzymatic
component, e.g., a mono-component composition. Alternatively, the
composition may comprise multiple enzymatic activities, such as an
aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase,
cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase,
deoxyribonuclease, esterase, alpha-galactosidase,
beta-galactosidase, glucoamylase, alpha-glucosidase,
beta-glucosidase, haloperoxidase, invertase, laccase, lipase,
mannosidase, oxidase, pectinolytic enzyme, peptidoglutaminase,
peroxidase, phytase, polyphenoloxidase, proteolytic enzyme,
ribonuclease, transglutaminase, or xylanase. The additional
enzyme(s) may be producible by means of a microorganism belonging
to the genus Aspergillus, preferably Aspergillus aculeatus,
Aspergillus awamori, Aspergillus niger, or Aspergillus oryzae, or
Trichoderma, Humicola, preferably Humicola insolens, or Fusarium,
preferably Fusarium bactridioides, Fusarium cerealis, Fusarium
crookwellense, Fusarium culmorum, Fusarium graminearum, Fusarium
graminum, Fusarium heterosporum, Fusarium negundi, Fusarium
oxysporum, Fusarium reticulatum, Fusarium roseum, Fusarium
sambucinum, Fusarium sarcochroum, Fusarium sulphureum, Fusarium
toruloseum, Fusarium trichothecioides, or Fusarium venenatum.
[0463] The alpha-amylase compositions may be prepared in accordance
with methods known in the art and may be in the form of a liquid or
a dry composition. For instance, the alpha-amylase composition may
be in the form of a granulate or a microgranulate. The polypeptide
to be included in the composition may be stabilized in accordance
with methods known in the art.
[0464] Examples are given below of preferred uses of the
alpha-amylase compositions of the invention. The dosage of the
alpha-amylase composition of the invention and other conditions
under which the composition is used may be determined on the basis
of methods known in the art.
Further Compositions
[0465] The invention also relates to a composition comprising a
mixture of one or more alpha-amylase or alpha-amylase variant of
the invention derived from (as the parent Termamyl-like
alpha-amylase) the B. stearothermophilus alpha-amylase having the
sequence shown in SEQ ID NO: 3 and a Termamyl-like alpha-amylase
derived from the B. licheniformis alpha-amylase having the sequence
shown in SEQ ID NO: 4.
[0466] Further, the invention also relates to a composition
comprising a mixture of one or more variants according the
invention derived from (as the parent Termamyl-like alpha-amylase)
the B. stearothermophilus alpha-amylase having the sequence shown
in SEQ ID NO: 3 and a hybrid alpha-amylase comprising a part of the
B. amyloliquefaciens alpha-amylase shown in SEQ ID NO: 5 and a part
of the B. licheniformis alpha-amylase shown in SEQ ID NO: 4. The
latter mentioned hydrid Termamyl-like alpha-amylase comprises the
445 C-terminal amino acid residues of the B. licheniformis
alpha-amylase shown in SEQ ID NO: 4 and the 37 N-terminal amino
acid residues of the alpha-amylase derived from B.
amyloliquefaciens shown in SEQ ID NO: 5. Said latter mentioned
hybrid alpha-amylase may suitably comprise the following mutations:
H156Y+A181T+N190F+A209V+Q264S (using the numbering in SEQ ID NO:
4). In the examples below said hybrid parent Termamyl-like
alpha-amylase, is used in combination with variants of the
invention, which variants may be used in compositions of the
invention.
[0467] In a specific embodiment of the invention the composition
comprises a mixture of TVB146 and LE174, e.g., in a ratio of 2:1 to
1:2, such as 1:1.
[0468] An alpha-amylase or alpha-amylase variant of the invention
or a composition of the invention may in an aspect of the invention
be used for washing and/or dishwashing; for textile desizing or for
starch liquefaction.
Detergent Compositions
[0469] The alpha-amylase or alpha-amylase variant of the invention
may be added to and thus become a component of a detergent
composition.
[0470] The detergent composition of the invention may for example
be formulated as a hand or machine laundry detergent composition
including a laundry additive composition suitable for pre-treatment
of stained fabrics and a rinse added fabric softener composition,
or be formulated as a detergent composition for use in general
household hard surface cleaning operations, or be formulated for
hand or machine dishwashing operations.
[0471] In a specific aspect, the invention provides a detergent
additive comprising the enzyme of the invention. The detergent
additive as well as the detergent composition may comprise one or
more other enzymes such as a protease, a lipase, a cutinase, an
amylase, a carbohydrase, a cellulase, a pectinase, a mannanase, an
arabinase, a galactanase, a xylanase, an oxidase, e.g., a laccase,
and/or a peroxidase.
[0472] In general the properties of the chosen enzyme(s) should be
compatible with the selected detergent, (i.e., pH-optimum,
compatibility with other enzymatic and non-enzymatic ingredients,
etc.), and the enzyme(s) should be present in effective
amounts.
Proteases: Suitable proteases include those of animal, vegetable or
microbial origin. Microbial origin is preferred. Chemically
modified or protein engineered mutants are included. The protease
may be a serine protease or a metallo protease, preferably an
alkaline microbial protease or a trypsin-like protease. Examples of
alkaline proteases are subtilisins, especially those derived from
Bacillus, e.g., subtilisin Novo, subtilisin Carlsberg, subtilisin
309, subtilisin 147 and subtilisin 168 (described in WO 89/06279).
Examples of trypsin-like proteases are trypsin (e.g., of porcine or
bovine origin) and the Fusarium protease described in WO 89/06270
and WO 94/25583.
[0473] Examples of useful proteases are the variants described in
WO 92/19729, WO 98/20115,
[0474] WO 98/20116, and WO 98/34946, especially the variants with
substitutions in one or more of the following positions: 27, 36,
57, 76, 87, 97, 101, 104, 120, 123, 167, 170, 194, 206, 218, 222,
224, 235 and 274.
[0475] Preferred commercially available protease enzymes include
Alcalase.RTM., Savinase.RTM., Primase.RTM., Duralase.RTM.,
Esperase.RTM., and Kannase.RTM. (Novo Nordisk A/S), Maxatase.RTM.,
Maxacal, Maxapem.RTM., Properase.RTM., Purafect.RTM., Purafect
OxP.RTM., FN2.RTM., and FN3.RTM. (Genencor International Inc.).
Lipases: Suitable lipases include those of bacterial or fungal
origin. Chemically modified or protein engineered mutants are
included. Examples of useful lipases include lipases from Humicola
(synonym Thermomyces), e.g., from H. lanuginosa (T. lanuginosus) as
described in EP 258 068 and EP 305 216 or from H. insolens as
described in WO 96/13580, a Pseudomonas lipase, e.g., from P.
alcaligenes or P. pseudoalcaligenes (EP 218 272), P. cepacia (EP
331 376), P. stutzeri (GB 1,372,034), P. fluorescens, Pseudomonas
sp. strain SD 705 (WO 95/06720 and WO 96/27002), P. wisconsinensis
(WO 96/12012), a Bacillus lipase, e.g., from B. subtilis (Dartois
et al. (1993), Biochemica et Biophysica Acta, 1131, 253-360), B.
stearothermophilus (JP 64/744992) or B. pumilus (WO 91/16422).
[0476] Other examples are lipase variants such as those described
in WO 92/05249, WO 94/01541, EP 407 225, EP 260 105, WO 95/35381,
WO 96/00292, WO 95/30744, WO 94/25578, WO 95/14783, WO 95/22615, WO
97/04079 and WO 97/07202.
[0477] Preferred commercially available lipase enzymes include
Lipolase.TM. and Lipolase Ultra.TM. (Novo Nordisk A/S).
[0478] Amylases: Suitable amylases (alpha- and/or beta-) include
those of bacterial or fungal origin. Chemically modified or protein
engineered mutants are included. Amylases include, for example,
alpha-amylases obtained from Bacillus, e.g., a special strain of B.
licheniformis, described in more detail in GB 1,296,839.
[0479] Examples of useful amylases are the variants described in WO
94/02597, WO 94/18314, WO 96/23873, and WO 97/43424, especially the
variants with substitutions in one or more of the following
positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 181, 188,
190, 197, 202, 208, 209, 243, 264, 304, 305, 391, 408, and 444.
[0480] Commercially available amylases are Duramyl.TM.,
Termamyl.TM., Fungamyl.TM. and BAN.TM. (Novo Nordisk A/S),
Rapidase.TM. and Purastar.TM. (from Genencor International
Inc.).
[0481] Cellulases: Suitable cellulases include those of bacterial
or fungal origin. Chemically modified or protein engineered mutants
are included. Suitable cellulases include cellulases from the
genera Bacillus, Pseudomonas, Humicola, Fusarium, Thielavia,
Acremonium, e.g., the fungal cellulases produced from Humicola
insolens, Myceliophthora thermophila and Fusarium oxysporum
disclosed in U.S. Pat. No. 4,435,307, U.S. Pat. No. 5,648,263, U.S.
Pat. No. 5,691,178, U.S. Pat. No. 5,776,757 and WO 89/09259.
[0482] Especially suitable cellulases are the alkaline or neutral
cellulases having colour care benefits. Examples of such cellulases
are cellulases described in EP 0 495 257, EP 0 531 372, WO
96/11262, WO 96/29397, WO 98/08940. Other examples are cellulase
variants such as those described in WO 94/07998, EP 0 531 315, U.S.
Pat. No. 5,457,046, U.S. Pat. No. 5,686,593, U.S. Pat. No.
5,763,254, WO 95/24471, WO 98/12307 and PCT/DK98/00299.
[0483] Commercially available cellulases include Celluzyme.RTM.,
and Carezyme.RTM. (Novo Nordisk A/S), Clazinase.RTM., and Puradax
HA.RTM. (Genencor International Inc.), and KAC-500(B).RTM. (Kao
Corporation).
[0484] Peroxidases/Oxidases: Suitable peroxidases/oxidases include
those of plant, bacterial or fungal origin. Chemically modified or
protein engineered mutants are included. Examples of useful
peroxidases include peroxidases from Coprinus, e.g., from C.
cinereus, and variants thereof as those described in WO 93/24618,
WO 95/10602, and WO 98/15257.
[0485] Commercially available peroxidases include Guardzyme.RTM.
(Novo Nordisk A/S).
[0486] The detergent enzyme(s) may be included in a detergent
composition by adding separate additives containing one or more
enzymes, or by adding a combined additive comprising all of these
enzymes. A detergent additive of the invention, i.e., a separate
additive or a combined additive, can be formulated e.g., as a
granulate, a liquid, a slurry, etc. Preferred detergent additive
formulations are granulates, in particular non-dusting granulates,
liquids, in particular stabilized liquids, or slurries.
[0487] Non-dusting granulates may be produced, e.g., as disclosed
in U.S. Pat. Nos. 4,106,991 and 4,661,452 and may optionally be
coated by methods known in the art. Examples of waxy coating
materials are poly(ethylene oxide) products (polyethyleneglycol,
PEG) with mean molar weights of 1000 to 20000; ethoxylated
nonyl-phenols having from 16 to 50 ethylene oxide units;
ethoxylated fatty alcohols in which the alcohol contains from 12 to
20 carbon atoms and in which there are 15 to 80 ethylene oxide
units; fatty alcohols; fatty acids; and mono- and di- and
triglycerides of fatty acids. Examples of film-forming coating
materials suitable for application by fluid bed techniques are
given in GB 1483591. Liquid enzyme preparations may, for instance,
be stabilized by adding a polyol such as propylene glycol, a sugar
or sugar alcohol, lactic acid or boric acid according to
established methods. Protected enzymes may be prepared according to
the method disclosed in EP 238,216.
[0488] The detergent composition of the invention may be in any
convenient form, e.g., a bar, a tablet, a powder, a granule, a
paste or a liquid. A liquid detergent may be aqueous, typically
containing up to 70% water and 0-30% organic solvent, or
non-aqueous.
[0489] The detergent composition comprises one or more surfactants,
which may be non-ionic including semi-polar and/or anionic and/or
cationic and/or zwitterionic. The surfactants are typically present
at a level of from 0.1% to 60% by weight.
[0490] When included therein the detergent will usually contain
from about 1% to about 40% of an anionic surfactant such as linear
alkylbenzenesulfonate, alpha-olefinsulfonate, alkyl sulfate (fatty
alcohol sulfate), alcohol ethoxysulfate, secondary alkanesulfonate,
alpha-sulfo fatty acid methyl ester, alkyl- or alkenylsuccinic acid
or soap.
[0491] When included therein the detergent will usually contain
from about 0.2% to about 40% of a non-ionic surfactant such as
alcohol ethoxylate, nonyl-phenol ethoxylate, alkylpolyglycoside,
alkyldimethylamine-oxide, ethoxylated fatty acid monoethanol-amide,
fatty acid monoethanolamide, polyhydroxy alkyl fatty acid amide, or
N-acyl N-alkyl derivatives of glucosamine ("glucamides").
[0492] The detergent may contain 0-65% of a detergent builder or
complexing agent such as zeolite, diphosphate, triphosphate,
phosphonate, carbonate, citrate, nitrilotriacetic acid,
ethylenediaminetetraacetic acid, diethylenetri-aminepen-taacetic
acid, alkyl- or alkenylsuccinic acid, soluble silicates or layered
silicates (e.g., SKS-6 from Hoechst).
[0493] The detergent may comprise one or more polymers. Examples
are carboxymethylcellulose, poly(vinyl-pyrrolidone), poly(ethylene
glycol), poly(vinyl alcohol), poly(vinylpyridine-N-oxide),
poly(vinylimidazole), polycarboxylates such as polyacrylates,
maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid
co-polymers.
[0494] The detergent may contain a bleaching system which may
comprise a H.sub.2O.sub.2 source such as perborate or percarbonate
which may be combined with a peracid-forming bleach activator such
as tetraacetylethylenediamine or nonanoyloxybenzenesulfonate.
Alternatively, the bleaching system may comprise peroxyacids of,
e.g., the amide, imide, or sulfone type.
[0495] The enzyme(s) of the detergent composition of the invention
may be stabilized using conventional stabilizing agents, e.g., a
polyol such as propylene glycol or glycerol, a sugar or sugar
alcohol, lactic acid, boric acid, or a boric acid derivative, e.g.,
an aromatic borate ester, or a phenyl boronic acid derivative such
as 4-formylphenyl boronic acid, and the composition may be
formulated as described in, e.g., WO 92/19709 and WO 92/19708.
[0496] The detergent may also contain other conventional detergent
ingredients such as, e.g., fabric conditioners including clays,
foam boosters, suds suppressors, anti-corrosion agents,
soil-suspending agents, anti-soil redeposition agents, dyes,
bactericides, optical brighteners, hydrotropes, tarnish inhibitors,
or perfumes.
[0497] It is at present contemplated that in the detergent
compositions any enzyme, in particular the enzyme of the invention,
may be added in an amount corresponding to 0.01-100 mg of enzyme
protein per liter of wash liquor, preferably 0.05-5 mg of enzyme
protein per liter of wash liquor, in particular 0.1-1 mg of enzyme
protein per liter of wash liquor.
[0498] The enzyme of the invention may additionally be incorporated
in the detergent formulations disclosed in WO 97/07202 which is
hereby incorporated as reference.
Further Detergent Compositions
[0499] As mentioned above, variants of the invention may suitably
be incorporated in detergent compositions. Increased
thermostability at low calcium concentrations would be very
beneficial for amylase performance in detergents, i.e., the
alkaline region. Reference is made, for example, to WO 96/23874 and
WO 97/07202 for further details concerning relevant ingredients of
detergent compositions (such as laundry or dishwashing detergents),
appropriate methods of formulating the variants in such detergent
compositions, and for examples of relevant types of detergent
compositions.
[0500] Detergent compositions comprising an alpha-amylase or
alpha-amylase variant of the invention may additionally comprise
one or more other enzymes, such as a lipase, cutinase, protease,
cellulase, peroxidase or laccase, and/or another alpha-amylase.
[0501] An alpha-amylase or alpha-amylase variant of the invention
may be incorporated in detergents at conventionally employed
concentrations. It is at present contemplated that a variant of the
invention may be incorporated in an amount corresponding to
0.00001-1 mg (calculated as pure, active enzyme protein) of
alpha-amylase per liter of wash/dishwash liquor using conventional
dosing levels of detergent.
Dishwash Deterget Compositions
[0502] The alpha-amylase or alpha-amylase variant of the invention
may also be used in dishwash detergent compositions, including the
following:
1) Powder Automatic Dishwashing Composition
TABLE-US-00003 [0503] Nonionic surfactant 0.4-2.5% Sodium
metasilicate 0-20% Sodium disilicate 3-20% Sodium triphosphate
20-40% Sodium carbonate 0-20% Sodium perborate 2-9% Tetraacetyl
ethylene diamine (TAED) 1-4% Sodium sulphate 5-33% Enzymes
0.0001-0.1%
2) Powder Automatic Dishwashing Composition
TABLE-US-00004 [0504] Nonionic surfactant (e.g., alcohol
ethoxylate) 1-2% Sodium disilicate 2-30% Sodium carbonate 10-50%
Sodium phosphonate 0-5% Trisodium citrate dihydrate 9-30%
Nitrilotrisodium acetate (NTA) 0-20% Sodium perborate monohydrate
5-10% Tetraacetyl ethylene diamine (TAED) 1-2% Polyacrylate polymer
(e.g., 6-25% maleic acid/acrylic acid copolymer) Enzymes
0.0001-0.1% Perfume 0.1-0.5% Water 5-10
3) Powder Automatic Dishwashing Composition
TABLE-US-00005 [0505] Nonionic surfactant 0.5-2.0% Sodium
disilicate 25-40% Sodium citrate 30-55% Sodium carbonate 0-29%
Sodium bicarbonate 0-20% Sodium perborate monohydrate 0-15%
Tetraacetyl ethylene diamine (TAED) 0-6% Maleic acid/acrylic acid
copolymer 0-5% Clay 1-3% Polyamino acids 0-20% Sodium polyacrylate
0-8% Enzymes 0.0001-0.1%
4) Powder Automatic Dishwashing Composition
TABLE-US-00006 [0506] Nonionic surfactant 1-2% Zeolite MAP 15-42%
Sodium disilicate 30-34% Sodium citrate 0-12% Sodium carbonate
0-20% Sodium perborate monohydrate 7-15% Tetraacetyl ethylene
diamine (TAED) 0-3% Polymer 0-4% Maleic acid/acrylic acid copolymer
0-5% Organic phosphonate 0-4% Clay 1-2% Enzymes 0.0001-0.1% Sodium
sulphate Balance
5) Powder Automatic Dishwashing Composition
TABLE-US-00007 [0507] Nonionic surfactant 1-7% Sodium disilicate
18-30% Trisodium citrate 10-24% Sodium carbonate 12-20%
Monopersulphate (2 KHSO.sub.5KHSO.sub.4K.sub.2SO.sub.4) 15-21%
Bleach stabilizer 0.1-2% Maleic acid/acrylic acid copolymer 0-6%
Diethylene triamine pentaacetate, pentasodium salt 0-2.5% Enzymes
0.0001-0.1% Sodium sulphate, water Balance
6) Powder and Liquid Dishwashing Composition with Cleaning
Surfactant System
TABLE-US-00008 Nonionic surfactant 0-1.5% Octadecyl dimethylamine
N-oxide dihydrate 0-5% 80:20 wt.C18/C16 blend of octadecyl 0-4%
dimethylamine N-oxide dihydrate and hexadecyldimethyl amine N-oxide
dihydrate 70:30 wt.C18/C16 blend of octadecyl bis (hydroxyethyl)
0-5% amine N-oxide anhydrous and hexadecyl bis (hydroxyethyl)amine
N-oxide anhydrous C.sub.13-C.sub.15 alkyl ethoxysulfate with an
average degree 0-10% of ethoxylation of 3 C.sub.12-C.sub.15 alkyl
ethoxysulfate with an average degree 0-5% of ethoxylation of 3
C.sub.13-C.sub.15 ethoxylated alcohol with an average degree 0-5%
of ethoxylation of 12 A blend of C.sub.12-C.sub.15 ethoxylated
alcohols with an 0-6.5% average degree of ethoxylation of 9 A blend
of C.sub.13-C.sub.15 ethoxylated alcohols with an 0-4% average
degree of ethoxylation of 30 Sodium disilicate 0-33% Sodium
tripolyphosphate 0-46% Sodium citrate 0-28% Citric acid 0-29%
Sodium carbonate 0-20% Sodium perborate monohydrate 0-11.5%
Tetraacetyl ethylene diamine (TAED) 0-4% Maleic acid/acrylic acid
copolymer 0-7.5% Sodium sulphate 0-12.5% Enzymes 0.0001-0.1%
7) Non-Aqueous Liquid Automatic Dishwashing Composition
TABLE-US-00009 [0508] Liquid nonionic surfactant (e.g., alcohol
ethoxylates) 2.0-10.0% Alkali metal silicate 3.0-15.0% Alkali metal
phosphate 20.0-40.0% Liquid carrier selected from higher 25.0-45.0%
glycols, polyglycols, polyoxides, glycolethers Stabilizer (e.g., a
partial ester of phosphoric acid 0.5-7.0% and a C.sub.16-C.sub.18
alkanol) Foam suppressor (e.g., silicone) 0-1.5% Enzymes
0.0001-0.1%
8) Non-Aqueous Liquid Dishwashing Composition
TABLE-US-00010 [0509] Liquid nonionic surfactant (e.g., alcohol
ethoxylates) 2.0-10.0% Sodium silicate 3.0-15.0% Alkali metal
carbonate 7.0-20.0% Sodium citrate 0.0-1.5% Stabilizing system
(e.g., mixtures of finely divided silicone 0.5-7.0% and low
molecular weight dialkyl polyglycol ethers) Low molecule weight
polyacrylate polymer 5.0-15.0% Clay gel thickener (e.g., bentonite)
0.0-10.0% Hydroxypropyl cellulose polymer 0.0-0.6% Enzymes
0.0001-0.1% Liquid carrier selected from higher lycols,
polyglycols, Balance polyoxides and glycol ethers
9) Thixotropic Liquid Automatic Dishwashing Composition
TABLE-US-00011 [0510] C.sub.12-C.sub.14 fatty acid 0-0.5% Block
co-polymer surfactant 1.5-15.0% Sodium citrate 0-12% Sodium
tripolyphosphate 0-15% Sodium carbonate 0-8% Aluminium tristearate
0-0.1% Sodium cumene sulphonate 0-1.7% Polyacrylate thickener
1.32-2.5% Sodium polyacrylate 2.4-6.0% Boric acid 0-4.0% Sodium
formate 0-0.45% Calcium formate 0-0.2% Sodium n-decydiphenyl oxide
disulphonate 0-4.0% Monoethanol amine (MEA) 0-1.86% Sodium
hydroxide (50%) 1.9-9.3% 1,2-Propanediol 0-9.4% Enzymes 0.0001-0.1%
Suds suppressor, dye, perfumes, water Balance
10) Liquid Automatic Dishwashing Composition
TABLE-US-00012 [0511] Alcohol ethoxylate 0-20% Fatty acid ester
sulphonate 0-30% Sodium dodecyl sulphate 0-20% Alkyl polyglycoside
0-21% Oleic acid 0-10% Sodium disilicate monohydrate 18-33% Sodium
citrate dihydrate 18-33% Sodium stearate 0-2.5% Sodium perborate
monohydrate 0-13% Tetraacetyl ethylene diamine (TAED) 0-8% Maleic
acid/acrylic acid copolymer 4-8% Enzymes 0.0001-0.1%
11) Liquid Automatic Dishwashing Composition Containing Protected
Bleach Particles
TABLE-US-00013 [0512] Sodium silicate 5-10% Tetrapotassium
pyrophosphate 15-25% Sodium triphosphate 0-2% Potassium carbonate
4-8% Protected bleach particles, e.g., chlorine 5-10% Polymeric
thickener 0.7-1.5% Potassium hydroxide 0-2% Enzymes 0.0001-0.1%
Water Balance
11) Automatic dishwashing compositions as described in 1), 2), 3),
4), 6) and 10), wherein perborate is replaced by percarbonate. 12)
Automatic dishwashing compositions as described in 1)-6) which
additionally contain a manganese catalyst. The manganese catalyst
may, e.g., be one of the compounds described in "Efficient
manganese catalysts for low-temperature bleaching", Nature 369:
637-639 (1994).
Uses
[0513] The present invention is also directed to methods for using
an alpha-amylase or alpha-amylase variant of the invention in
detergents, in particular laundry detergent compositions and
dishwash detergent compositions.
INDUSTRIAL APPLICATIONS
[0514] An alpha-amylase and alpha-amylase variant of the invention
are well suited for use in a variety of industrial processes, in
particular the enzymes of the invention finds potential
applications as a component in detergents, e.g., laundry, dishwash
and hard surface cleaning detergent compositions, but it may also
be useful in the production of sweeteners and ethanol from starch.
Thus, it may be used in conventional starch-converting processes,
such as liquefaction and saccharification processes described in
U.S. Pat. No. 3,912,590 and EP patent publications Nos. 252,730 and
63,909.
[0515] An alpha-amylase or alpha-amylase variant of the invention
may also be used in the production of lignocellulosic materials,
such as pulp, paper and cardboard, from starch reinforced waste
paper and cardboard, especially where repulping occurs at pH above
7 and where amylases can facilitate the disintegration of the waste
material through degradation of the reinforcing starch. The
alpha-amylase of the invention is especially useful in a process
for producing a papermaking pulp from starch-coated printed paper.
The process may be performed as described in WO 95/14807,
comprising the following steps: [0516] a) disintegrating the paper
to produce a pulp, [0517] b) treating with a starch-degrading
enzyme before, during or after step a), and [0518] c) separating
ink particles from the pulp after steps a) and b).
[0519] An alpha-amylase or alpha-amylase variant of the invention
may also be very useful in modifying starch where enzymatically
modified starch is used in papermaking together with alkaline
fillers such as calcium carbonate, kaolin and clays. With the
alkaline alpha-amylases of the invention it becomes possible to
modify the starch in the presence of the filler thus allowing for a
simpler integrated process.
[0520] An alpha-amylase or alpha-amylase variant of the invention
may also be very useful in textile desizing. In the textile
processing industry, alpha-amylases are traditionally used as
auxiliaries in the desizing process to facilitate the removal of
starch-containing size which has served as a protective coating on
weft yarns during weaving. Complete removal of the size coating
after weaving is import-ant to ensure optimum results in the
subsequent processes, in which the fabric is scoured, bleached and
dyed. Enzymatic starch break-down is preferred because it does not
involve any harmful effect on the fiber material. In order to
reduce processing cost and increase mill through-put, the desizing
processing is sometimes combined with the scouring and bleaching
steps. In such cases, non-enzymatic auxiliaries such as alkali or
oxidation agents are typically used to break down the starch,
because traditional alpha-amylases are not very compatible with
high pH levels and bleaching agents. The non-enzymatic breakdown of
the starch size does lead to some fiber damage because of the
rather aggressive chemicals used. Accordingly, it would be
desirable to use the alpha-amylases of the invention as they have
an improved performance in alkaline solutions. The alpha-amylases
may be used alone or in combination with a cellulase when desizing
cellulose-containing fabric or textile.
[0521] The alpha-amylases of the invention may also be very useful
in a beer-making process; the alpha-amylases will typically be
added during the mashing process.
Production of Sweeteners from Starch
[0522] A "traditional" process for conversion of starch to fructose
syrups normally consists of three consecutive enzymatic processes,
viz., a liquefaction process followed by a saccharification process
and an isomerization process. During the liquefaction process,
starch is degraded to dextrins by an alpha-amylase (e.g.,
Termamyl.TM.) at pH values between 5.5 and 6.2 and at temperatures
of 95-160.degree. C. for a period of approx. 2 hours. In order to
ensure an optimal enzyme stability under these conditions, 1 mM of
calcium is added (40 ppm free calcium ions).
[0523] After the liquefaction process the dextrins are converted
into dextrose by addition of a glucoamylase (e.g., AMG.TM.) and a
debranching enzyme, such as an isoamylase or a pullulanase (e.g.,
Promozyme.TM.). Before this step the pH is reduced to a value below
4.5, maintaining the high temperature (above 95.degree. C.), and
the liquefying alpha-amylase activity is denatured. The temperature
is lowered to 60.degree. C., and glucoamylase and debranching
enzyme are added. The saccharification process proceeds for 24-72
hours.
[0524] After the saccharification process the pH is increased to a
value in the range of 6-8, preferably pH 7.5, and the calcium is
removed by ion exchange. The dextrose syrup is then converted into
high fructose syrup using, e.g., an immmobilized glucoseisomerase
(such as Sweetzyme.TM.)
[0525] At least 1 enzymatic improvements of this process could be
envisaged.
[0526] Reduction of the calcium dependency of the liquefying
alpha-amylase. Addition of free calcium is required to ensure
adequately high stability of the alpha-amylase, but free calcium
strongly inhibits the activity of the glucoseisomerase and needs to
be removed, by means of an expensive unit operation, to an extent
which reduces the level of free calcium to below 3-5 ppm. Cost
savings could be obtained if such an operation could be avoided and
the liquefaction process could be performed without addition of
free calcium ions.
[0527] To achieve that, a less calcium-dependent Termamyl-like
alpha-amylase which is stable and highly active at low
concentrations of free calcium (<40 ppm) is required. Such a
Termamyl-like alpha-amylase should have a pH optimum at a pH in the
range of 4.5-6.5, preferably in the range of 4.5-5.5.
Materials and Methods
[0528] Chemicals used as buffers and substrates were commercial
products of at least reagent grade.
Enzymes:
[0529] SP690: alpha-amylase shown in SEQ ID NO: 1 SP722:
alpha-amylase shown in SEQ ID NO: 2 Termamyl.RTM.: alpha-amylase
from Bacillus licheniformis shown in SEQ ID NO: 4. AA560:
alpha-amylase of the invention shown in SEQ ID NO: 24 encoded by
the DNA sequence shown in SEQ ID NO: 23. AA360: alpha-amylase shown
in SEQ ID NO: 26 being identical to the AA560 alpha-amylase encoded
by the DNA sequence shown in SEQ ID NO: 25. BSG alpha-amylase: B.
stearothermophilus alpha-amylase depicted in SEQ ID NO: 3. TVB146
alpha-amylase variant: B. stearothermophilus alpha-amylase variant
depicted in SEQ ID NO: 3 with the following mutations: with the
deletion in positions I181-G182+N193F. LE174 hybrid alpha-amylase
variant: LE174 is a hybrid Termamyl-like alpha-amylase being
identical to the Termamyl sequence, i.e., the Bacillus
licheniformis alpha-amylase shown in SEQ ID NO: 4, except that the
N-terminal 35 amino acid residues (of the mature protein) has been
replaced by the N-terminal 33 residues of BAN (mature protein),
i.e., the Bacillus amyloliquefaciens alpha-amylase shown in SEQ ID
NO: 5, which further have the following mutations:
H156Y+A181T+N190F+A209V+Q264S (using the numbering in SEQ ID NO:
4). LE174 was constructed by SOE-PCR (Higuchi et al., 1988, Nucleic
Acids Research 16:7351).
Model Detergent:
[0530] A/P (Asia/Pacific) Model Detergent has the following
composition: 20% STPP (sodium tripolyphosphate), 25%
Na.sub.2SO.sub.4, 15% Na.sub.2CO.sub.3, 20% LAS (linear
alkylbenzene sulfonate, Nansa 80S), 5% C.sub.12-C.sub.15 alcohol
ethoxylate (Dobanol 25-7), 5% Na.sub.2Si.sub.2O.sub.5, 0.3%
NaCl.
Omo Multi Acao (Brazil),
[0531] Omo concentrated powder (Europe) (product of Unilever) Ariel
Futur liquid (Europe) (product of Procter and Gamble)
Deposit of Biological Material
[0532] The following biological material has been deposited under
the terms of the Budapest
[0533] Treaty with the Deutshe Sammmlung von Microorganismen and
Zellkulturen GmbH (DSMZ), Mascheroder Weg 1b, D-38124 Braunschweig
DE, and given the following accession number:
TABLE-US-00014 Deposit Accession Number Date of Deposit NN017557
DSM 12648 Jan. 25, 1999 NN017560 DSM 12649 Jan. 25, 1999 NN049467
DSM12761 Apr. 7, 1999 NN049470 DSM12764 Apr. 7, 1999
[0534] The strains have been deposited under conditions that assure
that access to the culture will be available during the pendency of
this patent application to one determined by the Commissioner of
Patents and Trademarks to be entitled thereto under 37 C.F.R.
.sctn.1.14 and 35 U.S.C. .sctn.122. The deposit represents a
substantially pure culture of the deposited strain. The deposit is
available as required by foreign patent laws in countries wherein
counterparts of the subject application, or its progeny are filed.
However, it should be understood that the availability of a deposit
does not constitute a license to practice the subject invention in
derogation of patent rights granted by governmental action.
Host Organism
[0535] Bacillus subtilis strain SHa273 is disclosed in WO
95/10603
[0536] E. coli strain SJ2 (Diderichsen et al. (1990)).
Plasmids:
[0537] The gene bank vector pSJ1678 is disclosed in WO 94/19454
which is hereby incorporated by reference.
[0538] pTVB110 is a plasmid replicating in Bacillus subtilis by the
use of origin of replication from pUB110 (Gryczan, 1978, J. Bact.
134:318-329). The plasmid further encodes the cat gene, conferring
resistance towards chlorampenicol, obtained from plasmid pC194
(Horinouchi and Weisblum, 1982, J. Bact. 150: 815-825). The plasmid
harbors a truncated version of the Bacillus licheniformis
alpha-amylase gene, amyL, such that the amyL promoter, signal
sequence and transcription terminator are present, but the plasmid
does not provide an amy-plus phenotype (halo formation on starch
containing agar).
Methods
General Molecular Biology Methods:
[0539] Unless otherwise mentioned the DNA manipulations and
transformations were performed using standard methods of molecular
biology (Sambrook et al. (1989); Ausubel et al. (1995); Harwood and
Cutting (1990).
Fermentation and Purification of Alpha-Amylase Variants
[0540] Fermentation may be performed by methods well known in the
art or as follows.
[0541] A B. subtilis strain harbouring the relevant expression
plasmid is streaked on an LB-agar plate with 10 .mu.g/ml kanamycin
from -80.degree. C. stock, and grown overnight at 37.degree. C.
[0542] The colonies are transferred to 100 ml BPX media
supplemented with 10 .mu.g/ml kanamycin in a 500 ml shaking
flask.
Composition of BPX Medium:
TABLE-US-00015 [0543] Potato starch 100 g/l Barley flour 50 g/l BAN
5000 SKB 0.1 g/l Sodium caseinate 10 g/l Soy Bean Meal 20 g/l
Na.sub.2HPO.sub.4, 12 H.sub.2O 9 g/l Pluronic .TM. 0.1 g/l
[0544] The culture is shaken at 37.degree. C. at 270 rpm for 5
days.
[0545] Cells and cell debris are removed from the fermentation
broth by centrifugation at 4500 rpm in 20-25 minutes. Afterwards
the supernatant is filtered to obtain a completely clear solution.
The filtrate is concentrated and washed on a UF-filter (10000 cut
off membrane) and the buffer is changed to 20 mM Acetate pH 5.5.
The UF-filtrate is applied on a S-sepharose F.F. and elution is
carried out by step elution with 0.2M NaCl in the same buffer. The
eluate is dialysed against 10 mM Tris, pH 9.0 and applied on a
Q-sepharose F.F. and eluted with a linear gradient from 0-0.3 M
NaCl over 6 column volumes. The fractions which contain the
activity to (measured by the Phadebas assay) are pooled, pH was
adjusted to pH 7.5 and remaining color was removed by a treatment
with 0.5% W/vol. active coal in 5 minutes.
Assays for Determining Alpha-Amylase Activity
Activity Determination--(KNU)
[0546] One Kilo alpha-amylase Unit (1 KNU) is the amount of enzyme
which breaks down 5.26 g starch (Merck, Amylum Solubile, Erg. B 6,
Batch 9947275) per hour in Novo Nordisk's standard method for
determination of alpha-amylase based upon the following
condition:
TABLE-US-00016 Substrate soluble starch Calcium content in solvent
0.0043 M Reaction time 7-20 minutes Temperature 37.degree. C. pH
5.6
[0547] Detailed description of Novo Nordisk's analytical method (AF
9) is available on request.
BS-Amylase Activity Determination--KNU(S)
1. Application Field
[0548] This method is used to determine alpha-amylase activity in
fermentation and recovery samples and formulated and granulated
products.
2. Principle
[0549] BS-amylase breaks down the substrate
(4,6-ethylidene(G.sub.7)-p-nitrophenyl(G.sub.1)-alpha,D-maltoheptaoside
(written as ethylidene-G.sub.7-PNP) into, among other things,
G.sub.2-PNP and G.sub.3-PNP, where G denoted glucose and PNP
p-nitrophenol.
[0550] G2-PNP and G3-PNP are broken down by alpha-glucosidase,
which is added in excess, into glucose and the yellow-coloured
p-nitrophenol.
[0551] The colour reaction is monitored in situ and the change in
absorbance over time calculated as an expression of the spreed of
the reaction and thus of the activity of the enzyme. See the
Boehringer Mannheim 1442 309 guidelines for further details.
2.1 Reaction conditions
Reaction:
[0552] Temperature: 37.degree. C.
[0553] pH: 7.1
[0554] Pre-incubation time: 2 minutes
Detection:
[0555] Wavelength: 405 nm
[0556] Measurement time: 3 minutes
3. Definition of Units
[0557] Bacillus stearothermophius alpha-amylase (BS-amylase)
activity is determined relative to a standard of declared activity
and stated in Kilo Novo Units (Stearothermophilus) or KNU(S)).
4. Specificity and Sensitivity
[0558] Limit of determination: approx. 0.4 KNU(s)/g
5. Apparatus
[0559] Cobas Fara analyser
Diluted (e.g., Hamilton Microlab 1000)
[0560] Analytical balance (e.g., Mettler AE 100) Stirrer plates
6. Reagents/Substrates
[0561] A ready-made kit is used in this analysis to determine
alpha-amylase activity. Note that the reagents specified for the
substrate and alpha-glucosidase are not used as described in the
Boehringer Mannheim guidelines. However, the designations "buffer",
"glass 1", glass 1a'' and Glass 2'' are those referred to in those
guidelines.
6.1. Substrate
[0562]
4,6-ethylidene(G.sub.7)-p-nitrophenyl(G.sub.1)-alpha,D-maltoheptaos-
ide (written as ethylidene-G.sub.7-PNP), e.g., Boehringer Mannheim
1442 309
6.2 Alpha-Glucosidase Help Reagent
[0563] alpha-glucosidase, e.g., Boehringer Mannheim 1442 309
6.3 BRIJ 35 solution
TABLE-US-00017 BRIJ 35 (30% W/V Sigma 430 AG-6) 1000 mL
Demineralized water up to 2,000 mL
6.4 Stabiliser
TABLE-US-00018 [0564] Brij 35 solution 33 mL CaCl.sub.2*2H.sub.2O
(Merck 2382) 882 g Demineralized water up to 2,000 mL
7. Samples and Standards
7.1 Standard Curve
Example: Preparation of BS-Amylase Standard Curve
[0565] The relevant standard is diluted to 0.60 KNU(s)/mL as
follows. A calculated quantity of standard is weighed out and added
to 200 mL volumetric flask, which is filled to around the 2/3 mark
with demineralized water. Stabiliser corresponding to 1% of the
volume of the flask is added and the flask is filled to the mark
with demineralized water.
[0566] A Hamilton Microlab 1000 is used to produce the dilutions
shown below. Demineralized water with 1% stabiliser is used as the
diluent.
TABLE-US-00019 Dilution No. Enzyme stock solution 1% stabilizer
KNU(s)/mL 1 20 .mu.L 580 .mu.L 0.02 2 30 .mu.L 570 .mu.L 0.03 3 40
.mu.L 560 .mu.L 0.04 4 50 .mu.L 550 .mu.L 0.05 5 60 .mu.L 540 .mu.L
0.06
7.2 Level Control
[0567] A Novo Nordisk A/S BS amylase level control is included in
all runs using the Cobas Fara. The control is diluted with 1%
stabilizer so that the final dilution is within the range of the
standard curve. All weights and dilutions are noted on the
worklist
7.3 Sample Solutions
Single Determination
[0568] Fermentation samples (not final samples) from production,
all fermentation samples from pilot plants and storage stability
samples are weighed out and analyzed once only.
[0569] Double determination over 1 run:
[0570] Process samples, final fermentation samples from production,
samples from GLP studies and R&D samples are weighed out and
analyzed twice.
[0571] Double determinations over 2 runs:
[0572] Finished product samples are weighed out and analyzed twice
over two separate runs.
[0573] Maximum concentration of samples in powder form: 5%
[0574] Test samples are diluted with demineralized water with 1%
stabilizer to approx. 0.037 KNU(S)/mL on the basis of their
expected activity. The final dilution is made direct into the
sample cup.
8. Procedure
8.1 Cobas Menu Program
[0575] The Cobas Menu Program is used to suggest the
weight/dilutions of samples and level control to be used.
[0576] The samples are entered into the program with a unique
identification code and a worklist is printed out
[0577] The samples and control are weighed out and diluted as
stated on the worklist with hand-written weight data is inserted
into the BS-amylase analysis logbook
[0578] The results are computerized automatically by the Cobas Fara
as described in item 9 and printed out along with the standard
curve.
[0579] Worklists and results printouts are inserted into the
BS-amylase analysis logbook.
8.2 Cobas Fara Set-Up
[0580] The samples are placed in the sample rack The five standards
are placed in the calibration rack at position 1 to 5 (strongest
standard at position 5), and control placed in the same rack at
position 10.
[0581] The substrate is transferred to a 30 mL reagent container
and placed in that reagent rack at position 2 (holder 1).
[0582] The alpha-glucosidase help reagent is transferred to a 50 mL
reagent container and placed in the reagent rack at position 2
(holder C)
8.3 Cobas Fare Analysis
[0583] The main principles of the analysis are as follows:
[0584] 20 .mu.L sample and 10.mu. rinse-water are pipetted into the
cuvette along with 250 .mu.L alpha-glucosidase help reagent. The
cuvette rotates for 10 seconds and the reagents are thrown out into
the horizontal cuvettes. 25 .mu.L substrate and 20 .mu.L
rinse-water are pipetted off. After a 1 second wait to ensure that
the temperature is 37.degree. C., the cuvette rotates again and the
substrate is mixed into the horizontal cuvettes. Absorbance is
measured for the first time after 120 seconds and then every 5
seconds. Absorbance is measured a total of 37 times for each
sample.
9. Calculations
[0585] The activity of the samples is calculated relative to Novo
Nordisk A/S standard.
[0586] The standard curve is plotted by the analyzer. The curve is
to be gently curved, rising steadily to an absorbance of around
0.25 for standard no. 5.
[0587] The activity of the samples in KNU(S)/mL is read off the
standard curve by the analyzer.
[0588] The final calculations to allow for the weights/dilutions
used employ the following formula:
Activity in KNU(S)/g=S.times.V.times.F/W
S=analysis result read off (KNU(S)/mL V=volume of volumetric flask
used in mL F=dilution factor for second dilution W=weight of enzyme
sample in g
9.2 Calculation of Mean Values
[0589] Results are stated with 3 significant digits. However, for
sample activity <10 KNU(S)/g, only 2 significant digits are
given.
[0590] The following rules apply on calculation of mean values:
1. Data which deviates more than 2 standard deviations from the
mean value is not included in the calculation. 2. Single and double
determination over one run: The mean value is calculated on basis
of results lying within the standard curve's activity area. 3.
Double determinations over two runs: All values are included in the
mean value. Outliers are omitted.
10. Accuracy and Precision
[0591] The coefficient of variation is 2.9% based on retrospective
validation of analysis results for a number of finished products
and the level control.
Phadebas Assay (for Alpha-Amylase Activity Determination)
[0592] Alpha-amylase activity is determined by a method employing
Phadebas.RTM. tablets as substrate. Phadebas tablets (Phadebas.RTM.
Amylase Test, supplied by Pharmacia Diagnostic) contain a
cross-linked insoluble blue-colored starch polymer which has been
mixed with bovine serum albumin and a buffer substance and
tabletted.
[0593] For every single measurement one tablet is suspended in a
tube containing 5 ml 50 mM Britton-Robinson buffer (50 mM acetic
acid, 50 mM phosphoric acid, 50 mM boric acid, 0.1 mM CaCl.sub.2,
pH adjusted to the value of interest with NaOH). The test is
performed in a water bath at the temperature of interest. The
alpha-amylase to be tested is diluted in x ml of 50 mM
Britton-Robinson buffer. 1 ml of this alpha-amylase solution is
added to the 5 ml 50 mM Britton-Robinson buffer. The starch is
hydrolyzed by the alpha-amylase giving soluble blue fragments. The
absorbance of the resulting blue solution, measured
spectrophotometrically at 620 nm, is a function of the
alpha-amylase activity.
[0594] It is important that the measured 620 nm absorbance after 10
or 15 minutes of incubation (testing time) is in the range of 0.2
to 2.0 absorbance units at 620 nm. In this absorbance range there
is linearity between activity and absorbance (Lambert-Beer law).
The dilution of the enzyme must therefore be adjusted to fit this
criterion. Under a specified set of conditions (temp., pH, reaction
time, buffer conditions) 1 mg of a given alpha-amylase will
hydrolyze a certain amount of substrate and a blue colour will be
produced. The colour intensity is measured at 620 nm. The measured
absorbance is directly proportional to the specific activity
(activity/mg of pure alpha-amylase protein) of the alpha-amylase in
question under the given set of conditions.
Alternative Alpha-Amylase Activity Method (PNP-G7 Assay)
[0595] Alpha-amylase activity is determined by a method employing
the PNP-G7 substrate. PNP-G7 which is a abbreviation for
p-nitrophenyl-alpha,D-maltoheptaoside is a blocked oligosaccharide
which can be cleaved by an endo-amylase. Following the cleavage,
the alpha-glucosidase included in the kit digest the substrate to
liberate a free PNP molecule which has a yellow colour and thus can
be measured by visible spectophometry at A=405 nm (400-420 nm).
Kits containing PNP-G7 substrate and alpha-glucosidase is
manufactured by Boehringer-Mannheim (cat. no. 1054635).
[0596] To prepare the substrate one bottle of substrate (BM
1442309) is added to 5 ml buffer (BM1442309). To prepare the
alpha-glucosidase one bottle of alpha-glucosidase (BM 1462309) is
added to 45 ml buffer (BM1442309). The working solution is made by
mixing 5 ml alpha-glucosidase solution with 0.5 ml substrate.
[0597] The assay is performed by transforming 20 .mu.l enzyme
solution to a 96 well microtiter plate and incubating at 25.degree.
C. 200 .mu.l working solution, 25.degree. C. is added. The solution
is mixed and pre-incubated 1 minute and absorption is measured
every 15 sec. over 3 minutes at OD 405 nm.
[0598] The slope of the time dependent absorption-curve is directly
proportional to the specific activity (activity per mg enzyme) of
the alpha-amylase in question under the given set of
conditions.
EXAMPLES
Example 1
Construction of Variants of BSG Alpha-Amylase (SEQ ID NO: 3)
[0599] The gene encoding BSG, amyS, is located in plasmid pPL1117.
This plasmid contains also the gene conferring resistance towards
kanamycin and an origin of replication, both obtained from plasmid
pUB110 (Gryczan et al., 1978, J. Bact. 134:318-329).
[0600] The DNA sequence of the mature part of amyS is shown as SEQ
ID NO: 11 and the amino acid sequence of the mature protein is
shown as SEQ ID NO: 3
[0601] BSG variant TVB145, which contains a deletion of 6
nucleotides corresponding to amino acids I181-G182 in the mature
protein, is constructed as follows:
[0602] Polymerase Chain Reaction (PCR) is utilized to amplify the
part of the amyS gene (from plasmid pPL1117), located between DNA
primers BSG1 (SEQ ID NO: 16) and BSGM2 (SEQ ID NO: 19). BSG1 is
identical to a part of the amyS gene whereas BSGM2 contains the 6
by nucleotide deletion. A standard PCR reaction is carried out:
94.degree. C. for 5 minutes, 25 cycles of (94.degree. C. for 45
seconds, 50.degree. C. for 45 seconds, 72.degree. C. for 90
seconds), 72.degree. C. for 7 minutes using the Pwo polymerase
under conditions as recommended by the manufacturer, Boehringer
Mannheim Gmbh.
[0603] The resulting approximately 550 by amplified band was used
as a megaprimer (Barik and Galinski, 1991, Biotechniques 10:
489-490) together with primer BSG3 in a second PCR with pPL1117 as
template resulting in a DNA fragment of approximately 1080 bp.
[0604] This DNA fragment is digested with restriction endonucleases
Acc651 and SalI and the resulting approximately 550 by fragment is
ligated into plasmid pPL1117 digested with the same enzymes and
transformed into the protease- and amylase-deleted Bacillus
subtilis strain SHA273 (described in WO 92/11357 and WO
95/10603).
[0605] Kanamycin resistant and starch degrading transformants were
analysed for the presence of the desired mutations (restriction
digest to verify the introduction of a HindIII site in the gene).
The DNA sequence between restriction sites Acc651 and SalI was
verified by DNA sequencing to ensure the presence of only the
desired mutations.
[0606] BSG variant TVB146 which contains the same 6 nucleotide
deletion as TVB145 and an additional substitution of asparagine 193
for a phenylalanine, N193F, was constructed in a similar way as
TVB145 utilizing primer BSGM3 (SEQ ID NO: 20) in the first PCR.
[0607] BSG variant TVB161, containing the deletion of I181-G182,
N193F, and L204F, is constructed in a similar way as the two
previous variants except that the template for the PCR reactions is
plasmid pTVB146 (pPL1117 containing the TVB146-mutations within
amyS and the mutagenic oligonucleotide for the first PCR is
BSGM3.
[0608] BSG variant TVB162, containing the deletion of I181-G182,
N193F, and E210H, is constructed in a similar way as TVB161 except
that the mutagenic oligonucleotide is BSGM4 (SEQ ID NO: 21).
[0609] BSG variant TVB163, containing the deletion of I181-G182,
N193F, and E214Q, is constructed in a similar way as TVB161 except
that the mutagenic oligonucleotide is BSGM5 (SEQ ID NO: 22).
[0610] The above constructed BSG variants were then fermented and
purified as described above in the "Material and Methods"
section.
Example 2
Measurement of the Calcium- and pH-Dependent Stability
[0611] Normally, the industrial liquefaction process runs using pH
6.0-6.2 as liquefaction pH and an addition of 40 ppm free calcium
in order to improve the stability at 95.degree. C.-105.degree. C.
Some of the herein proposed substitutions have been made in order
to improve the stability at
1. lower pH than pH 6.2 and/or 2. at free calcium levels lower than
40 ppm free calcium.
[0612] Two different methods have been used to measure the
improvements in stability obtained by the different substitutions
in the alpha-amylase from B. stearothermophilus:
[0613] Method 1. One assay which measures the stability at reduced
pH, pH 5.0, in the presence of 5 ppm free calcium.
[0614] 10 .mu.g of the variant were incubated under the following
conditions: A 0.1 M acetate solution, pH adjusted to pH 5.0,
containing 5 ppm calcium and 5% w/w common corn starch (free of
calcium). Incubation was made in a water bath at 95.degree. C. for
30 minutes.
[0615] Method 2. One assay which measure the stability in the
absence of free calcium and where the pH is maintained at pH 6.0.
This assay measures the decrease in calcium sensitivity:
[0616] 10 .mu.g of the variant were incubated under the following
conditions: A 0.1 M acetate solution, pH adjusted to pH 6.0,
containing 5% w/w common corn starch (free of calcium). Incubation
was made in a water bath at 95.degree. C. for 30 minutes.
Stability Determination
[0617] All the stability trials 1, 2 have been made using the same
set up. The method was:
[0618] The enzyme was incubated under the relevant conditions
(1-4). Samples were taken at 0, 5, 10, 15 and 30 minutes and
diluted 25 times (same dilution for all taken samples) in assay
buffer (0.1 M 50 mM Britton buffer pH 7.3) and the activity was
measured using the Phadebas assay (Pharmacia) under standard
conditions pH 7.3, 37.degree. C.
[0619] The activity measured before incubation (0 minutes) was used
as reference (100%). The decline in percent was calculated as a
function of the incubation time. The table shows the residual
activity after 30 minutes of incubation.
Stability Method 1./Low pH Stability Improvement
TABLE-US-00020 [0620] SEQ. ID NO: 3 SEQ. ID NO: 3 VARIANT WITH SEQ.
ID NO: 3 VARIANT WITH DELETION IN VARIANT WITH DELETION IN POS.
I181- WT. SEQ. ID. DELETION IN Pos. I181- G182 + N193F + MINUTES OF
NO: 3 AMYLASE Pos. I181-G182 G182 + N193F E214Q INCUBATION (BSG)
(TVB145) (TVB146) (TVB163) 0 100 100 100 100 5 29 71 83 77 10 9 62
77 70 15 3 50 72 67 30 1 33 62 60
Stability Method 1./Low pH Stability Improvement
[0621] The temperature described in method 1 has been reduced from
95.degree. C. to 70.degree. C. since the amylases mentioned for SEQ
ID NO: 1 and 2 have a lower thermostability than the one for SEQ ID
NO: 3.
TABLE-US-00021 SEQ. ID NO: 2 SEQ. ID NO: 1 VARIANT WITH VARIANT
WITH DELETION IN DELETION IN MINUTES OF WT. SEQ. ID. POS. D183-
SEQ. ID NO: 1 Pos. T183- INCUBATION NO: 2 AMYLASE G184 AMYLASE G184
0 100 100 100 100 5 73 92 41 76 10 59 88 19 69 15 48 91 11 62 30 28
92 3 59
Stability Method 2./Low Calcium Sensitivity
TABLE-US-00022 [0622] SEQ ID NO: 3 SEQ ID NO: 3 VARIANT WITH SEQ ID
NO: 3 VARIANT WITH DELETION IN WT. SEQ ID VARIANT WITH DELETION IN
Pos. I181- NO: 3 DELETION IN Pos. I181- G182 + N193F + MINUTES OF
AMYLASE Pos. I181-G182 G182 + N193F E214Q INCUBATION (BSG) (TVB145)
(TVB146) (TVB163) 0 100 100 100 100 5 60 82 81 82 10 42 76 80 83 15
31 77 81 79 30 15 67 78 79
Specific Activity Determination.
[0623] The specific activity was determined using the Phadebas
assay (Pharmacia) as activity/mg enzyme. The activity was
determined using the alpha-amylase assay described in the Materials
and Methods section herein.
[0624] The specific activity of the parent enzyme and a single and
a double mutation was determined to:
TABLE-US-00023 BSG: SEQ ID NO: 3 (Parent enzyme) 20000 NU/mg
TVB145: SEQ ID NO: 3 with the deletion in positions I181-G182:
(Single mutation) 34600 NU/mg TVB146: SEQ ID NO: 3 with the
deletion in positions I181-G182 + N193F: (Double mutation) 36600
NU/mg TVB163: SEQ ID NO: 3 with the deletion in positions I181-G182
+ N193F + E214Q: (Triple mutation) 36300 NU/mg
Example 3
Pilot Plant Jet Cook and Liquefaction with Alpha-Amylase Variant
TVB146
[0625] Pilot plant liquefaction experiments were run in the
mini-jet system using a dosage of 50 NU (S)/g DS at pH 5.5 with 5
ppm added Ca.sup.++, to compare the performance of formulated BSG
alpha-amylase variant TVB146 (SEQ ID NO: 3 with deletion in
positions I181-G182+N193F) with that of parent BSG alpha-amylase
(SEQ ID NO: 3). The reaction was monitored by measuring the DE
increase (Neocuproine method) as a function of time.
[0626] Corn starch slurries were prepared by suspending 11.8 kg
Cerestar C*Pharm GL 03406 (89% starch) in deionized water and
making up to 30 kg. The pH was adjusted to 5.5 at ambient
temperature, after the addition of 0.55 g CaCl.sub.2.
2H.sub.2O.
[0627] The following enzymes were used:
TABLE-US-00024 TVB146 108 KNU(S)/g, 146 KNU(SM9)/g BSG amylase 101
KNU(S)/g, 98 KNU(SM9)/g
[0628] An amount of enzyme corresponding to 50 NU (SM9)/g DS was
added, and the conductivity adjusted to 300 mS using NaCl. The
standard conditions were as follows:
TABLE-US-00025 Substrate concentration 35% w/w (initial) 31.6-31.9%
w/w (final) Temperature 105.degree. C., 5 minutes (Primary
liquefaction) 95.degree. C., 90 minutes (Secondary liquefaction) pH
(initial) 5.5
[0629] After jetting, the liquefied starch was collected and
transported in sealed thermos-flasks from the pilot plant to the
laboratory, where secondary liquefaction was continued at
95.degree. C.
[0630] 10 ml samples were taken at 15 minute intervals from 15-90
minutes. 2 drops of 1 N HCl were added to inactivate the enzyme.
From these samples, 0.3-0.1 g (according to the expected DE) were
weighed out and diluted to 100 ml. Reducing sugars were then
determined according to the Neocuproine method (Determination of
reducing sugar with improved precision. Dygert et al., 1965, Anal.
Biochem. 13: 368) and DE values determined. The development of DE
as a function of time is given in the following table:
TABLE-US-00026 DE (neocuproine) Time (min.) TVB146 BSG 15 2.80 2.32
30 4.88 3.56 45 6.58 4.98 60 8.17 6.00 75 9.91 7.40 90 11.23
8.03
[0631] As can be seen the alpha-amylase variant TVB146 performed
significantly better under industrially relevant application
conditions at low levels of calcium than the parent BSG
alpha-amylase.
Example 4
Jet Cook and Liquefaction with a Combination of Alpha-Amylase
Variants (TVB146 and LE174)
[0632] Jet cook and liquefaction using a combination of the
alpha-amylase variants, TVB146 and LE174 (ratio 1:1) were carried
out at the following conditions:
TABLE-US-00027 Substrate A.E. Staley food grade powdered corn
starch (100 lbs) D.S. 35% using DI water Free Ca.sup.2+ 2.7 ppm at
pH 5.3 (none added, from the starch only) Initial pH 5.3
Dose AF9 units (AF9 is available on request) for each enzyme
variant was 28 NU/g starch db for a total dose of 56 NU/g
Temperature in primary liquefaction 105.degree. C. Hold time in
primary liquefaction 5 minutes Temperature in secondary
liquefaction 95.degree. C.
[0633] At 15 minutes into secondary liquefaction 1.5 gms of
hydrolyzate was added to a tared one liter volumetric containing
500 cc of DI water and 1 ml of one normal HCl and the exact wt.
added was recorded. This was repeated at 15 minute intervals out to
90 minutes with an additional point at 127 minutes. These were
diluted to one liter and determined for dextrose equivalence via
Neocuproine method as described by Dygert et al., 1965,
Determination of reducing sugar with improved precision, Anal.
Biochem. 13: 368.
[0634] The results were as follows:
TABLE-US-00028 Time DE 15 3.2 30 4.8 45 6.3 60 7.8 75 9.4 90 10.4
127 13.1
Example 5
Isolation of Genomic DNA from DSM 12648 and DSM 12649
[0635] The strains Bacillus sp. DSM 12649 (the AA560 alpha-amylase)
and Bacillus sp. DSM 12648 (the AA349 alpha-amylase) were
propagated in liquid TY medium (as described in Ausubel et al.
(1995)). After 16 hours incubation at 37.degree. C. and 300 rpm,
the cells were harvested, and genomic DNA isolated by the method
described by Pitcher et al. (1989).
Genomic Library Construction
[0636] Genomic DNA of strain DSM 12649 was partially digested with
restriction enzyme Sau3A, and size-fractionated by electrophoresis
on a 0.7% agarose gel. Fragments between 2 and 10 kb in size were
isolated by electrophoresis onto DEAE-cellulose paper (Dretzen et
al. (1981).
[0637] Isolated DNA fragments were ligated to BamHI digested
pSJ1678 plasmid DNA, and the ligation mixture was used to transform
E. coli SJ2.
Transformation
[0638] E. coli SJ2 host cells were prepared for and transformed by
electroporation using a gene PULSER.TM. electroporator from BIO-RAD
as described by the supplier.
Identification of Positive Transformant:
[0639] A DNA library in E. coli SJ2, constructed as described
above, was screened on LB agar plates (described in Ausbel et al.
(1995)) containing 0.5% AZCL-amylose (Megazyme) and 10 ig/ml
Chloramphenicol and incubated overnight at 37.degree. C. Clones
expressing amylase activity appeared with blue diffusion haloes.
One such clone was named LiH1274. The DNA was further characterized
by DNA sequencing of part of the cloned Sau3A DNA fragment.
Example 6
Determination of the DNA Sequence of the Gene Encoding
Alpha-Amylase from Strain DSM 12648 (AA349)
[0640] The clone constituting a large chromosomal fragment
containing the gene encoding the amylolytic activity inserted into
plasmid pSJ1678, pLiH1247, was used as template to specifically PCR
amplify internal DNA fragments of the alpha-amylase encoding gene
by the use of degenerate primers directed towards the conserved
regions in known Bacillus alpha-amylases.
[0641] The degenerate primers were directed towards the following
regions/amino acid sequences:
TABLE-US-00029 For36: (SEQ ID NO: 27) GITA(L/V/I)W(I/L) For97: (SEQ
ID NO: 28) VY(G/A)D(V/F/L)V(M/L/I/F)NH For227: (SEQ ID NO: 29)
DG(F/I)R(F/L/I/V)DA(A/V)KH Rev235: (SEQ ID NO: 30)
DG(F/I)R(F/L/I/V)DA(A/V)KH Rev328: (SEQ ID NO: 31) VTFV(D/E)NHD
Rev410: (SEQ ID NO: 32) GWTREG
[0642] The various combinations of forward (For) and reverse (Rev)
primers were used in PCR and internal DNA fragments could be
amplified.
[0643] The DNA fragments were purified by QIAquick spin columns
(QUIGEN) and sequenced utilizing the same degenerate primers.
[0644] From sequence the DNA sequence (SEQ ID NO: 23) of the
complete coding region encoding the mature AA349 alpha-amylase (SEQ
ID NO: 26) was determined by a standard primers-walking
approach.
Example 7
Determination of the DNA Sequence of the Gene Encoding Alpha
Amylase from Strain DSM 12649 (AA560)
[0645] A preparation of chromosomal DNA from strain DSM 12649 was
utilized as template in a similar experiment to the one described
above in Example 7 in order to determine the DNA sequence of the
AA560 alpha-amylase (SEQ ID NO: 24).
Example 8
Subcloning of the AA349 Alpha-Amylase into pTVB110
[0646] pTVB110 is a plasmid replicating in Bacillus subtilis by the
use of origin of replication from pUB110 (Gryczan, 1978, J. Bact.
134:318-329). The plasmid further encodes the cat gene, conferring
resistance towards chlorampenicol, obtained from plasmid pC194
(Horinouchi and Weisblum, 1982, J. Bact. 150: 815-825). The plasmid
harbors a truncated version of the Bacillus licheniformis
alpha-amylase gene, amyL, such that the amyL promoter, signal
sequence and transcription terminator are present, but the plasmid
does not provide an amy-plus phenotype (halo formation on starch
containing agar).
[0647] In order to express high amount of the AA349 alpha-amylase
the mature gene was fused precisely to the amyL signal sequence so
that transcription is initiated by the amyL promoter and
translocation is directed by the amyL signal sequence.
[0648] A PstI site is found within the mature AA349 alpha-amylase.
Since the cloning of the gene into pTVB110 would utilize the PstI
site in pTVB110, the PstI site located within the AA349
alpha-amylase gene was destroyed during the cloning (by
introduction of a silent mutation for amino acid Alanine 88 (GCA to
GCG).
[0649] Primers 188cloningN and 188(Pst-) were used to amplify an
approximately 280 by fragment by PCR on plasmid pLiH1247 using the
Pwo polymerase under conditions recommended by the manufacturer
(Boehringer Mannheim). This fragment was purified from agarose gel
and used as a megaprimer (Sarkar and Sommer, 1990, Biotechniques 8:
404-407) together with primer 188 cloning C to amplify the full
length gene encoding the mature amylase in a second PCR.
[0650] The resulting approximately 1480 by fragment was digested
with restriction endonucleases PstI and SfiI and ligated with
plasmid pTVB110 digested with the same enzymes.
[0651] Protease and amylase deleted Bacillus subtilis strain SHa273
(mentioned in WO 95/10603) was transformed with the ligation
mixture and the DNA sequence of an amy-plus transformant was
verified. This plasmid is denoted pTVB231.
Oligonucleotides:
TABLE-US-00030 [0652] 188(Pst-): (SEQ ID NO: 33) 5' GGC GTT AAC CGC
AGC TTG TAA C 188cloningC: (SEQ ID NO: 34) 5' CCG AGC TCG GCC GGC
TGG GCC GTC GAC TTA TTT GTT TAC CCA AAT AGA AAC 188cloningN: (SEQ
ID NO: 35) 5' CAT TCT GCA GCA GCG GCG CAC CAT AAT GGT ACG AAC G
Example 9
Subcloning of the AA560 Alpha-Amylase into pTVB110
[0653] DNA sequencing revealed a high DNA identity between
alpha-amylases from stains DSM12648 (AA349) and DSM 12649 (AA560).
Consequently the same oligonucleotides and strategy was utilized
for the cloning of AA560 alpha-amylase into expression vector
pTVB110 resulting in plasmid pTVB232, which was then fermented
using standard techniques.
Example 10
Purification of the AA560 Alpha-Amylase
[0654] The culture broth was flocculated by adding 0.01 ml 50%
(w/w) CaCl.sub.2, 2H.sub.20, 0.0125 ml 12% (w/w) Sodium aluminate,
0.025 ml 10% C521 and 0.075 ml 0.1% A130 pr. ml culture broth. A
clear solution was obtained after centrifugation. The enzyme
solution was added ammonium sulphate to a final concentration of
1.2 M and applied on a Butyl Toyo Pearl column (100 ml) previously
equilibrated in 1.2 M ammonium sulphate, 10 mM Tris-HCl, pH 7.0.
The amylase was eluted using 5 mM Tris-HCl, pH 7.0 and the eluted
pool was dialysed against 5 mM Tris-HCl over night. The fraction
was then subjected to ion exchange chromatography using a
Q-Sepharose column (200 ml) previously equilibrated in 20 mM
Tris-HCl, pH 9.0. Unbound material was washed out with the
equilibration buffer, and the amylase was eluted using a linear
gradient 0-1 M NaCl, 20 mM Tris-HCl, pH 9.0. Purity of the amylase
preparation was above 95% judged by SDS-PAGE.
Example 11
Characterization of the AA560 Alpha-Amylase
[0655] The alpha-amylase activity was measured using both the
Phadebas assay (37.degree. C., pH 7.3) and the Alternative pNPG7
Assay (25.degree. C., pH 7.1) described above. pH- and temperature
profiles were made at selected pH- and temperature values. The
pH-profile was measured at 37.degree. C. and the temperature
profile was measured at pH 9.0
[0656] Isoelectric Point was determined using isoelectric focusing
(Pharmacia, Ampholine, pH 3.5-9.3).
TABLE-US-00031 TABLE 1 Specific activity and pl. Specific activity
NU/ml NU/ml Enzyme Phadebas pNPG7 pl AA560 (SEQ ID NO: 4) 35000
6000 7-8 SP722 (SEQ ID NO: 2) 35000 6000 7-9 SP690 (SEQ ID NO: 1)
35000 7000 5-6 E = 3.2 cm.sup.-1*(g/l).sup.-1 for AA560, SP722 and
SP690
[0657] The result of the pH-optimum determination and temperature
optimum determination is shown in FIG. 2 and FIG. 3,
respectively.
Example 12
Washing Test
[0658] Washing performance was evaluated by washing soiled test
swatches for 15 and 30 minutes at 25.degree. C. and 40.degree. C.,
respectively, in detergent solutions with the AA560 alpha-amylase
of the invention.
[0659] The detergents used are disclosed in Table 2 below. The A/P
Model Detergent is described in the Materials section above. The
other detergents are commercially available detergents. Commercial
detergents containing amylase were inactivated by microwaves before
wash.
[0660] The purified recombinant AA560 alpha-amylase of Example 6
was added to the detergent solutions at the concentration indicated
below. The test swatches were soiled with orange rice starch (CS-28
swatches available from CFT, Center for Test Material, Holland).
After washing, the swatches were evaluated by measuring the
remission at 460 nm using a Elrepho Remission Spectrophotometer.
The results are expressed as .DELTA.R=remission of the swatch
washed with the alpha-amylase minus the remission of a swatch
washed at the same conditions without the alpha-amylase.
TABLE-US-00032 TABLE 2 Detergents and wash conditions. Det. Enzyme
Water Dose dose Temp. Time hardness Area Detergent g/l Inactivation
mg/l .degree. C. min pH .degree. dH Ca:Mg A/P Model 3 - 1 25 15
10.5 6 2:1 detergent 97 Latin Omo Multi 3 - 1 25 15 10.6 6 2:1
America Acao Europe Omo conc. 4 + 0.2 40 30 10.2 15 4:1 Powder
Europe Ariel Futur 5 + 0.2 40 30 9.0 15 4:1 liquid
[0661] The results are shown in FIGS. 4-7. The results demonstrate
that the alpha-amylase of the invention is effective in both
detergents at highly alkaline pH.
[0662] The invention described and claimed herein is not to be
limited in scope by the specific embodiments herein disclosed,
since these embodiments are intended as illustrations of several
aspects of the invention. Any equivalent embodiments are intended
to be within the scope of this invention. Indeed, various
modifications of the invention in addition to those shown and
described herein will become apparent to those skilled in the art
from the foregoing description. Such modifications are also
intended to fall within the scope of the appended claims. In the
case of conflict, the present disclosure including definitions will
control.
[0663] Various references are cited herein, the disclosures of
which are incorporated by reference in their entireties.
REFERENCES CITED
[0664] Klein et al., 1992, Biochemistry 31: 8740-8746. Mizuno et
al., 1993, J. Mol. Biol. 234: 1282-1283. [0665] Chang et al, 1993,
J. Mol. Biol. 229: 235-238. [0666] Larson, 1994, J. Mol. Biol. 235:
1560-1584. [0667] Lawson, 1994, J. Mol. Biol. 236: 590-600. [0668]
Qian et al., 1993, J. Mol. Biol. 231: 785-799. [0669] Brady et al.,
Acta Crystallogr. sect. B, 47, 527-535. [0670] Swift et al., Acta
Crystallogr. sect. B, 47, 535-544. [0671] A. Kadziola, Ph.D.
Thesis: "An alpha-amylase from Barley and its Complex with a
Substrate Analogue Inhibitor Studied by X-ray Crystallography",
Department of Chemistry University of Copenhagen 1993. [0672]
MacGregor, 1987, Food Hydrocolloids, Vol. 1, No. 5-6. [0673]
Diderichsen and Christiansen, 1998, Cloning of a maltogenic
alpha-amylase from Bacillus stearothermophilus, FEMS Microbiol.
Letters 56: 53-60. [0674] Hudson et al., Practical Immunology,
Third edition (1989), Blackwell Scientific Publications. Sambrook
et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold
Spring Harbor, 1989. [0675] Beaucage and Caruthers, 1981,
Tetrahedron Letters 22: 1859-1869 [0676] Matthes et al., 1984, The
EMBO J. 3: 801-805. [0677] Saiki et al., 1988, Science 239:
487-491. [0678] Morinaga et al., 1984, Biotechnology 2:646-639)
[0679] Nelson and Long, 1989, Analytical Biochemistry 180: 147-151
[0680] Hunkapiller et al., 1984, Nature 310:105-111 [0681] Higuchi
et al., 1988, A general method of in vitro preparation and specific
mutagenesis of DNA fragments: study of protein and DNA
interactions. Nucl. Acids Res. 16:7351-7367. [0682] Dubnau et al.,
1971, J. Mol. Biol. 56: 209-221. [0683] Gryczan et al., 1978, J.
Bacteriol. 134: 318-329. [0684] S. D. Erlich, 1977, Proc. Natl.
Acad. Sci. 74: 1680-1682. [0685] Boel et al., 1990, Biochemistry
29: 6244-6249. [0686] Ausubel, F. M. et al. (eds.); Current
protocols in Molecular Biology; 1995; John Wiley and Sons. [0687]
Harwood C. R., and Cutting S. M. (eds.); Molecular Biological
Methods for Bacillus; 1990; John Wiley and Sons. [0688] Diderichsen
et al., 1990, Cloning of aldB, which encodes alpha-acetolactate
decarboxylase, an exoenzyme from Bacillus brevis; J. Bacteriol.
172: 4315-4321. [0689] Pitcher et al., 1989, Rapid extraction of
bacterial genomic DNA with guanidium thiocyanate; Lett. Appl.
Microbiol. 8: 151-156. [0690] Dretzen et al., 1981, A reliable
method for the recovery of DNA fragments from agarose and
acrylamide gels; Anal. Biochem. 112: 295-298.
Sequence CWU 1
1
371485PRTBacillus sp. 1His His Asn Gly Thr Asn Gly Thr Met Met Gln
Tyr Phe Glu Trp Tyr 1 5 10 15 Leu Pro Asn Asp Gly Asn His Trp Asn
Arg Leu Arg Asp Asp Ala Ala 20 25 30 Asn Leu Lys Ser Lys Gly Ile
Thr Ala Val Trp Ile Pro Pro Ala Trp 35 40 45 Lys Gly Thr Ser Gln
Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr 50 55 60 Asp Leu Gly
Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly 65 70 75 80 Thr
Arg Asn Gln Leu Gln Ala Ala Val Thr Ser Leu Lys Asn Asn Gly 85 90
95 Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp
100 105 110 Gly Thr Glu Ile Val Asn Ala Val Glu Val Asn Arg Ser Asn
Arg Asn 115 120 125 Gln Glu Thr Ser Gly Glu Tyr Ala Ile Glu Ala Trp
Thr Lys Phe Asp 130 135 140 Phe Pro Gly Arg Gly Asn Asn His Ser Ser
Phe Lys Trp Arg Trp Tyr 145 150 155 160 His Phe Asp Gly Thr Asp Trp
Asp Gln Ser Arg Gln Leu Gln Asn Lys 165 170 175 Ile Tyr Lys Phe Arg
Gly Thr Gly Lys Ala Trp Asp Trp Glu Val Asp 180 185 190 Thr Glu Asn
Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Val Asp Met 195 200 205 Asp
His Pro Glu Val Ile His Glu Leu Arg Asn Trp Gly Val Trp Tyr 210 215
220 Thr Asn Thr Leu Asn Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His
225 230 235 240 Ile Lys Tyr Ser Phe Thr Arg Asp Trp Leu Thr His Val
Arg Asn Thr 245 250 255 Thr Gly Lys Pro Met Phe Ala Val Ala Glu Phe
Trp Lys Asn Asp Leu 260 265 270 Gly Ala Ile Glu Asn Tyr Leu Asn Lys
Thr Ser Trp Asn His Ser Val 275 280 285 Phe Asp Val Pro Leu His Tyr
Asn Leu Tyr Asn Ala Ser Asn Ser Gly 290 295 300 Gly Tyr Tyr Asp Met
Arg Asn Ile Leu Asn Gly Ser Val Val Gln Lys 305 310 315 320 His Pro
Thr His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro 325 330 335
Gly Glu Ala Leu Glu Ser Phe Val Gln Gln Trp Phe Lys Pro Leu Ala 340
345 350 Tyr Ala Leu Val Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe
Tyr 355 360 365 Gly Asp Tyr Tyr Gly Ile Pro Thr His Gly Val Pro Ala
Met Lys Ser 370 375 380 Lys Ile Asp Pro Leu Leu Gln Ala Arg Gln Thr
Phe Ala Tyr Gly Thr 385 390 395 400 Gln His Asp Tyr Phe Asp His His
Asp Ile Ile Gly Trp Thr Arg Glu 405 410 415 Gly Asn Ser Ser His Pro
Asn Ser Gly Leu Ala Thr Ile Met Ser Asp 420 425 430 Gly Pro Gly Gly
Asn Lys Trp Met Tyr Val Gly Lys Asn Lys Ala Gly 435 440 445 Gln Val
Trp Arg Asp Ile Thr Gly Asn Arg Thr Gly Thr Val Thr Ile 450 455 460
Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val Ser 465
470 475 480 Val Trp Val Lys Gln 485 2485PRTBacillus sp. 2His His
Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp His 1 5 10 15
Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Asp Asp Ala Ser 20
25 30 Asn Leu Arg Asn Arg Gly Ile Thr Ala Ile Trp Ile Pro Pro Ala
Trp 35 40 45 Lys Gly Thr Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr
Asp Leu Tyr 50 55 60 Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val
Arg Thr Lys Tyr Gly 65 70 75 80 Thr Arg Ser Gln Leu Glu Ser Ala Ile
His Ala Leu Lys Asn Asn Gly 85 90 95 Val Gln Val Tyr Gly Asp Val
Val Met Asn His Lys Gly Gly Ala Asp 100 105 110 Ala Thr Glu Asn Val
Leu Ala Val Glu Val Asn Pro Asn Asn Arg Asn 115 120 125 Gln Glu Ile
Ser Gly Asp Tyr Thr Ile Glu Ala Trp Thr Lys Phe Asp 130 135 140 Phe
Pro Gly Arg Gly Asn Thr Tyr Ser Asp Phe Lys Trp Arg Trp Tyr 145 150
155 160 His Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Gln Phe Gln Asn
Arg 165 170 175 Ile Tyr Lys Phe Arg Gly Asp Gly Lys Ala Trp Asp Trp
Glu Val Asp 180 185 190 Ser Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr
Ala Asp Val Asp Met 195 200 205 Asp His Pro Glu Val Val Asn Glu Leu
Arg Arg Trp Gly Glu Trp Tyr 210 215 220 Thr Asn Thr Leu Asn Leu Asp
Gly Phe Arg Ile Asp Ala Val Lys His 225 230 235 240 Ile Lys Tyr Ser
Phe Thr Arg Asp Trp Leu Thr His Val Arg Asn Ala 245 250 255 Thr Gly
Lys Glu Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu 260 265 270
Gly Ala Leu Glu Asn Tyr Leu Asn Lys Thr Asn Trp Asn His Ser Val 275
280 285 Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Asn Ser
Gly 290 295 300 Gly Asn Tyr Asp Met Ala Lys Leu Leu Asn Gly Thr Val
Val Gln Lys 305 310 315 320 His Pro Met His Ala Val Thr Phe Val Asp
Asn His Asp Ser Gln Pro 325 330 335 Gly Glu Ser Leu Glu Ser Phe Val
Gln Glu Trp Phe Lys Pro Leu Ala 340 345 350 Tyr Ala Leu Ile Leu Thr
Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr 355 360 365 Gly Asp Tyr Tyr
Gly Ile Pro Thr His Ser Val Pro Ala Met Lys Ala 370 375 380 Lys Ile
Asp Pro Ile Leu Glu Ala Arg Gln Asn Phe Ala Tyr Gly Thr 385 390 395
400 Gln His Asp Tyr Phe Asp His His Asn Ile Ile Gly Trp Thr Arg Glu
405 410 415 Gly Asn Thr Thr His Pro Asn Ser Gly Leu Ala Thr Ile Met
Ser Asp 420 425 430 Gly Pro Gly Gly Glu Lys Trp Met Tyr Val Gly Gln
Asn Lys Ala Gly 435 440 445 Gln Val Trp His Asp Ile Thr Gly Asn Lys
Pro Gly Thr Val Thr Ile 450 455 460 Asn Ala Asp Gly Trp Ala Asn Phe
Ser Val Asn Gly Gly Ser Val Ser 465 470 475 480 Ile Trp Val Lys Arg
485 3514PRTB. stearothermophilus 3Ala Ala Pro Phe Asn Gly Thr Met
Met Gln Tyr Phe Glu Trp Tyr Leu 1 5 10 15 Pro Asp Asp Gly Thr Leu
Trp Thr Lys Val Ala Asn Glu Ala Asn Asn 20 25 30 Leu Ser Ser Leu
Gly Ile Thr Ala Leu Trp Leu Pro Pro Ala Tyr Lys 35 40 45 Gly Thr
Ser Arg Ser Asp Val Gly Tyr Gly Val Tyr Asp Leu Tyr Asp 50 55 60
Leu Gly Glu Phe Asn Gln Lys Gly Ala Val Arg Thr Lys Tyr Gly Thr 65
70 75 80 Lys Ala Gln Tyr Leu Gln Ala Ile Gln Ala Ala His Ala Ala
Gly Met 85 90 95 Gln Val Tyr Ala Asp Val Val Phe Asp His Lys Gly
Gly Ala Asp Gly 100 105 110 Thr Glu Trp Val Asp Ala Val Glu Val Asn
Pro Ser Asp Arg Asn Gln 115 120 125 Glu Ile Ser Gly Thr Tyr Gln Ile
Gln Ala Trp Thr Lys Phe Asp Phe 130 135 140 Pro Gly Arg Gly Asn Thr
Tyr Ser Ser Phe Lys Trp Arg Trp Tyr His 145 150 155 160 Phe Asp Gly
Val Asp Trp Asp Glu Ser Arg Lys Leu Ser Arg Ile Tyr 165 170 175 Lys
Phe Arg Gly Ile Gly Lys Ala Trp Asp Trp Glu Val Asp Thr Glu 180 185
190 Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Leu Asp Met Asp His
195 200 205 Pro Glu Val Val Thr Glu Leu Lys Ser Trp Gly Lys Trp Tyr
Val Asn 210 215 220 Thr Thr Asn Ile Asp Gly Phe Arg Leu Asp Ala Val
Lys His Ile Lys 225 230 235 240 Phe Ser Phe Phe Pro Asp Trp Leu Ser
Asp Val Arg Ser Gln Thr Gly 245 250 255 Lys Pro Leu Phe Thr Val Gly
Glu Tyr Trp Ser Tyr Asp Ile Asn Lys 260 265 270 Leu His Asn Tyr Ile
Met Lys Thr Asn Gly Thr Met Ser Leu Phe Asp 275 280 285 Ala Pro Leu
His Asn Lys Phe Tyr Thr Ala Ser Lys Ser Gly Gly Thr 290 295 300 Phe
Asp Met Arg Thr Leu Met Thr Asn Thr Leu Met Lys Asp Gln Pro 305 310
315 320 Thr Leu Ala Val Thr Phe Val Asp Asn His Asp Thr Glu Pro Gly
Gln 325 330 335 Ala Leu Gln Ser Trp Val Asp Pro Trp Phe Lys Pro Leu
Ala Tyr Ala 340 345 350 Phe Ile Leu Thr Arg Gln Glu Gly Tyr Pro Cys
Val Phe Tyr Gly Asp 355 360 365 Tyr Tyr Gly Ile Pro Gln Tyr Asn Ile
Pro Ser Leu Lys Ser Lys Ile 370 375 380 Asp Pro Leu Leu Ile Ala Arg
Arg Asp Tyr Ala Tyr Gly Thr Gln His 385 390 395 400 Asp Tyr Leu Asp
His Ser Asp Ile Ile Gly Trp Thr Arg Glu Gly Val 405 410 415 Thr Glu
Lys Pro Gly Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro 420 425 430
Gly Gly Ser Lys Trp Met Tyr Val Gly Lys Gln His Ala Gly Lys Val 435
440 445 Phe Tyr Asp Leu Thr Gly Asn Arg Ser Asp Thr Val Thr Ile Asn
Ser 450 455 460 Asp Gly Trp Gly Glu Phe Lys Val Asn Gly Gly Ser Val
Ser Val Trp 465 470 475 480 Val Pro Arg Lys Thr Thr Val Ser Thr Ile
Ala Trp Ser Ile Thr Thr 485 490 495 Arg Pro Trp Thr Asp Glu Phe Val
Arg Trp Thr Glu Pro Arg Leu Val 500 505 510 Ala Trp 4483PRTB.
licheniformis 4Ala Asn Leu Asn Gly Thr Leu Met Gln Tyr Phe Glu Trp
Tyr Met Pro 1 5 10 15 Asn Asp Gly Gln His Trp Arg Arg Leu Gln Asn
Asp Ser Ala Tyr Leu 20 25 30 Ala Glu His Gly Ile Thr Ala Val Trp
Ile Pro Pro Ala Tyr Lys Gly 35 40 45 Thr Ser Gln Ala Asp Val Gly
Tyr Gly Ala Tyr Asp Leu Tyr Asp Leu 50 55 60 Gly Glu Phe His Gln
Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys 65 70 75 80 Gly Glu Leu
Gln Ser Ala Ile Lys Ser Leu His Ser Arg Asp Ile Asn 85 90 95 Val
Tyr Gly Asp Val Val Ile Asn His Lys Gly Gly Ala Asp Ala Thr 100 105
110 Glu Asp Val Thr Ala Val Glu Val Asp Pro Ala Asp Arg Asn Arg Val
115 120 125 Ile Ser Gly Glu His Leu Ile Lys Ala Trp Thr His Phe His
Phe Pro 130 135 140 Gly Arg Gly Ser Thr Tyr Ser Asp Phe Lys Trp His
Trp Tyr His Phe 145 150 155 160 Asp Gly Thr Asp Trp Asp Glu Ser Arg
Lys Leu Asn Arg Ile Tyr Lys 165 170 175 Phe Gln Gly Lys Ala Trp Asp
Trp Glu Val Ser Asn Glu Asn Gly Asn 180 185 190 Tyr Asp Tyr Leu Met
Tyr Ala Asp Ile Asp Tyr Asp His Pro Asp Val 195 200 205 Ala Ala Glu
Ile Lys Arg Trp Gly Thr Trp Tyr Ala Asn Glu Leu Gln 210 215 220 Leu
Asp Gly Phe Arg Leu Asp Ala Val Lys His Ile Lys Phe Ser Phe 225 230
235 240 Leu Arg Asp Trp Val Asn His Val Arg Glu Lys Thr Gly Lys Glu
Met 245 250 255 Phe Thr Val Ala Glu Tyr Trp Gln Asn Asp Leu Gly Ala
Leu Glu Asn 260 265 270 Tyr Leu Asn Lys Thr Asn Phe Asn His Ser Val
Phe Asp Val Pro Leu 275 280 285 His Tyr Gln Phe His Ala Ala Ser Thr
Gln Gly Gly Gly Tyr Asp Met 290 295 300 Arg Lys Leu Leu Asn Gly Thr
Val Val Ser Lys His Pro Leu Lys Ser 305 310 315 320 Val Thr Phe Val
Asp Asn His Asp Thr Gln Pro Gly Gln Ser Leu Glu 325 330 335 Ser Thr
Val Gln Thr Trp Phe Lys Pro Leu Ala Tyr Ala Phe Ile Leu 340 345 350
Thr Arg Glu Ser Gly Tyr Pro Gln Val Phe Tyr Gly Asp Met Tyr Gly 355
360 365 Thr Lys Gly Asp Ser Gln Arg Glu Ile Pro Ala Leu Lys His Lys
Ile 370 375 380 Glu Pro Ile Leu Lys Ala Arg Lys Gln Tyr Ala Tyr Gly
Ala Gln His 385 390 395 400 Asp Tyr Phe Asp His His Asp Ile Val Gly
Trp Thr Arg Glu Gly Asp 405 410 415 Ser Ser Val Ala Asn Ser Gly Leu
Ala Ala Leu Ile Thr Asp Gly Pro 420 425 430 Gly Gly Ala Lys Arg Met
Tyr Val Gly Arg Gln Asn Ala Gly Glu Thr 435 440 445 Trp His Asp Ile
Thr Gly Asn Arg Ser Glu Pro Val Val Ile Asn Ser 450 455 460 Glu Gly
Trp Gly Glu Phe His Val Asn Gly Gly Ser Val Ser Ile Tyr 465 470 475
480 Val Gln Arg 5480PRTB. amyloliquefaciens 5Val Asn Gly Thr Leu
Met Gln Tyr Phe Glu Trp Tyr Thr Pro Asn Asp 1 5 10 15 Gly Gln His
Trp Lys Arg Leu Gln Asn Asp Ala Glu His Leu Ser Asp 20 25 30 Ile
Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly Leu Ser 35 40
45 Gln Ser Asp Asn Gly Tyr Gly Pro Tyr Asp Leu Tyr Asp Leu Gly Glu
50 55 60 Phe Gln Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys
Ser Glu 65 70 75 80 Leu Gln Asp Ala Ile Gly Ser Leu His Ser Arg Asn
Val Gln Val Tyr 85 90 95 Gly Asp Val Val Leu Asn His Lys Ala Gly
Ala Asp Ala Thr Glu Asp 100 105 110 Val Thr Ala Val Glu Val Asn Pro
Ala Asn Arg Asn Gln Glu Thr Ser 115 120 125 Glu Glu Tyr Gln Ile Lys
Ala Trp Thr Asp Phe Arg Phe Pro Gly Arg 130 135 140 Gly Asn Thr Tyr
Ser Asp Phe Lys Trp His Trp Tyr His Phe Asp Gly 145 150 155 160 Ala
Asp Trp Asp Glu Ser Arg Lys Ile Ser Arg Ile Phe Lys Phe Arg 165 170
175 Gly Glu Gly Lys Ala Trp Asp Trp Glu Val Ser Ser Glu Asn Gly Asn
180 185 190 Tyr Asp Tyr Leu Met Tyr Ala Asp Val Asp Tyr Asp His Pro
Asp Val 195 200 205 Val Ala Glu Thr Lys Lys Trp Gly Ile Trp Tyr Ala
Asn Glu Leu Ser 210 215 220 Leu Asp Gly Phe Arg Ile Asp Ala Ala Lys
His Ile Lys Phe Ser Phe 225 230 235 240 Leu Arg Asp Trp Val Gln Ala
Val Arg Gln Ala Thr Gly Lys Glu Met 245 250 255 Phe Thr Val Ala Glu
Tyr Trp Gln Asn Asn Ala Gly Lys Leu Glu Asn 260 265 270 Tyr Leu Asn
Lys Thr Ser Phe Asn Gln Ser Val Phe Asp Val Pro Leu 275 280 285 His
Phe Asn Leu Gln Ala Ala Ser Ser Gln Gly Gly Gly Tyr Asp Met 290 295
300 Arg Arg Leu Leu Asp Gly Thr Val Val Ser Arg His Pro Glu Lys Ala
305 310 315 320 Val Thr Phe Val Glu Asn His Asp Thr Gln Pro Gly Gln
Ser Leu Glu
325 330 335 Ser Thr Val Gln Thr Trp Phe Lys Pro Leu Ala Tyr Ala Phe
Ile Leu 340 345 350 Thr Arg Glu Ser Gly Tyr Pro Gln Val Phe Tyr Gly
Asp Met Tyr Gly 355 360 365 Thr Lys Gly Thr Ser Pro Lys Glu Ile Pro
Ser Leu Lys Asp Asn Ile 370 375 380 Glu Pro Ile Leu Lys Ala Arg Lys
Glu Tyr Ala Tyr Gly Pro Gln His 385 390 395 400 Asp Tyr Ile Asp His
Pro Asp Val Ile Gly Trp Thr Arg Glu Gly Asp 405 410 415 Ser Ser Ala
Ala Lys Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro 420 425 430 Gly
Gly Ser Lys Arg Met Tyr Ala Gly Leu Lys Asn Ala Gly Glu Thr 435 440
445 Trp Tyr Asp Ile Thr Gly Asn Arg Ser Asp Thr Val Lys Ile Gly Ser
450 455 460 Asp Gly Trp Gly Glu Phe His Val Asn Asp Gly Ser Val Ser
Ile Tyr 465 470 475 480 6485PRTBacillus sp. 6His His Asn Gly Thr
Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr 1 5 10 15 Leu Pro Asn
Asp Gly Asn His Trp Asn Arg Leu Asn Ser Asp Ala Ser 20 25 30 Asn
Leu Lys Ser Lys Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Trp 35 40
45 Lys Gly Ala Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr
50 55 60 Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys
Tyr Gly 65 70 75 80 Thr Arg Ser Gln Leu Gln Ala Ala Val Thr Ser Leu
Lys Asn Asn Gly 85 90 95 Ile Gln Val Tyr Gly Asp Val Val Met Asn
His Lys Gly Gly Ala Asp 100 105 110 Ala Thr Glu Met Val Arg Ala Val
Glu Val Asn Pro Asn Asn Arg Asn 115 120 125 Gln Glu Val Thr Gly Glu
Tyr Thr Ile Glu Ala Trp Thr Arg Phe Asp 130 135 140 Phe Pro Gly Arg
Gly Asn Thr His Ser Ser Phe Lys Trp Arg Trp Tyr 145 150 155 160 His
Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Arg Leu Asn Asn Arg 165 170
175 Ile Tyr Lys Phe Arg Gly His Gly Lys Ala Trp Asp Trp Glu Val Asp
180 185 190 Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Ile
Asp Met 195 200 205 Asp His Pro Glu Val Val Asn Glu Leu Arg Asn Trp
Gly Val Trp Tyr 210 215 220 Thr Asn Thr Leu Gly Leu Asp Gly Phe Arg
Ile Asp Ala Val Lys His 225 230 235 240 Ile Lys Tyr Ser Phe Thr Arg
Asp Trp Ile Asn His Val Arg Ser Ala 245 250 255 Thr Gly Lys Asn Met
Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu 260 265 270 Gly Ala Ile
Glu Asn Tyr Leu Gln Lys Thr Asn Trp Asn His Ser Val 275 280 285 Phe
Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Lys Ser Gly 290 295
300 Gly Asn Tyr Asp Met Arg Asn Ile Phe Asn Gly Thr Val Val Gln Arg
305 310 315 320 His Pro Ser His Ala Val Thr Phe Val Asp Asn His Asp
Ser Gln Pro 325 330 335 Glu Glu Ala Leu Glu Ser Phe Val Glu Glu Trp
Phe Lys Pro Leu Ala 340 345 350 Tyr Ala Leu Thr Leu Thr Arg Glu Gln
Gly Tyr Pro Ser Val Phe Tyr 355 360 365 Gly Asp Tyr Tyr Gly Ile Pro
Thr His Gly Val Pro Ala Met Arg Ser 370 375 380 Lys Ile Asp Pro Ile
Leu Glu Ala Arg Gln Lys Tyr Ala Tyr Gly Lys 385 390 395 400 Gln Asn
Asp Tyr Leu Asp His His Asn Ile Ile Gly Trp Thr Arg Glu 405 410 415
Gly Asn Thr Ala His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp 420
425 430 Gly Ala Gly Gly Ser Lys Trp Met Phe Val Gly Arg Asn Lys Ala
Gly 435 440 445 Gln Val Trp Ser Asp Ile Thr Gly Asn Arg Thr Gly Thr
Val Thr Ile 450 455 460 Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn
Gly Gly Ser Val Ser 465 470 475 480 Ile Trp Val Asn Lys 485
7485PRTBacillus sp. 7His His Asn Gly Thr Asn Gly Thr Met Met Gln
Tyr Phe Glu Trp Tyr 1 5 10 15 Leu Pro Asn Asp Gly Asn His Trp Asn
Arg Leu Arg Asp Asp Ala Ala 20 25 30 Asn Leu Lys Ser Lys Gly Ile
Thr Ala Val Trp Ile Pro Pro Ala Trp 35 40 45 Lys Gly Thr Ser Gln
Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr 50 55 60 Asp Leu Gly
Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly 65 70 75 80 Thr
Arg Asn Gln Leu Gln Ala Ala Val Thr Ser Leu Lys Asn Asn Gly 85 90
95 Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp
100 105 110 Gly Thr Glu Ile Val Asn Ala Val Glu Val Asn Arg Ser Asn
Arg Asn 115 120 125 Gln Glu Thr Ser Gly Glu Tyr Ala Ile Glu Ala Trp
Thr Lys Phe Asp 130 135 140 Phe Pro Gly Arg Gly Asn Asn His Ser Ser
Phe Lys Trp Arg Trp Tyr 145 150 155 160 His Phe Asp Gly Thr Asp Trp
Asp Gln Ser Arg Gln Leu Gln Asn Lys 165 170 175 Ile Tyr Lys Phe Arg
Gly Thr Gly Lys Ala Trp Asp Trp Glu Val Asp 180 185 190 Thr Glu Asn
Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Val Asp Met 195 200 205 Asp
His Pro Glu Val Ile His Glu Leu Arg Asn Trp Gly Val Trp Tyr 210 215
220 Thr Asn Thr Leu Asn Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His
225 230 235 240 Ile Lys Tyr Ser Phe Thr Arg Asp Trp Leu Thr His Val
Arg Asn Thr 245 250 255 Thr Gly Lys Pro Met Phe Ala Val Ala Glu Phe
Trp Lys Asn Asp Leu 260 265 270 Gly Ala Ile Glu Asn Tyr Leu Asn Lys
Thr Ser Trp Asn His Ser Val 275 280 285 Phe Asp Val Pro Leu His Tyr
Asn Leu Tyr Asn Ala Ser Asn Ser Gly 290 295 300 Gly Tyr Tyr Asp Met
Arg Asn Ile Leu Asn Gly Ser Val Val Gln Lys 305 310 315 320 His Pro
Thr His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro 325 330 335
Gly Glu Ala Leu Glu Ser Phe Val Gln Gln Trp Phe Lys Pro Leu Ala 340
345 350 Tyr Ala Leu Val Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe
Tyr 355 360 365 Gly Asp Tyr Tyr Gly Ile Pro Thr His Gly Val Pro Ala
Met Lys Ser 370 375 380 Lys Ile Asp Pro Leu Leu Gln Ala Arg Gln Thr
Phe Ala Tyr Gly Thr 385 390 395 400 Gln His Asp Tyr Phe Asp His His
Asp Ile Ile Gly Trp Thr Arg Glu 405 410 415 Gly Asn Ser Ser His Pro
Asn Ser Gly Leu Ala Thr Ile Met Ser Asp 420 425 430 Gly Pro Gly Gly
Asn Lys Trp Met Tyr Val Gly Lys Asn Lys Ala Gly 435 440 445 Gln Val
Trp Arg Asp Ile Thr Gly Asn Arg Thr Gly Thr Val Thr Ile 450 455 460
Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val Ser 465
470 475 480 Val Trp Val Lys Gln 485 8485PRTBacillus sp. 8His His
Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp His 1 5 10 15
Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Asp Asp Ala Ser 20
25 30 Asn Leu Arg Asn Arg Gly Ile Thr Ala Ile Trp Ile Pro Pro Ala
Trp 35 40 45 Lys Gly Thr Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr
Asp Leu Tyr 50 55 60 Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val
Arg Thr Lys Tyr Gly 65 70 75 80 Thr Arg Ser Gln Leu Glu Ser Ala Ile
His Ala Leu Lys Asn Asn Gly 85 90 95 Val Gln Val Tyr Gly Asp Val
Val Met Asn His Lys Gly Gly Ala Asp 100 105 110 Ala Thr Glu Asn Val
Leu Ala Val Glu Val Asn Pro Asn Asn Arg Asn 115 120 125 Gln Glu Ile
Ser Gly Asp Tyr Thr Ile Glu Ala Trp Thr Lys Phe Asp 130 135 140 Phe
Pro Gly Arg Gly Asn Thr Tyr Ser Asp Phe Lys Trp Arg Trp Tyr 145 150
155 160 His Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Gln Phe Gln Asn
Arg 165 170 175 Ile Tyr Lys Phe Arg Gly Asp Gly Lys Ala Trp Asp Trp
Glu Val Asp 180 185 190 Ser Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr
Ala Asp Val Asp Met 195 200 205 Asp His Pro Glu Val Val Asn Glu Leu
Arg Arg Trp Gly Glu Trp Tyr 210 215 220 Thr Asn Thr Leu Asn Leu Asp
Gly Phe Arg Ile Asp Ala Val Lys His 225 230 235 240 Ile Lys Tyr Ser
Phe Thr Arg Asp Trp Leu Thr His Val Arg Asn Ala 245 250 255 Thr Gly
Lys Glu Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu 260 265 270
Gly Ala Leu Glu Asn Tyr Leu Asn Lys Thr Asn Trp Asn His Ser Val 275
280 285 Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Asn Ser
Gly 290 295 300 Gly Asn Tyr Asp Met Ala Lys Leu Leu Asn Gly Thr Val
Val Gln Lys 305 310 315 320 His Pro Met His Ala Val Thr Phe Val Asp
Asn His Asp Ser Gln Pro 325 330 335 Gly Glu Ser Leu Glu Ser Phe Val
Gln Glu Trp Phe Lys Pro Leu Ala 340 345 350 Tyr Ala Leu Ile Leu Thr
Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr 355 360 365 Gly Asp Tyr Tyr
Gly Ile Pro Thr His Ser Val Pro Ala Met Lys Ala 370 375 380 Lys Ile
Asp Pro Ile Leu Glu Ala Arg Gln Asn Phe Ala Tyr Gly Thr 385 390 395
400 Gln His Asp Tyr Phe Asp His His Asn Ile Ile Gly Trp Thr Arg Glu
405 410 415 Gly Asn Thr Thr His Pro Asn Ser Gly Leu Ala Thr Ile Met
Ser Asp 420 425 430 Gly Pro Gly Gly Glu Lys Trp Met Tyr Val Gly Gln
Asn Lys Ala Gly 435 440 445 Gln Val Trp His Asp Ile Thr Gly Asn Lys
Pro Gly Thr Val Thr Ile 450 455 460 Asn Ala Asp Gly Trp Ala Asn Phe
Ser Val Asn Gly Gly Ser Val Ser 465 470 475 480 Ile Trp Val Lys Arg
485 91455DNABacillus sp. 9catcataatg gaacaaatgg tactatgatg
caatatttcg aatggtattt gccaaatgac 60gggaatcatt ggaacaggtt gagggatgac
gcagctaact taaagagtaa agggataaca 120gctgtatgga tcccacctgc
atggaagggg acttcccaga atgatgtagg ttatggagcc 180tatgatttat
atgatcttgg agagtttaac cagaagggga cggttcgtac aaaatatgga
240acacgcaacc agctacaggc tgcggtgacc tctttaaaaa ataacggcat
tcaggtatat 300ggtgatgtcg tcatgaatca taaaggtgga gcagatggta
cggaaattgt aaatgcggta 360gaagtgaatc ggagcaaccg aaaccaggaa
acctcaggag agtatgcaat agaagcgtgg 420acaaagtttg attttcctgg
aagaggaaat aaccattcca gctttaagtg gcgctggtat 480cattttgatg
ggacagattg ggatcagtca cgccagcttc aaaacaaaat atataaattc
540aggggaacag gcaaggcctg ggactgggaa gtcgatacag agaatggcaa
ctatgactat 600cttatgtatg cagacgtgga tatggatcac ccagaagtaa
tacatgaact tagaaactgg 660ggagtgtggt atacgaatac actgaacctt
gatggattta gaatagatgc agtgaaacat 720ataaaatata gctttacgag
agattggctt acacatgtgc gtaacaccac aggtaaacca 780atgtttgcag
tggctgagtt ttggaaaaat gaccttggtg caattgaaaa ctatttgaat
840aaaacaagtt ggaatcactc ggtgtttgat gttcctctcc actataattt
gtacaatgca 900tctaatagcg gtggttatta tgatatgaga aatattttaa
atggttctgt ggtgcaaaaa 960catccaacac atgccgttac ttttgttgat
aaccatgatt ctcagcccgg ggaagcattg 1020gaatcctttg ttcaacaatg
gtttaaacca cttgcatatg cattggttct gacaagggaa 1080caaggttatc
cttccgtatt ttatggggat tactacggta tcccaaccca tggtgttccg
1140gctatgaaat ctaaaataga ccctcttctg caggcacgtc aaacttttgc
ctatggtacg 1200cagcatgatt actttgatca tcatgatatt atcggttgga
caagagaggg aaatagctcc 1260catccaaatt caggccttgc caccattatg
tcagatggtc caggtggtaa caaatggatg 1320tatgtgggga aaaataaagc
gggacaagtt tggagagata ttaccggaaa taggacaggc 1380accgtcacaa
ttaatgcaga cggatggggt aatttctctg ttaatggagg gtccgtttcg
1440gtttgggtga agcaa 1455101455DNABacillus sp. 10catcataatg
ggacaaatgg gacgatgatg caatactttg aatggcactt gcctaatgat 60gggaatcact
ggaatagatt aagagatgat gctagtaatc taagaaatag aggtataacc
120gctatttgga ttccgcctgc ctggaaaggg acttcgcaaa atgatgtggg
gtatggagcc 180tatgatcttt atgatttagg ggaatttaat caaaagggga
cggttcgtac taagtatggg 240acacgtagtc aattggagtc tgccatccat
gctttaaaga ataatggcgt tcaagtttat 300ggggatgtag tgatgaacca
taaaggagga gctgatgcta cagaaaacgt tcttgctgtc 360gaggtgaatc
caaataaccg gaatcaagaa atatctgggg actacacaat tgaggcttgg
420actaagtttg attttccagg gaggggtaat acatactcag actttaaatg
gcgttggtat 480catttcgatg gtgtagattg ggatcaatca cgacaattcc
aaaatcgtat ctacaaattc 540cgaggtgatg gtaaggcatg ggattgggaa
gtagattcgg aaaatggaaa ttatgattat 600ttaatgtatg cagatgtaga
tatggatcat ccggaggtag taaatgagct tagaagatgg 660ggagaatggt
atacaaatac attaaatctt gatggattta ggatcgatgc ggtgaagcat
720attaaatata gctttacacg tgattggttg acccatgtaa gaaacgcaac
gggaaaagaa 780atgtttgctg ttgctgaatt ttggaaaaat gatttaggtg
ccttggagaa ctatttaaat 840aaaacaaact ggaatcattc tgtctttgat
gtcccccttc attataatct ttataacgcg 900tcaaatagtg gaggcaacta
tgacatggca aaacttctta atggaacggt tgttcaaaag 960catccaatgc
atgccgtaac ttttgtggat aatcacgatt ctcaacctgg ggaatcatta
1020gaatcatttg tacaagaatg gtttaagcca cttgcttatg cgcttatttt
aacaagagaa 1080caaggctatc cctctgtctt ctatggtgac tactatggaa
ttccaacaca tagtgtccca 1140gcaatgaaag ccaagattga tccaatctta
gaggcgcgtc aaaattttgc atatggaaca 1200caacatgatt attttgacca
tcataatata atcggatgga cacgtgaagg aaataccacg 1260catcccaatt
caggacttgc gactatcatg tcggatgggc cagggggaga gaaatggatg
1320tacgtagggc aaaataaagc aggtcaagtt tggcatgaca taactggaaa
taaaccagga 1380acagttacga tcaatgcaga tggatgggct aatttttcag
taaatggagg atctgtttcc 1440atttgggtga aacga 1455111548DNAB.
stearothermophilus 11gccgcaccgt ttaacggcac catgatgcag tattttgaat
ggtacttgcc ggatgatggc 60acgttatgga ccaaagtggc caatgaagcc aacaacttat
ccagccttgg catcaccgct 120ctttggctgc cgcccgctta caaaggaaca
agccgcagcg acgtagggta cggagtatac 180gacttgtatg acctcggcga
attcaatcaa aaagggaccg tccgcacaaa atacggaaca 240aaagctcaat
atcttcaagc cattcaagcc gcccacgccg ctggaatgca agtgtacgcc
300gatgtcgtgt tcgaccataa aggcggcgct gacggcacgg aatgggtgga
cgccgtcgaa 360gtcaatccgt ccgaccgcaa ccaagaaatc tcgggcacct
atcaaatcca agcatggacg 420aaatttgatt ttcccgggcg gggcaacacc
tactccagct ttaagtggcg ctggtaccat 480tttgacggcg ttgattggga
cgaaagccga aaattgagcc gcatttacaa attccgcggc 540atcggcaaag
cgtgggattg ggaagtagac acggaaaacg gaaactatga ctacttaatg
600tatgccgacc ttgatatgga tcatcccgaa gtcgtgaccg agctgaaaaa
ctgggggaaa 660tggtatgtca acacaacgaa cattgatggg ttccggcttg
atgccgtcaa gcatattaag 720ttcagttttt ttcctgattg gttgtcgtat
gtgcgttctc agactggcaa gccgctattt 780accgtcgggg aatattggag
ctatgacatc aacaagttgc acaattacat tacgaaaaca 840gacggaacga
tgtctttgtt tgatgccccg ttacacaaca aattttatac cgcttccaaa
900tcagggggcg catttgatat gcgcacgtta atgaccaata ctctcatgaa
agatcaaccg 960acattggccg tcaccttcgt tgataatcat gacaccgaac
ccggccaagc gctgcagtca 1020tgggtcgacc catggttcaa accgttggct
tacgccttta ttctaactcg gcaggaagga 1080tacccgtgcg tcttttatgg
tgactattat ggcattccac aatataacat tccttcgctg 1140aaaagcaaaa
tcgatccgct cctcatcgcg cgcagggatt atgcttacgg aacgcaacat
1200gattatcttg atcactccga catcatcggg tggacaaggg aagggggcac
tgaaaaacca 1260ggatccggac tggccgcact gatcaccgat gggccgggag
gaagcaaatg gatgtacgtt 1320ggcaaacaac acgctggaaa agtgttctat
gaccttaccg gcaaccggag tgacaccgtc 1380accatcaaca gtgatggatg
gggggaattc aaagtcaatg gcggttcggt ttcggtttgg 1440gttcctagaa
aaacgaccgt ttctaccatc gctcggccga tcacaacccg accgtggact
1500ggtgaattcg tccgttggac cgaaccacgg ttggtggcat ggccttga
1548121920DNAB. licheniformis 12cggaagattg gaagtacaaa aataagcaaa
agattgtcaa tcatgtcatg agccatgcgg 60gagacggaaa aatcgtctta atgcacgata
tttatgcaac gttcgcagat gctgctgaag 120agattattaa aaagctgaaa
gcaaaaggct atcaattggt aactgtatct cagcttgaag 180aagtgaagaa
gcagagaggc tattgaataa atgagtagaa gcgccatatc ggcgcttttc
240ttttggaaga aaatataggg aaaatggtac ttgttaaaaa ttcggaatat
ttatacaaca 300tcatatgttt cacattgaaa ggggaggaga atcatgaaac
aacaaaaacg gctttacgcc 360cgattgctga cgctgttatt tgcgctcatc
ttcttgctgc ctcattctgc agcagcggcg 420gcaaatctta atgggacgct
gatgcagtat tttgaatggt acatgcccaa tgacggccaa 480cattggaggc
gtttgcaaaa cgactcggca tatttggctg aacacggtat tactgccgtc
540tggattcccc cggcatataa gggaacgagc caagcggatg tgggctacgg
tgcttacgac 600ctttatgatt taggggagtt tcatcaaaaa gggacggttc
ggacaaagta cggcacaaaa 660ggagagctgc aatctgcgat caaaagtctt
cattcccgcg acattaacgt ttacggggat 720gtggtcatca accacaaagg
cggcgctgat gcgaccgaag atgtaaccgc ggttgaagtc 780gatcccgctg
accgcaaccg cgtaatttca ggagaacacc taattaaagc ctggacacat
840tttcattttc cggggcgcgg cagcacatac agcgatttta aatggcattg
gtaccatttt 900gacggaaccg attgggacga gtcccgaaag ctgaaccgca
tctataagtt tcaaggaaag 960gcttgggatt gggaagtttc caatgaaaac
ggcaactatg attatttgat gtatgccgac 1020atcgattatg accatcctga
tgtcgcagca gaaattaaga gatggggcac ttggtatgcc 1080aatgaactgc
aattggacgg tttccgtctt gatgctgtca aacacattaa attttctttt
1140ttgcgggatt gggttaatca tgtcagggaa aaaacgggga aggaaatgtt
tacggtagct 1200gaatattggc agaatgactt gggcgcgctg gaaaactatt
tgaacaaaac aaattttaat 1260cattcagtgt ttgacgtgcc gcttcattat
cagttccatg ctgcatcgac acagggaggc 1320ggctatgata tgaggaaatt
gctgaacggt acggtcgttt ccaagcatcc gttgaaatcg 1380gttacatttg
tcgataacca tgatacacag ccggggcaat cgcttgagtc gactgtccaa
1440acatggttta agccgcttgc ttacgctttt attctcacaa gggaatctgg
ataccctcag 1500gttttctacg gggatatgta cgggacgaaa ggagactccc
agcgcgaaat tcctgccttg 1560aaacacaaaa ttgaaccgat cttaaaagcg
agaaaacagt atgcgtacgg agcacagcat 1620gattatttcg accaccatga
cattgtcggc tggacaaggg aaggcgacag ctcggttgca 1680aattcaggtt
tggcggcatt aataacagac ggacccggtg gggcaaagcg aatgtatgtc
1740ggccggcaaa acgccggtga gacatggcat gacattaccg gaaaccgttc
ggagccggtt 1800gtcatcaatt cggaaggctg gggagagttt cacgtaaacg
gcgggtcggt ttcaatttat 1860gttcaaagat agaagagcag agaggacgga
tttcctgaag gaaatccgtt tttttatttt 1920132084DNAB. amyloliquefaciens
13gccccgcaca tacgaaaaga ctggctgaaa acattgagcc tttgatgact gatgatttgg
60ctgaagaagt ggatcgattg tttgagaaaa gaagaagacc ataaaaatac cttgtctgtc
120atcagacagg gtatttttta tgctgtccag actgtccgct gtgtaaaaat
aaggaataaa 180ggggggttgt tattatttta ctgatatgta aaatataatt
tgtataagaa aatgagaggg 240agaggaaaca tgattcaaaa acgaaagcgg
acagtttcgt tcagacttgt gcttatgtgc 300acgctgttat ttgtcagttt
gccgattaca aaaacatcag ccgtaaatgg cacgctgatg 360cagtattttg
aatggtatac gccgaacgac ggccagcatt ggaaacgatt gcagaatgat
420gcggaacatt tatcggatat cggaatcact gccgtctgga ttcctcccgc
atacaaagga 480ttgagccaat ccgataacgg atacggacct tatgatttgt
atgatttagg agaattccag 540caaaaaggga cggtcagaac gaaatacggc
acaaaatcag agcttcaaga tgcgatcggc 600tcactgcatt cccggaacgt
ccaagtatac ggagatgtgg ttttgaatca taaggctggt 660gctgatgcaa
cagaagatgt aactgccgtc gaagtcaatc cggccaatag aaatcaggaa
720acttcggagg aatatcaaat caaagcgtgg acggattttc gttttccggg
ccgtggaaac 780acgtacagtg attttaaatg gcattggtat catttcgacg
gagcggactg ggatgaatcc 840cggaagatca gccgcatctt taagtttcgt
ggggaaggaa aagcgtggga ttgggaagta 900tcaagtgaaa acggcaacta
tgactattta atgtatgctg atgttgacta cgaccaccct 960gatgtcgtgg
cagagacaaa aaaatggggt atctggtatg cgaatgaact gtcattagac
1020ggcttccgta ttgatgccgc caaacatatt aaattttcat ttctgcgtga
ttgggttcag 1080gcggtcagac aggcgacggg aaaagaaatg tttacggttg
cggagtattg gcagaataat 1140gccgggaaac tcgaaaacta cttgaataaa
acaagcttta atcaatccgt gtttgatgtt 1200ccgcttcatt tcaatttaca
ggcggcttcc tcacaaggag gcggatatga tatgaggcgt 1260ttgctggacg
gtaccgttgt gtccaggcat ccggaaaagg cggttacatt tgttgaaaat
1320catgacacac agccgggaca gtcattggaa tcgacagtcc aaacttggtt
taaaccgctt 1380gcatacgcct ttattttgac aagagaatcc ggttatcctc
aggtgttcta tggggatatg 1440tacgggacaa aagggacatc gccaaaggaa
attccctcac tgaaagataa tatagagccg 1500attttaaaag cgcgtaagga
gtacgcatac gggccccagc acgattatat tgaccacccg 1560gatgtgatcg
gatggacgag ggaaggtgac agctccgccg ccaaatcagg tttggccgct
1620ttaatcacgg acggacccgg cggatcaaag cggatgtatg ccggcctgaa
aaatgccggc 1680gagacatggt atgacataac gggcaaccgt tcagatactg
taaaaatcgg atctgacggc 1740tggggagagt ttcatgtaaa cgatgggtcc
gtctccattt atgttcagaa ataaggtaat 1800aaaaaaacac ctccaagctg
agtgcgggta tcagcttgga ggtgcgttta ttttttcagc 1860cgtatgacaa
ggtcggcatc aggtgtgaca aatacggtat gctggctgtc ataggtgaca
1920aatccgggtt ttgcgccgtt tggctttttc acatgtctga tttttgtata
atcaacaggc 1980acggagccgg aatctttcgc cttggaaaaa taagcggcga
tcgtagctgc ttccaatatg 2040gattgttcat cgggatcgct gcttttaatc
acaacgtggg atcc 2084141395DNABacillus sp. 14gggaatcatt ggaacaggtt
gagggatgac gcagctaact taaagagtaa agggataaca 60gctgtatgga tcccacctgc
atggaagggg acttcccaga atgatgtagg ttatggagcc 120tatgatttat
atgatcttgg agagtttaac cagaagggga cggttcgtac aaaatatgga
180acacgcaacc agctacaggc tgcggtgacc tctttaaaaa ataacggcat
tcaggtatat 240ggtgatgtcg tcatgaatca taaaggtgga gcagatggta
cggaaattgt aaatgcggta 300gaagtgaatc ggagcaaccg aaaccaggaa
acctcaggag agtatgcaat agaagcgtgg 360acaaagtttg attttcctgg
aagaggaaat aaccattcca gctttaagtg gcgctggtat 420cattttgatg
ggacagattg ggatcagtca cgccagcttc aaaacaaaat atataaattc
480aggggaacag gcaaggcctg ggactgggaa gtcgatacag agaatggcaa
ctatgactat 540cttatgtatg cagacgtgga tatggatcac ccagaagtaa
tacatgaact tagaaactgg 600ggagtgtggt atacgaatac actgaacctt
gatggattta gaatagatgc agtgaaacat 660ataaaatata gctttacgag
agattggctt acacatgtgc gtaacaccac aggtaaacca 720atgtttgcag
tggctgagtt ttggaaaaat gaccttggtg caattgaaaa ctatttgaat
780aaaacaagtt ggaatcactc ggtgtttgat gttcctctcc actataattt
gtacaatgca 840tctaatagcg gtggttatta tgatatgaga aatattttaa
atggttctgt ggtgcaaaaa 900catccaacac atgccgttac ttttgttgat
aaccatgatt ctcagcccgg ggaagcattg 960gaatcctttg ttcaacaatg
gtttaaacca cttgcatatg cattggttct gacaagggaa 1020caaggttatc
cttccgtatt ttatggggat tactacggta tcccaaccca tggtgttccg
1080gctatgaaat ctaaaataga ccctcttctg caggcacgtc aaacttttgc
ctatggtacg 1140cagcatgatt actttgatca tcatgatatt atcggttgga
caagagaggg aaatagctcc 1200catccaaatt caggccttgc caccattatg
tcagatggtc caggtggtaa caaatggatg 1260tatgtgggga aaaataaagc
gggacaagtt tggagagata ttaccggaaa taggacaggc 1320accgtcacaa
ttaatgcaga cggatggggt aatttctctg ttaatggagg gtccgtttcg
1380gtttgggtga agcaa 1395151455DNABacillus sp. 15catcataatg
ggacaaatgg gacgatgatg caatactttg aatggcactt gcctaatgat 60gggaatcact
ggaatagatt aagagatgat gctagtaatc taagaaatag aggtataacc
120gctatttgga ttccgcctgc ctggaaaggg acttcgcaaa atgatgtggg
gtatggagcc 180tatgatcttt atgatttagg ggaatttaat caaaagggga
cggttcgtac taagtatggg 240acacgtagtc aattggagtc tgccatccat
gctttaaaga ataatggcgt tcaagtttat 300ggggatgtag tgatgaacca
taaaggagga gctgatgcta cagaaaacgt tcttgctgtc 360gaggtgaatc
caaataaccg gaatcaagaa atatctgggg actacacaat tgaggcttgg
420actaagtttg attttccagg gaggggtaat acatactcag actttaaatg
gcgttggtat 480catttcgatg gtgtagattg ggatcaatca cgacaattcc
aaaatcgtat ctacaaattc 540cgaggtgatg gtaaggcatg ggattgggaa
gtagattcgg aaaatggaaa ttatgattat 600ttaatgtatg cagatgtaga
tatggatcat ccggaggtag taaatgagct tagaagatgg 660ggagaatggt
atacaaatac attaaatctt gatggattta ggatcgatgc ggtgaagcat
720attaaatata gctttacacg tgattggttg acccatgtaa gaaacgcaac
gggaaaagaa 780atgtttgctg ttgctgaatt ttggaaaaat gatttaggtg
ccttggagaa ctatttaaat 840aaaacaaact ggaatcattc tgtctttgat
gtcccccttc attataatct ttataacgcg 900tcaaatagtg gaggcaacta
tgacatggca aaacttctta atggaacggt tgttcaaaag 960catccaatgc
atgccgtaac ttttgtggat aatcacgatt ctcaacctgg ggaatcatta
1020gaatcatttg tacaagaatg gtttaagcca cttgcttatg cgcttatttt
aacaagagaa 1080caaggctatc cctctgtctt ctatggtgac tactatggaa
ttccaacaca tagtgtccca 1140gcaatgaaag ccaagattga tccaatctta
gaggcgcgtc aaaattttgc atatggaaca 1200caacatgatt attttgacca
tcataatata atcggatgga cacgtgaagg aaataccacg 1260catcccaatt
caggacttgc gactatcatg tcggatgggc cagggggaga gaaatggatg
1320tacgtagggc aaaataaagc aggtcaagtt tggcatgaca taactggaaa
taaaccagga 1380acagttacga tcaatgcaga tggatgggct aatttttcag
taaatggagg atctgtttcc 1440atttgggtga aacga 14551623DNAArtificial
SequencePrimer 16ccatgatgca gtattttgaa tgg 231722DNAArtificial
SequencePrimer 17gtcaccataa aagacgcacg gg 221868DNAArtificial
SequencePrimer 18gtcatagttt ccgaattccg tgtctacttc ccaatcccaa
tcccaagctt tgccgcggaa 60tttgtaaa 681941DNAArtificial SequencePrimer
19ctacttccca atcccaagct ttgccgcgga atttgtaaat g 412027DNAArtificial
SequencePrimer 20ggatgatcca tgtcaaagtc ggcatac 272125DNAArtificial
SequencePrimer 21ctcggtcacc acgtggggat gatcc 252224DNAArtificial
SequencePrimer 22ccagtttttc agctgggtca cgac 24231458DNABacillus
spmat_peptide(1)..(1455)CDS(1)..(1455) 23cac cat aat ggt acg aac
ggc aca atg atg cag tac ttt gaa tgg tat 48His His Asn Gly Thr Asn
Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr 1 5 10 15 cta cca aat gac
gga aac cat tgg aat aga tta agg tct gat gca agt 96Leu Pro Asn Asp
Gly Asn His Trp Asn Arg Leu Arg Ser Asp Ala Ser 20 25 30 aac cta
aaa gat aaa ggg atc tca gcg gtt tgg att cct cct gca tgg 144Asn Leu
Lys Asp Lys Gly Ile Ser Ala Val Trp Ile Pro Pro Ala Trp 35 40 45
aag ggt gcc tct caa aat gat gtg ggg tat ggt gct tat gat ctg tat
192Lys Gly Ala Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr
50 55 60 gat tta gga gaa ttc aat caa aaa gga acc att cgt aca aaa
tat gga 240Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Ile Arg Thr Lys
Tyr Gly 65 70 75 80 acg cgc aat cag tta caa gct gca gtt aac gcc ttg
aaa agt aat gga 288Thr Arg Asn Gln Leu Gln Ala Ala Val Asn Ala Leu
Lys Ser Asn Gly 85 90 95 att caa gtg tat ggc gat gtt gta atg aat
cat aaa ggg gga gca gac 336Ile Gln Val Tyr Gly Asp Val Val Met Asn
His Lys Gly Gly Ala Asp 100 105 110 gct acc gaa atg gtt agg gca gtt
gaa gta aac ccg aat aat aga aat 384Ala Thr Glu Met Val Arg Ala Val
Glu Val Asn Pro Asn Asn Arg Asn 115 120 125 caa gaa gtg tcc ggt gaa
tat aca att gag gct tgg aca aag ttt gac 432Gln Glu Val Ser Gly Glu
Tyr Thr Ile Glu Ala Trp Thr Lys Phe Asp 130 135 140 ttt cca gga cga
ggt aat act cat tca aac ttc aaa tgg aga tgg tat 480Phe Pro Gly Arg
Gly Asn Thr His Ser Asn Phe Lys Trp Arg Trp Tyr 145 150 155 160 cac
ttt gat gga gta gat tgg gat cag tca cgt aag ctg aac aat cga 528His
Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Lys Leu Asn Asn Arg 165 170
175 att tat aaa ttt aga ggt gat gga aaa ggg tgg gat tgg gaa gtc gat
576Ile Tyr Lys Phe Arg Gly Asp Gly Lys Gly Trp Asp Trp Glu Val Asp
180 185 190 aca gaa aac ggt aac tat gat tac cta atg tat gca gat att
gac atg 624Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Ile
Asp Met 195 200 205 gat cac cca gag gta gtg aat gag cta aga aat tgg
ggt gtt tgg tat 672Asp His Pro Glu Val Val Asn Glu Leu Arg Asn Trp
Gly Val Trp Tyr 210 215 220 acg aat aca tta ggc ctt gat ggt ttt aga
ata gat gca gta aaa cat 720Thr Asn Thr Leu Gly Leu Asp Gly Phe Arg
Ile Asp Ala Val Lys His 225 230 235 240 ata aaa tac agc ttt act cgt
gat tgg att aat cat gtt aga agt gca 768Ile Lys Tyr Ser Phe Thr Arg
Asp Trp Ile Asn His Val Arg Ser Ala 245 250 255 act ggc aaa aat atg
ttt gcg gtt gcg gaa ttt tgg aaa aat gat tta 816Thr Gly Lys Asn Met
Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu 260 265 270 ggt gct att
gaa aac tat tta aac aaa aca aac tgg aac cat tca gtc 864Gly Ala Ile
Glu Asn Tyr Leu Asn Lys Thr Asn Trp Asn His Ser Val 275 280 285 ttt
gat gtt ccg ctg cac tat aac ctc tat aat gct tca aaa agc gga 912Phe
Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Lys Ser Gly 290 295
300 ggg aat tat gat atg agg caa ata ttt aat ggt aca gtc gtg caa aga
960Gly Asn Tyr Asp Met Arg Gln Ile Phe Asn Gly Thr Val Val Gln Arg
305 310 315 320 cat cca atg cat gct gtt aca ttt gtt gat aat cat gat
tcg caa cct 1008His Pro Met His Ala Val Thr Phe Val Asp Asn His Asp
Ser Gln Pro 325 330 335 gaa gaa gct tta gag tct ttt gtt gaa gaa tgg
ttc aaa cca tta gcg 1056Glu Glu Ala Leu Glu Ser Phe Val Glu Glu Trp
Phe Lys Pro Leu Ala 340 345 350 tat gct ttg aca tta aca cgt gaa caa
ggc tac cct tct gta ttt tat 1104Tyr Ala Leu Thr Leu Thr Arg Glu Gln
Gly Tyr Pro Ser Val Phe Tyr 355 360 365 gga gat tat tat ggc att cca
acg cat ggt gta cca gcg atg aaa tcg 1152Gly Asp Tyr Tyr Gly Ile Pro
Thr His Gly Val Pro Ala Met Lys Ser 370 375 380 aaa att gac ccg att
cta gaa gcg cgt caa aag tat gca tat gga aga 1200Lys Ile Asp Pro Ile
Leu Glu Ala Arg Gln Lys Tyr Ala Tyr Gly Arg 385 390 395 400 caa aat
gac tac tta gac cat cat aat atc atc ggt tgg aca cgt gaa 1248Gln Asn
Asp Tyr Leu Asp His His Asn Ile Ile Gly Trp Thr Arg Glu 405 410 415
ggg aat aca gca cac ccc aac tcc ggt tta gct act atc atg tcc gat
1296Gly Asn Thr Ala His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp
420 425 430 ggg gca gga gga aat aag tgg atg ttt gtt ggg cgt aat aaa
gct ggt 1344Gly Ala Gly Gly Asn Lys Trp Met Phe Val Gly Arg Asn Lys
Ala Gly 435 440 445 caa gtt tgg acc gat atc act gga aat cgt gca ggt
act gtt acg att 1392Gln Val Trp Thr Asp Ile Thr Gly Asn Arg Ala Gly
Thr Val Thr Ile 450 455 460 aat gct gat gga tgg ggt aat ttt tct gta
aat gga gga tca gtt tct 1440Asn Ala Asp Gly Trp Gly Asn Phe Ser Val
Asn Gly Gly Ser Val Ser 465 470 475 480 att tgg gta aac aaa taa
1458Ile Trp Val Asn Lys 485 24485PRTBacillus sp 24His His Asn Gly
Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr 1 5 10 15 Leu Pro
Asn Asp Gly Asn His Trp Asn Arg Leu Arg Ser Asp Ala Ser 20 25 30
Asn Leu Lys Asp Lys Gly Ile Ser Ala Val Trp Ile Pro Pro Ala Trp 35
40 45 Lys Gly Ala Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu
Tyr 50 55 60 Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Ile Arg Thr
Lys Tyr Gly 65 70 75 80 Thr Arg Asn Gln Leu Gln Ala Ala Val Asn Ala
Leu Lys Ser Asn Gly 85 90 95 Ile Gln Val Tyr Gly Asp Val Val Met
Asn His Lys Gly Gly Ala Asp 100 105 110 Ala Thr Glu Met Val Arg Ala
Val Glu Val Asn Pro Asn Asn Arg Asn 115 120 125 Gln Glu Val Ser Gly
Glu Tyr Thr Ile Glu Ala Trp Thr Lys Phe Asp 130 135 140 Phe Pro Gly
Arg Gly Asn Thr His Ser Asn Phe Lys Trp Arg Trp Tyr 145 150 155 160
His Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Lys Leu Asn Asn Arg 165
170 175 Ile Tyr Lys Phe Arg Gly Asp Gly Lys Gly Trp Asp Trp Glu Val
Asp 180 185 190 Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp
Ile Asp Met 195 200 205 Asp His Pro Glu Val Val Asn Glu Leu Arg Asn
Trp Gly Val Trp Tyr 210 215 220 Thr Asn Thr Leu Gly Leu Asp Gly Phe
Arg Ile Asp Ala Val Lys His 225 230 235 240 Ile Lys Tyr Ser Phe Thr
Arg Asp Trp Ile Asn
His Val Arg Ser Ala 245 250 255 Thr Gly Lys Asn Met Phe Ala Val Ala
Glu Phe Trp Lys Asn Asp Leu 260 265 270 Gly Ala Ile Glu Asn Tyr Leu
Asn Lys Thr Asn Trp Asn His Ser Val 275 280 285 Phe Asp Val Pro Leu
His Tyr Asn Leu Tyr Asn Ala Ser Lys Ser Gly 290 295 300 Gly Asn Tyr
Asp Met Arg Gln Ile Phe Asn Gly Thr Val Val Gln Arg 305 310 315 320
His Pro Met His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro 325
330 335 Glu Glu Ala Leu Glu Ser Phe Val Glu Glu Trp Phe Lys Pro Leu
Ala 340 345 350 Tyr Ala Leu Thr Leu Thr Arg Glu Gln Gly Tyr Pro Ser
Val Phe Tyr 355 360 365 Gly Asp Tyr Tyr Gly Ile Pro Thr His Gly Val
Pro Ala Met Lys Ser 370 375 380 Lys Ile Asp Pro Ile Leu Glu Ala Arg
Gln Lys Tyr Ala Tyr Gly Arg 385 390 395 400 Gln Asn Asp Tyr Leu Asp
His His Asn Ile Ile Gly Trp Thr Arg Glu 405 410 415 Gly Asn Thr Ala
His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp 420 425 430 Gly Ala
Gly Gly Asn Lys Trp Met Phe Val Gly Arg Asn Lys Ala Gly 435 440 445
Gln Val Trp Thr Asp Ile Thr Gly Asn Arg Ala Gly Thr Val Thr Ile 450
455 460 Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val
Ser 465 470 475 480 Ile Trp Val Asn Lys 485 251458DNABacillus
sp.mat_peptide(1)..(1455)CDS(1)..(1455) 25cac cat aat ggt acg aac
ggc aca atg atg cag tac ttt gaa tgg tat 48His His Asn Gly Thr Asn
Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr 1 5 10 15 cta cca aat gac
gga aac cat tgg aat aga tta agg tct gat gca agt 96Leu Pro Asn Asp
Gly Asn His Trp Asn Arg Leu Arg Ser Asp Ala Ser 20 25 30 aac cta
aaa gat aaa ggg atc tca gcg gtt tgg att cct cct gca tgg 144Asn Leu
Lys Asp Lys Gly Ile Ser Ala Val Trp Ile Pro Pro Ala Trp 35 40 45
aag ggt gcc tct caa aat gat gtg ggg tat ggt gct tat gat ctg tat
192Lys Gly Ala Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr
50 55 60 gat tta gga gaa ttc aat caa aaa gga acc att cgt aca aaa
tat gga 240Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Ile Arg Thr Lys
Tyr Gly 65 70 75 80 acg cgc aat cag tta caa gct gca gtt aac gcc ttg
aaa agt aat gga 288Thr Arg Asn Gln Leu Gln Ala Ala Val Asn Ala Leu
Lys Ser Asn Gly 85 90 95 att caa gtg tat ggc gat gtt gta atg aat
cat aaa ggg gga gca gac 336Ile Gln Val Tyr Gly Asp Val Val Met Asn
His Lys Gly Gly Ala Asp 100 105 110 gct acc gaa atg gtt agg gcg gtt
gaa gta aac ccg aat aat aga aat 384Ala Thr Glu Met Val Arg Ala Val
Glu Val Asn Pro Asn Asn Arg Asn 115 120 125 caa gaa gtg tcc ggt gaa
tat aca att gag gct tgg aca aag ttt gac 432Gln Glu Val Ser Gly Glu
Tyr Thr Ile Glu Ala Trp Thr Lys Phe Asp 130 135 140 ttt cct gga cga
ggt aat acc cat tca aac ttc aaa tgg aga tgg tat 480Phe Pro Gly Arg
Gly Asn Thr His Ser Asn Phe Lys Trp Arg Trp Tyr 145 150 155 160 cac
ttt gat gga gta gat tgg gat cag tca cgt aag ctg aac aat cga 528His
Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Lys Leu Asn Asn Arg 165 170
175 att tat aaa ttt aga ggt gat gga aaa ggg tgg gat tgg gaa gtc gat
576Ile Tyr Lys Phe Arg Gly Asp Gly Lys Gly Trp Asp Trp Glu Val Asp
180 185 190 aca gaa aac ggt aac tat gat tac cta atg tat gca gat att
gac atg 624Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Ile
Asp Met 195 200 205 gat cac cca gag gta gtg aat gag cta aga aat tgg
ggt gtt tgg tat 672Asp His Pro Glu Val Val Asn Glu Leu Arg Asn Trp
Gly Val Trp Tyr 210 215 220 acg aat aca tta ggc ctt gat ggt ttt aga
ata gat gca gta aaa cat 720Thr Asn Thr Leu Gly Leu Asp Gly Phe Arg
Ile Asp Ala Val Lys His 225 230 235 240 ata aaa tac agc ttt act cgt
gat tgg atc aat cat gtt aga agt gca 768Ile Lys Tyr Ser Phe Thr Arg
Asp Trp Ile Asn His Val Arg Ser Ala 245 250 255 act ggc aaa aat atg
ttt gcg gtt gcg gaa ttt tgg aaa aat gat tta 816Thr Gly Lys Asn Met
Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu 260 265 270 ggt gct att
gaa aac tat tta aac aaa aca aac tgg aac cat tca gtc 864Gly Ala Ile
Glu Asn Tyr Leu Asn Lys Thr Asn Trp Asn His Ser Val 275 280 285 ttt
gat gtt ccg ctg cac tat aac ctc tat aat gct tca aaa agc gga 912Phe
Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Lys Ser Gly 290 295
300 ggg aat tat gat atg agg caa ata ttt aat ggt aca gtc gtg caa aga
960Gly Asn Tyr Asp Met Arg Gln Ile Phe Asn Gly Thr Val Val Gln Arg
305 310 315 320 cat cca atg cat gct gtt aca ttt gtt gat aat cat gat
tcg caa cct 1008His Pro Met His Ala Val Thr Phe Val Asp Asn His Asp
Ser Gln Pro 325 330 335 gaa gaa gct tta gag tct ttt gtt gaa gaa tgg
ttc aaa cca tta gcg 1056Glu Glu Ala Leu Glu Ser Phe Val Glu Glu Trp
Phe Lys Pro Leu Ala 340 345 350 tat gct ttg aca tta aca cgt gaa caa
ggc tac cct tct gta ttt tat 1104Tyr Ala Leu Thr Leu Thr Arg Glu Gln
Gly Tyr Pro Ser Val Phe Tyr 355 360 365 gga gat tat tat ggc att cca
acg cat ggt gta cca gcg atg aaa tcg 1152Gly Asp Tyr Tyr Gly Ile Pro
Thr His Gly Val Pro Ala Met Lys Ser 370 375 380 aaa att gac ccg att
cta gaa gcg cgt caa aag tat gca tat gga aga 1200Lys Ile Asp Pro Ile
Leu Glu Ala Arg Gln Lys Tyr Ala Tyr Gly Arg 385 390 395 400 caa aat
gac tac tta gac cat cat aat atc att ggt tgg aca cgt gaa 1248Gln Asn
Asp Tyr Leu Asp His His Asn Ile Ile Gly Trp Thr Arg Glu 405 410 415
ggg aat aca gca cac ccc aac tct ggt tta gct act atc atg tcc gat
1296Gly Asn Thr Ala His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp
420 425 430 gga gca gga gga aat aag tgg atg ttt gtt ggg cgt aat aaa
gct ggt 1344Gly Ala Gly Gly Asn Lys Trp Met Phe Val Gly Arg Asn Lys
Ala Gly 435 440 445 caa gtt tgg acc gat atc act gga aat cgt gca ggt
act gtt acg att 1392Gln Val Trp Thr Asp Ile Thr Gly Asn Arg Ala Gly
Thr Val Thr Ile 450 455 460 aat gct gat gga tgg ggt aat ttt tct gta
aat gga gga tca gtt tct 1440Asn Ala Asp Gly Trp Gly Asn Phe Ser Val
Asn Gly Gly Ser Val Ser 465 470 475 480 att tgg gta aac aaa taa
1458Ile Trp Val Asn Lys 485 26485PRTBacillus sp. 26His His Asn Gly
Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr 1 5 10 15 Leu Pro
Asn Asp Gly Asn His Trp Asn Arg Leu Arg Ser Asp Ala Ser 20 25 30
Asn Leu Lys Asp Lys Gly Ile Ser Ala Val Trp Ile Pro Pro Ala Trp 35
40 45 Lys Gly Ala Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu
Tyr 50 55 60 Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Ile Arg Thr
Lys Tyr Gly 65 70 75 80 Thr Arg Asn Gln Leu Gln Ala Ala Val Asn Ala
Leu Lys Ser Asn Gly 85 90 95 Ile Gln Val Tyr Gly Asp Val Val Met
Asn His Lys Gly Gly Ala Asp 100 105 110 Ala Thr Glu Met Val Arg Ala
Val Glu Val Asn Pro Asn Asn Arg Asn 115 120 125 Gln Glu Val Ser Gly
Glu Tyr Thr Ile Glu Ala Trp Thr Lys Phe Asp 130 135 140 Phe Pro Gly
Arg Gly Asn Thr His Ser Asn Phe Lys Trp Arg Trp Tyr 145 150 155 160
His Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Lys Leu Asn Asn Arg 165
170 175 Ile Tyr Lys Phe Arg Gly Asp Gly Lys Gly Trp Asp Trp Glu Val
Asp 180 185 190 Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp
Ile Asp Met 195 200 205 Asp His Pro Glu Val Val Asn Glu Leu Arg Asn
Trp Gly Val Trp Tyr 210 215 220 Thr Asn Thr Leu Gly Leu Asp Gly Phe
Arg Ile Asp Ala Val Lys His 225 230 235 240 Ile Lys Tyr Ser Phe Thr
Arg Asp Trp Ile Asn His Val Arg Ser Ala 245 250 255 Thr Gly Lys Asn
Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu 260 265 270 Gly Ala
Ile Glu Asn Tyr Leu Asn Lys Thr Asn Trp Asn His Ser Val 275 280 285
Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Lys Ser Gly 290
295 300 Gly Asn Tyr Asp Met Arg Gln Ile Phe Asn Gly Thr Val Val Gln
Arg 305 310 315 320 His Pro Met His Ala Val Thr Phe Val Asp Asn His
Asp Ser Gln Pro 325 330 335 Glu Glu Ala Leu Glu Ser Phe Val Glu Glu
Trp Phe Lys Pro Leu Ala 340 345 350 Tyr Ala Leu Thr Leu Thr Arg Glu
Gln Gly Tyr Pro Ser Val Phe Tyr 355 360 365 Gly Asp Tyr Tyr Gly Ile
Pro Thr His Gly Val Pro Ala Met Lys Ser 370 375 380 Lys Ile Asp Pro
Ile Leu Glu Ala Arg Gln Lys Tyr Ala Tyr Gly Arg 385 390 395 400 Gln
Asn Asp Tyr Leu Asp His His Asn Ile Ile Gly Trp Thr Arg Glu 405 410
415 Gly Asn Thr Ala His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp
420 425 430 Gly Ala Gly Gly Asn Lys Trp Met Phe Val Gly Arg Asn Lys
Ala Gly 435 440 445 Gln Val Trp Thr Asp Ile Thr Gly Asn Arg Ala Gly
Thr Val Thr Ile 450 455 460 Asn Ala Asp Gly Trp Gly Asn Phe Ser Val
Asn Gly Gly Ser Val Ser 465 470 475 480 Ile Trp Val Asn Lys 485
277PRTArtificial SequencePrimer 27Gly Ile Thr Ala Xaa Trp Xaa 1 5
289PRTArtificial SequencePrimer 28Val Tyr Xaa Asp Xaa Val Xaa Asn
His 1 5 2910PRTArtificial SequencePrimer 29Asp Gly Xaa Arg Xaa Asp
Ala Xaa Lys His 1 5 10 3010PRTArtificial SequencePrimer 30Asp Gly
Xaa Arg Xaa Asp Ala Xaa Lys His 1 5 10 318PRTArtificial
SequencePrimer 31Val Thr Phe Val Xaa Asn His Asp 1 5
326PRTArtificial SequencePrimer 32Gly Trp Thr Arg Glu Gly 1 5
3322DNAArtificial SequencePrimer 33ggcgttaacc gcagcttgta ac
223451DNAArtificial SequencePrimer 34ccgagctcgg ccggctgggc
cgtcgactta tttgtttacc caaatagaaa c 513537DNAArtificial
SequencePrimer 35cattctgcag cagcggcgca ccataatggt acgaacg
3736400PRTArtificial SequencePartial Alpha-Amylase 36Asn Gly Thr
Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr Leu Pro 1 5 10 15 Asn
Asp Gly Asn His Trp Asn Arg Leu Arg Ser Asp Ala Ser Asn Leu 20 25
30 Lys Asp Lys Gly Ile Ser Ala Val Trp Ile Pro Pro Ala Trp Lys Gly
35 40 45 Ala Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr
Asp Leu 50 55 60 Gly Glu Phe Asn Gln Lys Gly Thr Ile Arg Thr Lys
Tyr Gly Thr Arg 65 70 75 80 Asn Gln Leu Gln Ala Ala Val Asn Ala Leu
Lys Ser Asn Gly Ile Gln 85 90 95 Val Tyr Gly Asp Val Val Met Asn
His Lys Gly Gly Ala Asp Ala Thr 100 105 110 Glu Met Val Arg Ala Val
Glu Val Asn Pro Asn Asn Arg Asn Gln Glu 115 120 125 Val Ser Gly Glu
Tyr Thr Ile Glu Ala Trp Thr Lys Phe Asp Phe Pro 130 135 140 Gly Arg
Gly Asn Thr His Ser Asn Phe Lys Trp Arg Trp Tyr His Phe 145 150 155
160 Asp Gly Val Asp Trp Asp Gln Ser Arg Lys Leu Asn Asn Arg Ile Tyr
165 170 175 Lys Phe Arg Gly Asp Gly Lys Gly Trp Asp Trp Glu Val Asp
Thr Glu 180 185 190 Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Ile
Asp Met Asp His 195 200 205 Pro Glu Val Val Asn Glu Leu Arg Asn Trp
Gly Val Trp Tyr Thr Asn 210 215 220 Thr Leu Gly Leu Asp Gly Phe Arg
Ile Asp Ala Val Lys His Ile Lys 225 230 235 240 Tyr Ser Phe Thr Arg
Asp Trp Ser Ile His Val Arg Ser Ala Thr Gly 245 250 255 Lys Asn Met
Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu Gly Ala 260 265 270 Ile
Glu Asn Tyr Leu Asn Lys Thr Asn Trp Asn His Ser Val Phe Asp 275 280
285 Val Pro Leu His Tyr Asn Phe Tyr Asn Ala Ser Lys Ser Gly Gly Asn
290 295 300 Tyr Asp Met Arg Gln Ile Phe Asn Gly Thr Val Val Gln Arg
His Pro 305 310 315 320 Met His Ala Val Thr Phe Val Asp Asn His Asp
Ser Gln Pro Glu Glu 325 330 335 Ala Leu Glu Ser Phe Val Glu Glu Trp
Phe Lys Pro Leu Ala Tyr Ala 340 345 350 Leu Thr Leu Thr Arg Glu Gln
Gly Tyr Pro Ser Val Phe Tyr Gly Asp 355 360 365 Tyr Tyr Gly Ile Pro
Thr His Gly Val Pro Ala Met Lys Ser Lys Ile 370 375 380 Asp Pro Ile
Leu Glu Ala Arg Gln Lys Tyr Ala Tyr Gly Arg Gln Asn 385 390 395 400
37485PRTBacillus sp. 37His His Asn Gly Thr Asn Gly Thr Met Met Gln
Tyr Phe Glu Trp His 1 5 10 15 Leu Pro Asn Asp Gly Asn His Trp Asn
Arg Leu Arg Asp Asp Ala Ala 20 25 30 Asn Leu Lys Ser Lys Gly Ile
Thr Ala Val Trp Ile Pro Pro Ala Trp 35 40 45 Lys Gly Thr Ser Gln
Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr 50 55 60 Asp Leu Gly
Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly 65 70 75 80 Thr
Arg Ser Gln Leu Gln Gly Ala Val Thr Ser Leu Lys Asn Asn Gly 85 90
95 Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp
100 105 110 Gly Thr Glu Met Val Asn Ala Val Glu Val Asn Arg Ser Asn
Arg Asn 115 120 125 Gln Glu Ile Ser Gly Glu Tyr Thr Ile Glu Ala Trp
Thr Lys Phe Asp 130 135 140 Phe Pro Gly Arg Gly Asn Thr His Ser Asn
Phe Lys Trp Arg Trp Tyr 145 150 155 160 His Phe Asp Gly Thr Asp Trp
Asp Gln Ser Arg Gln Leu Gln Asn Lys 165 170 175 Ile Tyr Lys Phe Arg
Gly Thr Gly Lys Ala Trp Asp Trp Glu Val Asp 180 185 190 Ile Glu Asn
Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp
Ile Asp Met 195 200 205 Asp His Pro Glu Val Ile Asn Glu Leu Arg Asn
Trp Gly Val Trp Tyr 210 215 220 Thr Asn Thr Leu Asn Leu Asp Gly Phe
Arg Ile Asp Ala Val Lys His 225 230 235 240 Ile Lys Tyr Ser Tyr Thr
Arg Asp Trp Leu Thr His Val Arg Asn Thr 245 250 255 Thr Gly Lys Pro
Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu 260 265 270 Ala Ala
Ile Glu Asn Tyr Leu Asn Lys Thr Ser Trp Asn His Ser Val 275 280 285
Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Asn Ser Gly 290
295 300 Gly Tyr Phe Asp Met Arg Asn Ile Leu Asn Gly Ser Val Val Gln
Lys 305 310 315 320 His Pro Ile His Ala Val Thr Phe Val Asp Asn His
Asp Ser Gln Pro 325 330 335 Gly Glu Ala Leu Glu Ser Phe Val Gln Ser
Trp Phe Lys Pro Leu Ala 340 345 350 Tyr Ala Leu Ile Leu Thr Arg Glu
Gln Gly Tyr Pro Ser Val Phe Tyr 355 360 365 Gly Asp Tyr Tyr Gly Ile
Pro Thr His Gly Val Pro Ser Met Lys Ser 370 375 380 Lys Ile Asp Pro
Leu Leu Gln Ala Arg Gln Thr Tyr Ala Tyr Gly Thr 385 390 395 400 Gln
His Asp Tyr Phe Asp His His Asp Ile Ile Gly Trp Thr Arg Glu 405 410
415 Gly Asp Ser Ser His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp
420 425 430 Gly Pro Gly Gly Asn Lys Trp Met Tyr Val Gly Lys His Lys
Ala Gly 435 440 445 Gln Val Trp Arg Asp Ile Thr Gly Asn Arg Ser Gly
Thr Val Thr Ile 450 455 460 Asn Ala Asp Gly Trp Gly Asn Phe Thr Val
Asn Gly Gly Ala Val Ser 465 470 475 480 Val Trp Val Lys Gln 485
* * * * *
References